{"matching_results": 16601, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1001, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 872}, {"key": "negative", "matching_results": 126}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "tickerreport.com", "matching_results": 820, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 719}, {"key": "negative", "matching_results": 100}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "freelancer.com.co", "matching_results": 796, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 695}, {"key": "negative", "matching_results": 93}, {"key": "neutral", "matching_results": 8}]}]}, {"key": "watchlistnews.com", "matching_results": 765, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 659}, {"key": "negative", "matching_results": 106}]}]}, {"key": "dailypolitical.com", "matching_results": 760, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 647}, {"key": "negative", "matching_results": 113}]}]}, {"key": "wkrb13.com", "matching_results": 750, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 648}, {"key": "negative", "matching_results": 102}]}]}, {"key": "theolympiareport.com", "matching_results": 693, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 550}, {"key": "negative", "matching_results": 143}]}]}, {"key": "zolmax.com", "matching_results": 620, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 531}, {"key": "negative", "matching_results": 89}]}]}, {"key": "thelincolnianonline.com", "matching_results": 542, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 445}, {"key": "negative", "matching_results": 97}]}]}, {"key": "reed.co.uk", "matching_results": 341, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 337}, {"key": "negative", "matching_results": 4}]}]}]}], "results": [{"id": "KASrT_uWYqMwGh3413o35biYm5NiLeXd5_33OYbRlCqv5O3Mya2fXUntrc5oUpDq", "result_metadata": {"score": 36.3405}, "author": "tanuj", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.5%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Years in the future", "relevance": 0.862267, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}], "categories": [{"score": 0.567699, "label": "/health and fitness"}, {"score": 0.491153, "label": "/food and drink/healthy eating"}, {"score": 0.441007, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Orally Disintegrating Tablets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998121}, {"text": "Showcase Healthy Expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.845995}, {"text": "CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.340292}]}, "crawl_date": "2018-11-11T05:53:55Z", "url": "https://www.findmarketresearch.org/2018/09/orally-disintegrating-tablets-market-to-showcase-healthy-expansion-at-11-5-cagr-during-2017-2025/", "host": "findmarketresearch.org", "text": "Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-09-20T12:28:00+05:00", "enriched_text": {"entities": [{"count": 5, "sentiment": {"score": -0.469403, "label": "negative"}, "text": "Persistence Market Research", "relevance": 0.462502, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regional Forecast", "relevance": 0.160692, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": -0.54819, "label": "negative"}, "text": "North America", "relevance": 0.124446, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 3, "sentiment": {"score": -0.292714, "label": "negative"}, "text": "Hospital Pharmacies", "relevance": 0.120146, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.113691, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergy", "relevance": 0.109695, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Allergy", "dbpedia_resource": "http://dbpedia.org/resource/Allergy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.107412, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. Reddy\u2019s Laboratories Ltd", "relevance": 0.104952, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.100869, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.100744, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.223483, "label": "negative"}, "text": "Bayer AG", "relevance": 0.100026, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Unichem Laboratories", "relevance": 0.0985307, "type": "Company", "disambiguation": {"subtype": [], "name": "Unichem Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Unichem_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zydus Cadila", "relevance": 0.0965269, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.095879, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEOS Therapeutics, Inc.", "relevance": 0.0931706, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.0901657, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0897337, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0895119, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.238398, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.0885252, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant", "relevance": 0.0882985, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sun Pharmaceutical Industries Ltd.", "relevance": 0.0873345, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.0871242, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Services, Inc.", "relevance": 0.0857087, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0849794, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.084976, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.0831952, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "F. Hoffmann-La Roche Ltd.", "relevance": 0.0826535, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mylan N.V.", "relevance": 0.0791039, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glenmark", "relevance": 0.0782893, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0759924, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "eight year", "relevance": 0.0759924, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "13.2%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.5%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.7%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "15.7%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "49%", "relevance": 0.0759924, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "55%", "relevance": 0.0759924, "type": "Quantity"}], "sentiment": {"document": {"score": -0.478324, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "a new report", "keywords": [{"text": "new report"}]}, "sentence": "In a new report titled \u2018Orally Disintegrating Tablets Market: Global Industry Analysis 2012 \u2013 2016 and Forecast 2017 \u2013 2025,\u2019 Persistence Market Research studies the performance of the global orally disintegrating tablets market over an eight year period from 2017 to 2025 and presents a detailed forecast of the market both for the historical period 2012 \u2013 2016 as well as for the forecasted period of 2017 \u2013 2025.", "object": {"text": "\u2018Orally Disintegrating Tablets Market", "keywords": [{"text": "\u2018Orally Disintegrating Tablets"}, {"text": "Market"}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}, {"subject": {"text": "tablets", "keywords": [{"text": "tablets"}]}, "sentence": " According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "action": {"verb": {"text": "disintegrate", "tense": "present"}, "text": "disintegrating", "normalized": "disintegrate"}}, {"subject": {"text": "orally disintegrating tablets", "keywords": [{"text": "orally disintegrating tablets"}]}, "sentence": " According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "object": {"text": "the scope for dosage errors", "keywords": [{"text": "dosage errors"}, {"text": "scope"}]}, "action": {"verb": {"text": "minimize", "tense": "present"}, "text": "minimize", "normalized": "minimize"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors are likely to boost revenue growth of the global orally disintegrating tablets market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value during the forecast period.", "object": {"text": "revenue growth of the global", "keywords": [{"text": "revenue growth"}], "entities": []}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "to boost", "normalized": "to boost"}}, {"subject": {"text": "tablets market", "keywords": [{"text": "tablets market"}]}, "sentence": " These factors are likely to boost revenue growth of the global orally disintegrating tablets market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value during the forecast period.", "object": {"text": "anticipated to rise from an estimated US$ 11.4 Bn", "keywords": [{"text": "Bn"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a CAGR of 11.5% in terms of value", "keywords": [{"text": "CAGR"}, {"text": "terms"}, {"text": "value"}], "entities": [{"type": "Quantity", "text": "11.5"}]}, "sentence": " These factors are likely to boost revenue growth of the global orally disintegrating tablets market, which is anticipated to rise from an estimated US$ 11.4 Bn in 2017 to about US$ 27 Bn by the end of 2025, witnessing a CAGR of 11.5% in terms of value during the forecast period.", "action": {"verb": {"text": "witness", "tense": "present"}, "text": "witnessing", "normalized": "witness"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " In this report, Persistence Market Research segments the global orally disintegrating tablets market on the basis of drug class, disease indication, distribution channel, and region.", "object": {"text": "the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "segment", "tense": "present"}, "text": "segments", "normalized": "segment"}}, {"subject": {"text": "by Drug Class", "keywords": [{"text": "Drug Class"}]}, "sentence": " Global Orally Disintegrating Tablets Market, Forecast by Drug Class", "object": {"text": "Global Orally Disintegrating Tablets Market", "keywords": [{"text": "Orally Disintegrating Tablets"}, {"text": "Market"}], "entities": []}, "action": {"verb": {"text": "Forecast", "tense": "past"}, "text": "Forecast", "normalized": "Forecast"}}, {"subject": {"text": "the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "market"}], "entities": []}, "sentence": " In terms of drug class, the global orally disintegrating tablets market is further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, and Others.", "object": {"text": "further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS", "keywords": [{"text": "CNS Stimulants"}, {"text": "Anti-Parkinsonian Drugs"}, {"text": "NSAIDS"}, {"text": "Anti-Psychotics"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "market"}], "entities": []}, "sentence": " In terms of drug class, the global orally disintegrating tablets market is further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, and Others.", "object": {"text": "into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS", "keywords": [{"text": "CNS Stimulants"}, {"text": "Anti-Parkinsonian Drugs"}, {"text": "NSAIDS"}, {"text": "Anti-Psychotics"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is further segmented", "normalized": "be further segment"}}, {"subject": {"text": "Anti-Psychotics drug class", "keywords": [{"text": "Anti-Psychotics drug class"}]}, "sentence": " Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20% revenue share of the global market by 2025 end.", "object": {"text": "the reigning segment", "keywords": [{"text": "segment"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Anti-Psychotics drug class", "keywords": [{"text": "Anti-Psychotics drug class"}]}, "sentence": " Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20% revenue share of the global market by 2025 end.", "object": {"text": "to hold about 20% revenue share of the global market by 2025 end", "keywords": [{"text": "revenue share"}, {"text": "global market"}, {"text": "end"}], "entities": [{"type": "Quantity", "text": "20"}]}, "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "anticipated", "normalized": "anticipate"}}, {"subject": {"text": "about 20% revenue share of the global market", "keywords": [{"text": "revenue share"}, {"text": "global market"}], "entities": [{"type": "Quantity", "text": "20"}]}, "sentence": " Anti-Psychotics drug class will be the reigning segment in terms of market revenue share throughout the forecast period, anticipated to hold about 20% revenue share of the global market by 2025 end.", "action": {"verb": {"text": "hold", "tense": "future"}, "text": "anticipated to hold", "normalized": "anticipate to hold"}}, {"subject": {"text": "this segment", "keywords": [{"text": "segment"}]}, "sentence": " With a noteworthy 15.7% CAGR, this segment will retain its supremacy over other drug class segments during the eight year period.", "object": {"text": "its supremacy over other drug class segments", "keywords": [{"text": "drug class segments"}, {"text": "supremacy"}]}, "action": {"verb": {"text": "retain", "tense": "future"}, "text": "will retain", "normalized": "will retain"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "object": {"text": "segmented into Central Nervous System", "keywords": [{"text": "Central Nervous"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "object": {"text": "into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others", "keywords": [{"text": "Central Nervous"}, {"text": "GI"}, {"text": "Gastrointestinal"}, {"text": "Allergy"}], "entities": [{"type": "HealthCondition", "text": "Allergy", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Allergy", "dbpedia_resource": "http://dbpedia.org/resource/Allergy"}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "CNS Diseases segment", "keywords": [{"text": "CNS Diseases segment"}], "entities": []}, "sentence": " CNS Diseases segment will hold maximum revenue share in the global market, and Persistence Market Research forecasts indicate a 55% market share for this segment by the end of the forecast period in 2025.", "object": {"text": "maximum revenue share", "keywords": [{"text": "maximum revenue share"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "will hold", "normalized": "will hold"}}, {"subject": {"text": "Persistence Market Research forecasts", "keywords": [{"text": "Persistence Market Research"}, {"text": "forecasts"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " CNS Diseases segment will hold maximum revenue share in the global market, and Persistence Market Research forecasts indicate a 55% market share for this segment by the end of the forecast period in 2025.", "object": {"text": "a 55% market share for this segment by the end of the forecast period in 2025", "keywords": [{"text": "forecast period"}, {"text": "market share"}, {"text": "segment"}, {"text": "end"}], "entities": [{"type": "Quantity", "text": "55"}]}, "action": {"verb": {"text": "indicate", "tense": "present"}, "text": "indicate", "normalized": "indicate"}}, {"subject": {"text": "The CNS Diseases segment", "keywords": [{"text": "CNS Diseases segment"}]}, "sentence": " The CNS Diseases segment is forecasted to reach a market valuation of about US$ 15 Bn by 2025 end, registering a CAGR of 13.2%.", "object": {"text": "forecasted"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The CNS Diseases segment", "keywords": [{"text": "CNS Diseases segment"}]}, "sentence": " The CNS Diseases segment is forecasted to reach a market valuation of about US$ 15 Bn by 2025 end, registering a CAGR of 13.2%.", "object": {"text": "a market valuation of about US$ 15 Bn", "keywords": [{"text": "market valuation"}, {"text": "Bn"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is forecasted to reach", "normalized": "be forecast to reach"}}, {"subject": {"text": "This"}, "sentence": " This is slated to be the most dominant segment by disease indication in the global orally disintegrating tablets market.", "object": {"text": "to be the most dominant segment by disease indication in the global orally disintegrating tablets market", "keywords": [{"text": "orally disintegrating tablets"}, {"text": "dominant segment"}, {"text": "disease indication"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "slate", "tense": "past"}, "text": "slated", "normalized": "slate"}}, {"subject": {"text": "This"}, "sentence": " This is slated to be the most dominant segment by disease indication in the global orally disintegrating tablets market.", "object": {"text": "the most dominant segment", "keywords": [{"text": "dominant segment"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is slated to be", "normalized": "be slate to be"}}, {"subject": {"text": "by Distribution Channel", "keywords": [{"text": "Distribution Channel"}]}, "sentence": " Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel", "object": {"text": "Global Orally Disintegrating Tablets Market", "keywords": [{"text": "Orally Disintegrating Tablets"}, {"text": "Market"}], "entities": []}, "action": {"verb": {"text": "Forecast", "tense": "past"}, "text": "Forecast", "normalized": "Forecast"}}, {"subject": {"text": "Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies", "keywords": [{"text": "Hospital Pharmacies"}, {"text": "Retail Pharmacies"}, {"text": "Online Pharmacies"}, {"text": "Drug Stores"}], "entities": [{"type": "Company", "text": "Hospital Pharmacies"}, {"type": "Company", "text": "Hospital Pharmacies"}]}, "sentence": " Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "object": {"text": "the undisputed leader in terms of market share", "keywords": [{"text": "undisputed leader"}, {"text": "market share"}, {"text": "terms"}], "entities": [{"type": "Company", "text": "Hospital Pharmacies"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies", "keywords": [{"text": "Hospital Pharmacies"}, {"text": "Retail Pharmacies"}, {"text": "Online Pharmacies"}, {"text": "Drug Stores"}], "entities": [{"type": "Company", "text": "Hospital Pharmacies"}, {"type": "Company", "text": "Hospital Pharmacies"}]}, "sentence": " Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "object": {"text": "for nearly 49% value share", "keywords": [{"text": "value"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "49"}]}, "action": {"verb": {"text": "account", "tense": "future"}, "text": "anticipated to account", "normalized": "anticipate to account"}}, {"subject": {"text": "a 13.2% CAGR", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "13.2"}]}, "sentence": " A market valuation of about US$ 13 Bn by the end of 2025 with a 13.2% CAGR is likely to be in store for this segment.", "object": {"text": "in store", "keywords": [{"text": "store"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "to be", "normalized": "to be"}}, {"subject": {"text": "Persistence Market Research", "keywords": [{"text": "Persistence Market Research"}], "entities": [{"type": "Company", "text": "Persistence Market Research"}]}, "sentence": " Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "object": {"text": "the performance of the global", "keywords": [{"text": "performance"}], "entities": []}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "tracks", "normalized": "track"}}, {"subject": {"text": "tablets market", "keywords": [{"text": "tablets market"}]}, "sentence": " Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "action": {"verb": {"text": "disintegrate", "tense": "present"}, "text": "disintegrating", "normalized": "disintegrate"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is slated to dominate the global market throughout the forecast period, with an estimated 35% market share and a market value of about US$ 9.7 Bn by the end of 2025.", "object": {"text": "to dominate the global market throughout the forecast period", "keywords": [{"text": "forecast period"}, {"text": "global market"}], "entities": []}, "action": {"verb": {"text": "slate", "tense": "past"}, "text": "slated", "normalized": "slate"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is slated to dominate the global market throughout the forecast period, with an estimated 35% market share and a market value of about US$ 9.7 Bn by the end of 2025.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "future"}, "text": "is slated to dominate", "normalized": "be slate to dominate"}}, {"subject": {"text": "This"}, "sentence": " This is reflective of a CAGR of 11.7% during the forecast period.", "object": {"text": "reflective of a CAGR of 11.7%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "11.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "object": {"text": "some of the leading companies operating", "keywords": [{"text": "leading companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "tablets market", "keywords": [{"text": "tablets market"}]}, "sentence": " The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "object": {"text": "Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy\u2019s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories", "keywords": [{"text": "F. Hoffmann-La Roche"}, {"text": "Sun Pharmaceutical Industries"}, {"text": "Novartis AG"}, {"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Mylan N.V."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Johnson & Johnson Services, Inc."}, {"type": "Company", "text": "F. Hoffmann-La Roche Ltd."}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Valeant", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Sun Pharmaceutical Industries Ltd."}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Dr. Reddy\u2019s Laboratories Ltd"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Person", "text": "Zydus Cadila"}, {"type": "Company", "text": "NEOS Therapeutics, Inc."}, {"type": "Company", "text": "Glenmark"}, {"type": "Company", "text": "Unichem Laboratories", "disambiguation": {"subtype": [], "name": "Unichem Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Unichem_Laboratories"}}]}, "action": {"verb": {"text": "disintegrate", "tense": "present"}, "text": "disintegrating", "normalized": "disintegrate"}}], "concepts": [{"text": "Pharmaceutical industry", "relevance": 0.985618, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.950582, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmacology", "relevance": 0.83213, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Marketing", "relevance": 0.770294, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Pharmacy", "relevance": 0.733401, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.723333, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Pharmaceutical drug", "relevance": 0.523555, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.500498, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Marketing research", "relevance": 0.498465, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}, {"text": "Distribution", "relevance": 0.479159, "dbpedia_resource": "http://dbpedia.org/resource/Distribution_(business)"}, {"text": "Central nervous system", "relevance": 0.457596, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "GlaxoSmithKline", "relevance": 0.456375, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Novartis", "relevance": 0.449589, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Years in the future", "relevance": 0.433761, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Generic drug", "relevance": 0.406714, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Hoffmann-La Roche", "relevance": 0.398549, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann-La_Roche"}, {"text": "Benzodiazepine", "relevance": 0.382133, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Periodization", "relevance": 0.38104, "dbpedia_resource": "http://dbpedia.org/resource/Periodization"}, {"text": "Revenue", "relevance": 0.379283, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}], "categories": [{"score": 0.506141, "label": "/health and fitness"}, {"score": 0.503855, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.490004, "label": "/health and fitness/disease"}], "relations": [{"type": "partOf", "sentence": "In a new report titled \u02bbOrally Disintegrating Tablets Market: Global Industry Analysis 2012 - 2016 and Forecast 2017 - 2025,' Persistence Market Research studies the performance of the global orally disintegrating tablets market over an eight year period from 2017 to 2025 and presents a detailed forecast of the market both for the historical period 2012 - 2016 as well as for the forecasted period of 2017 - 2025. According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "score": 0.521024, "arguments": [{"text": "Global Industry Analysis", "location": [62, 86], "entities": [{"type": "Organization", "text": "Global Industry Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Disintegrating Tablets Market", "location": [31, 60], "entities": [{"type": "Organization", "text": "Disintegrating Tablets Market"}]}]}, {"type": "managerOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "score": 0.67108, "arguments": [{"text": "leader", "location": [2947, 2953], "entities": [{"type": "Person", "text": "Persistence Market"}]}, {"text": "Hospital Pharmacies", "location": [2904, 2923], "entities": [{"type": "Organization", "text": "Hospital Pharmacies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global Orally Disintegrating Tablets Market, Regional Forecast Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "score": 0.742459, "arguments": [{"text": "Persistence Market", "location": [3262, 3280], "entities": [{"type": "Person", "text": "Persistence Market"}]}, {"text": "Regional Forecast", "location": [3244, 3261], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Orally Disintegrating Tablets Market, Regional Forecast Persistence Market Research tracks the performance of the global orally disintegrating tablets market across the key geographies of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.", "score": 0.684628, "arguments": [{"text": "Asia", "location": [3432, 3436], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3437, 3444], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOfMany", "sentence": "Request For Report Sample@ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.6004, "arguments": [{"text": "Teva Pharmaceutical Industries Ltd.", "location": [3982, 4017], "entities": [{"type": "Organization", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3903, 3912], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Request For Report Sample@ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.612395, "arguments": [{"text": "Novartis AG", "location": [4019, 4030], "entities": [{"type": "Organization", "text": "Novartis AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3903, 3912], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Request For Report Sample@ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.471911, "arguments": [{"text": "AstraZeneca", "location": [4032, 4043], "entities": [{"type": "Organization", "text": "AstraZeneca", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3903, 3912], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Request For Report Sample@ https://www.persistencemarketresearch.com/samples/14572 Global Orally Disintegrating Tablets Market, Vendor Ecosystem The report profiles some of the leading companies operating in the global orally disintegrating tablets market such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Zydus Cadila, NEOS Therapeutics, Inc., Glenmark, and Unichem Laboratories.", "score": 0.358422, "arguments": [{"text": "Reddy", "location": [4254, 4259], "entities": [{"type": "Person", "text": "Reddy"}]}, {"text": "Laboratories Ltd", "location": [4262, 4278], "entities": [{"type": "Organization", "text": "Laboratories Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "In a new report titled \u02bbOrally Disintegrating Tablets Market: Global Industry Analysis 2012 - 2016 and Forecast 2017 - 2025,' Persistence Market Research studies the performance of the global orally disintegrating tablets market over an eight year period from 2017 to 2025 and presents a detailed forecast of the market both for the historical period 2012 - 2016 as well as for the forecasted period of 2017 - 2025. According to Persistence Market Research, the global orally disintegrating tablets market is predicted to grow at a significant pace during the assessment period owing to a rising preference for orally disintegrating tablets among patients and physicians alike; coupled with the fact that orally disintegrating tablets minimize the scope for dosage errors and are ideal for administering to patients of all age groups.", "score": 0.61113, "arguments": [{"text": "patients", "location": [807, 815], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "groups", "location": [827, 833], "entities": [{"type": "Person", "text": "groups"}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Drug Class In terms of drug class, the global orally disintegrating tablets market is further segmented into Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitor, and Others.", "score": 0.429244, "arguments": [{"text": "Drug Class", "location": [1355, 1365], "entities": [{"type": "Organization", "text": "Drug Class", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Forecast", "location": [1343, 1351], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.558207, "arguments": [{"text": "Disease Indication", "location": [2021, 2039], "entities": [{"type": "Organization", "text": "Disease Indication"}]}, {"text": "Forecast", "location": [2009, 2017], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.500095, "arguments": [{"text": "CNS", "location": [2121, 2124], "entities": [{"type": "Organization", "text": "CNS Stimulants", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Central Nervous System", "location": [2097, 2119], "entities": [{"type": "Organization", "text": "Central Nervous System"}]}]}, {"type": "hasAttribute", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.837419, "arguments": [{"text": "Gastrointestinal", "location": [2136, 2152], "entities": [{"type": "Person", "text": "Gastrointestinal"}]}, {"text": "Diseases", "location": [2158, 2166], "entities": [{"type": "HealthCondition", "text": "Diseases"}]}]}, {"type": "hasAttribute", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.696635, "arguments": [{"text": "Gastrointestinal", "location": [2136, 2152], "entities": [{"type": "Person", "text": "Gastrointestinal"}]}, {"text": "Allergy", "location": [2199, 2206], "entities": [{"type": "HealthCondition", "text": "Allergy"}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Disease Indication Under this category, the global market is segmented into Central Nervous System (CNS) Diseases, Gastrointestinal (GI) Diseases, Cardiovascular (CVS) Diseases, Allergy, and Others.", "score": 0.461439, "arguments": [{"text": "Cardiovascular", "location": [2168, 2182], "entities": [{"type": "Organization", "text": "Cardiovascular"}]}, {"text": "CVS", "location": [2184, 2187], "entities": [{"type": "Organization", "text": "CVS", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Global Orally Disintegrating Tablets Market, Forecast by Distribution Channel Of the various distribution channels of orally disintegrating tablets viz., Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies, Hospital Pharmacies will be the undisputed leader in terms of market share throughout the forecast period, anticipated to account for nearly 49% value share by the end of 2025.", "score": 0.497412, "arguments": [{"text": "Distribution Channel", "location": [2731, 2751], "entities": [{"type": "Organization", "text": "Distribution Channel", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Forecast", "location": [2719, 2727], "entities": [{"type": "Organization", "text": "Regional Forecast", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "orally disintegrating tablets", "sentiment": {"score": -0.505917, "label": "negative"}, "relevance": 0.969243}, {"text": "tablets market", "sentiment": {"score": -0.49123, "label": "negative"}, "relevance": 0.71769}, {"text": "Global Orally Disintegrating", "sentiment": {"score": -0.529513, "label": "negative"}, "relevance": 0.630887}, {"text": "Disintegrating Tablets Market", "sentiment": {"score": -0.529513, "label": "negative"}, "relevance": 0.61635}, {"text": "Persistence Market Research", "sentiment": {"score": -0.469403, "label": "negative"}, "relevance": 0.603846}, {"text": "forecast period", "sentiment": {"score": -0.0758052, "label": "negative"}, "relevance": 0.539166}, {"text": "drug class", "sentiment": {"score": -0.444069, "label": "negative"}, "relevance": 0.501964}, {"text": "CNS Diseases segment", "sentiment": {"score": -0.567536, "label": "negative"}, "relevance": 0.478553}, {"text": "global market", "sentiment": {"score": -0.496604, "label": "negative"}, "relevance": 0.47851}, {"text": "disease indication", "sentiment": {"score": -0.688221, "label": "negative"}, "relevance": 0.469742}, {"text": "Pharmaceutical Industries Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463209}, {"text": "market share", "sentiment": {"score": -0.509426, "label": "negative"}, "relevance": 0.4609}, {"text": "revenue share", "sentiment": {"score": -0.479519, "label": "negative"}, "relevance": 0.45769}, {"text": "market revenue share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457483}, {"text": "tablets viz.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45725}, {"text": "Global Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454864}, {"text": "market valuation", "sentiment": {"score": -0.579921, "label": "negative"}, "relevance": 0.446968}, {"text": "Anti-Psychotics drug class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442819}, {"text": "distribution channel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442698}, {"text": "maximum revenue share", "sentiment": {"score": -0.555152, "label": "negative"}, "relevance": 0.44251}, {"text": "drug class segments", "sentiment": {"score": -0.260101, "label": "negative"}, "relevance": 0.442352}, {"text": "Proton Pump Inhibitor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440529}, {"text": "North America", "sentiment": {"score": -0.54819, "label": "negative"}, "relevance": 0.43931}, {"text": "Hospital Pharmacies", "sentiment": {"score": -0.292714, "label": "negative"}, "relevance": 0.438502}, {"text": "Teva Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438091}, {"text": "Regional Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437993}, {"text": "Hoffmann-La Roche Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437661}, {"text": "various distribution channels", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437498}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.437377}, {"text": "Sun Pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.436961}, {"text": "market value", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431574}, {"text": "dominant segment", "sentiment": {"score": -0.800445, "label": "negative"}, "relevance": 0.430507}, {"text": "end", "sentiment": {"score": -0.48724, "label": "negative"}, "relevance": 0.43001}, {"text": "Bn", "sentiment": {"score": -0.497123, "label": "negative"}, "relevance": 0.429977}, {"text": "historical period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429693}, {"text": "assessment period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429396}, {"text": "CNS Stimulants", "sentiment": {"score": -0.301306, "label": "negative"}, "relevance": 0.42805}, {"text": "revenue growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426335}, {"text": "new report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42555}, {"text": "age groups", "sentiment": {"score": -0.623409, "label": "negative"}, "relevance": 0.424649}, {"text": "Retail Pharmacies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424481}, {"text": "Online Pharmacies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424455}, {"text": "dosage errors", "sentiment": {"score": -0.623409, "label": "negative"}, "relevance": 0.423282}, {"text": "significant pace", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423224}, {"text": "value share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422453}, {"text": "CAGR", "sentiment": {"score": 0.453003, "label": "positive"}, "relevance": 0.422431}, {"text": "Anti-Allergy Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422402}, {"text": "undisputed leader", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421428}, {"text": "Central Nervous", "sentiment": {"score": -0.479188, "label": "negative"}, "relevance": 0.42141}, {"text": "Anti-Parkinsonian Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421292}]}, "extracted_metadata": {"sha1": "4727c31fe10658b386ebdaba9794b92cba563796", "filename": "1541915635669.zip-31a4544960a77a2ce646b4654c73560d.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/14572", "https://www.persistencemarketresearch.com/market-research/orally-disintegrating-tablet-market.asp"], "title": "Orally Disintegrating Tablets to Showcase Healthy Expansion at 11.5% CAGR During 2017 \u2013 2025", "forum_title": "Research Insights \u2013 Page 68 \u2013 Find Market Research"}, {"id": "4ECo5nlYG6TEF4JI4EmM24RW9HSiUppdRyjacHcTCFnaB1Hf9HRQfKf_FhmQt8DF", "result_metadata": {"score": 33.36458}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Favorable Media Coverage", "keywords": [{"text": "Favorable Media Coverage"}], "entities": []}, "sentence": "Favorable Media Coverage Extremely Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price", "object": {"text": "Takeda Pharmaceutical (TKPYY) Stock Price", "keywords": [{"text": "Stock Price"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "Affect", "tense": "future"}, "text": "to Affect", "normalized": "to Affect"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Stock", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.82944, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.73507, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.401204, "label": "/finance/investing/options"}], "relations": [], "keywords": [{"text": "Favorable Media Coverage", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.903334}, {"text": "Stock Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642094}]}, "crawl_date": "2018-11-11T01:50:24Z", "url": "https://www.americanbankingnews.com/2018/11/10/favorable-media-coverage-extremely-likely-to-affect-takeda-pharmaceutical-tkpyy-stock-price.html", "host": "americanbankingnews.com", "text": "Receive News & Ratings for Takeda Pharmaceutical analysts' ratings for Takeda Pharmaceutical and related companies daily email newsletter", "main_image_url": "https://www.marketbeat.com/logos/takeda-pharmaceutical-co-ltd-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-11T01:26:00Z", "enriched_text": {"entities": [{"count": 8, "sentiment": {"score": -0.473185, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.957, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.348728, "label": "positive"}, "text": "Takeda", "relevance": 0.346683, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Banking News", "relevance": 0.14302, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": -0.228403, "label": "negative"}, "text": "ValuEngine", "relevance": 0.138858, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.348728, "label": "positive"}, "text": "CEO", "relevance": 0.134924, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Consumer Healthcare", "relevance": 0.119913, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "OTC", "relevance": 0.117674, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.360129, "label": "negative"}, "text": "U.S.", "relevance": 0.114498, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "52-week", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$32.34 billion", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.86 billion", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$18.93", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$19.80", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$31.29", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.35%", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.53", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.61", "relevance": 0.114498, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.84%", "relevance": 0.114498, "type": "Quantity"}], "sentiment": {"document": {"score": -0.567843, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}], "entities": [{"type": "Company", "text": "ValuEngine"}]}, "sentence": " Separately, ValuEngine raised shares of Takeda Pharmaceutical from a \u201csell\u201d rating to a \u201chold\u201d rating in a research note on Thursday, September 27th.", "object": {"text": "shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Separately, ValuEngine raised shares of Takeda Pharmaceutical from a \u201csell\u201d rating to a \u201chold\u201d rating in a research note on Thursday, September 27th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "TKPYY", "keywords": [{"text": "TKPYY"}]}, "sentence": " Shares of OTCMKTS:TKPYY traded down $0.53 on Friday, reaching $19.80.", "action": {"verb": {"text": "trade", "tense": "past"}, "text": "traded", "normalized": "trade"}}, {"subject": {"text": "TKPYY", "keywords": [{"text": "TKPYY"}]}, "sentence": " Shares of OTCMKTS:TKPYY traded down $0.53 on Friday, reaching $19.80.", "object": {"text": "$19.80", "entities": [{"type": "Quantity", "text": "$19.80"}]}, "action": {"verb": {"text": "reach", "tense": "present"}, "text": "reaching", "normalized": "reach"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company\u2019s stock had a trading volume of 1,760,916 shares, compared to its average volume of 938,429.", "object": {"text": "stock had a trading volume of 1,760,916 shares", "keywords": [{"text": "trading volume"}, {"text": "stock"}, {"text": "shares"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}]}, "sentence": " The company\u2019s stock had a trading volume of 1,760,916 shares, compared to its average volume of 938,429.", "object": {"text": "a trading volume of 1,760,916 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "a trading volume of 1,760,916 shares", "keywords": [{"text": "trading volume"}, {"text": "shares"}]}, "sentence": " The company\u2019s stock had a trading volume of 1,760,916 shares, compared to its average volume of 938,429.", "object": {"text": "to its average volume of 938,429", "keywords": [{"text": "average volume"}]}, "action": {"verb": {"text": "compare", "tense": "past"}, "text": "compared", "normalized": "compare"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical has a 52-week low of $18.93 and a 52-week high of $31.29.", "object": {"text": "a 52-week low of $18.93 and a 52-week high of $31.29", "keywords": [{"text": "52-week low"}, {"text": "52-week high"}], "entities": [{"type": "Quantity", "text": "52-week"}, {"type": "Quantity", "text": "$18.93"}, {"type": "Quantity", "text": "$31.29"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market capitalization of $32.34 billion, a P/E ratio of 15.11 and a beta of 0.44.", "object": {"text": "a market capitalization of $32.34 billion, a P/E ratio of 15.11 and a beta of 0.44", "keywords": [{"text": "market capitalization"}, {"text": "P/E ratio"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$32.34 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company has a quick ratio of 1.12, a current ratio of 1.42 and a debt-to-equity ratio of 0.48.", "object": {"text": "a quick ratio of 1.12, a current ratio of 1.42 and a debt-to-equity ratio of 0.48", "keywords": [{"text": "quick ratio"}, {"text": "current ratio"}, {"text": "debt-to-equity ratio"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical (OTCMKTS:TKPYY)", "keywords": [{"text": "(OTCMKTS:TKPYY)"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical (OTCMKTS:TKPYY) last issued its quarterly earnings data on Wednesday, October 31st.", "object": {"text": "its quarterly earnings data", "keywords": [{"text": "quarterly earnings data"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company reported $0.61 EPS for the quarter.", "object": {"text": "$0.61 EPS for the quarter", "keywords": [{"text": "EPS"}, {"text": "quarter"}], "entities": [{"type": "Quantity", "text": "$0.61"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Takeda Pharmaceutical", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical had a net margin of 7.84% and a return on equity of 11.35%.", "object": {"text": "a net margin of 7.84% and a return on equity of 11.35%", "keywords": [{"text": "net margin"}, {"text": "return"}, {"text": "equity"}], "entities": [{"type": "Quantity", "text": "11.35"}, {"type": "Quantity", "text": "7.84"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "The business", "keywords": [{"text": "business"}]}, "sentence": " The business had revenue of $3.86 billion during the quarter.", "object": {"text": "revenue of $3.86 billion", "keywords": [{"text": "revenue"}], "entities": [{"type": "Quantity", "text": "$3.86 billion"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "This piece", "keywords": [{"text": "piece"}]}, "sentence": " COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News.", "object": {"text": "reported by American Banking News", "keywords": [{"text": "American Banking News"}], "entities": [{"type": "PrintMedia", "text": "American Banking News"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by American Banking News", "keywords": [{"text": "American Banking News"}], "entities": [{"type": "PrintMedia", "text": "American Banking News"}]}, "sentence": " COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News.", "object": {"text": "This piece", "keywords": [{"text": "piece"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "was reported", "normalized": "be report"}}, {"subject": {"text": "This piece", "keywords": [{"text": "piece"}]}, "sentence": " COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News.", "object": {"text": "owned by of American Banking News", "keywords": [{"text": "American Banking News"}], "entities": [{"type": "PrintMedia", "text": "American Banking News"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by of American Banking News", "keywords": [{"text": "American Banking News"}], "entities": [{"type": "PrintMedia", "text": "American Banking News"}]}, "sentence": " COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News.", "object": {"text": "This piece", "keywords": [{"text": "piece"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "is owned", "normalized": "be own"}}, {"subject": {"text": "you"}, "sentence": " If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws.", "object": {"text": "this piece", "keywords": [{"text": "piece"}]}, "action": {"verb": {"text": "view", "tense": "present"}, "text": "are viewing", "normalized": "be view"}}, {"subject": {"text": "it"}, "sentence": " If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws.", "object": {"text": "in violation of U.S. and international copyright & trademark laws", "keywords": [{"text": "international copyright"}, {"text": "trademark laws"}, {"text": "violation"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "republish", "tense": "past"}, "text": "republished", "normalized": "republish"}}, {"subject": {"text": "The legal version of this piece", "keywords": [{"text": "legal version"}, {"text": "piece"}]}, "sentence": " The legal version of this piece can be read at https://www.americanbankingnews.com/2018/11/10/favorable-media-coverage-extremely-likely-to-affect-takeda-pharmaceutical-tkpyy-stock-price.html.", "object": {"text": "at https://www.americanbankingnews.com/2018/11/10/favorable-media-coverage-extremely-likely-to-affect-takeda-pharmaceutical-tkpyy-stock-price.html"}, "action": {"verb": {"text": "read", "tense": "future"}, "text": "can be read", "normalized": "can be read"}}, {"subject": {"text": "It"}, "sentence": " It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others.", "object": {"text": "prescription, OTC, and quasi-drugs", "keywords": [{"text": "OTC"}, {"text": "prescription"}, {"text": "quasi-drugs"}], "entities": [{"type": "Company", "text": "OTC"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "oncology, gastroenterology, central nervous system (CNS), vaccines, and others", "keywords": [{"text": "gastroenterology"}, {"text": "vaccines"}], "entities": []}, "sentence": " It offers prescription, OTC, and quasi-drugs; and reagents in various therapeutic areas, including oncology, gastroenterology, central nervous system (CNS), vaccines, and others.", "object": {"text": "reagents in various therapeutic areas", "keywords": [{"text": "various therapeutic areas"}, {"text": "reagents"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "News & Ratings", "keywords": [{"text": "News"}, {"text": "Ratings"}]}, "sentence": " Receive News & Ratings for Takeda Pharmaceutical analysts' ratings for Takeda Pharmaceutical and related companies daily email newsletter . \u00ab", "object": {"text": "for Takeda Pharmaceutical analysts' ratings for Takeda Pharmaceutical and related companies daily email newsletter", "keywords": [{"text": "Takeda Pharmaceutical analysts"}, {"text": "companies daily email"}, {"text": "ratings"}, {"text": "newsletter"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "Receive", "tense": "present"}, "text": "Receive", "normalized": "Receive"}}], "concepts": [{"text": "Financial ratios", "relevance": 0.981797, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratios"}, {"text": "Central nervous system", "relevance": 0.955172, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "Financial ratio", "relevance": 0.939017, "dbpedia_resource": "http://dbpedia.org/resource/Financial_ratio"}, {"text": "Nervous system", "relevance": 0.890937, "dbpedia_resource": "http://dbpedia.org/resource/Nervous_system"}, {"text": "Pharmacology", "relevance": 0.797146, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Stock", "relevance": 0.790066, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.71022, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Over-the-counter drug", "relevance": 0.65599, "dbpedia_resource": "http://dbpedia.org/resource/Over-the-counter_drug"}, {"text": "Stock market", "relevance": 0.610414, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.647432, "label": "/finance/financial news"}, {"score": 0.452221, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.397457, "label": "/finance/investing"}], "relations": [{"type": "managerOf", "sentence": "Takeda CEO confident of investor backing for $62 billion Shire deal (finance.yahoo.com) Separately, ValuEngine raised shares of Takeda Pharmaceutical from a \"sell\" rating to a \"hold\" rating in a research note on Thursday, September 27th.", "score": 0.774397, "arguments": [{"text": "CEO", "location": [7, 10], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Takeda", "location": [0, 6], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Takeda Pharmaceutical (OTCMKTS:TKPYY) last issued its quarterly earnings data on Wednesday, October 31st.", "score": 0.920616, "arguments": [{"text": "Takeda Pharmaceutical", "location": [690, 711], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "TKPYY", "location": [721, 726], "entities": [{"type": "Ticker", "text": "TKPYY"}]}]}, {"type": "agentOf", "sentence": "The company reported $0.61 EPS for the quarter.", "score": 0.869998, "arguments": [{"text": "company", "location": [800, 807], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "reported", "location": [808, 816], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "The company reported $0.61 EPS for the quarter.", "score": 0.320558, "arguments": [{"text": "EPS", "location": [823, 826], "entities": [{"type": "Organization", "text": "EPS"}]}, {"text": "$0.61", "location": [817, 822], "entities": [{"type": "Money", "text": "$0.61"}]}]}, {"type": "agentOf", "sentence": "COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News.", "score": 0.855394, "arguments": [{"text": "American Banking News", "location": [1044, 1065], "entities": [{"type": "Organization", "text": "American Banking News"}]}, {"text": "reported", "location": [1032, 1040], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "employedBy", "sentence": "Receive News & Ratings for Takeda Pharmaceutical analysts' ratings for Takeda Pharmaceutical and related companies daily email newsletter . \u00ab", "score": 0.813098, "arguments": [{"text": "analysts", "location": [1958, 1966], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "Takeda Pharmaceutical", "location": [1936, 1957], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical\nTakeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.473185, "label": "negative"}, "relevance": 0.956034}, {"text": "Takeda Pharmaceutical analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.783767}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.781671}, {"text": "Takeda CEO", "sentiment": {"score": 0.348728, "label": "positive"}, "relevance": 0.753336}, {"text": "American Banking News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.734108}, {"text": "quarterly earnings data", "sentiment": {"score": -0.365275, "label": "negative"}, "relevance": 0.613078}, {"text": "various therapeutic areas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595333}, {"text": "companies daily email", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593494}, {"text": "P/E ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549991}, {"text": "quick ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548502}, {"text": "current ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548211}, {"text": "debt-to-equity ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547921}, {"text": "investor backing", "sentiment": {"score": 0.348728, "label": "positive"}, "relevance": 0.529276}, {"text": "Shire deal", "sentiment": {"score": 0.348728, "label": "positive"}, "relevance": 0.527996}, {"text": "COPYRIGHT VIOLATION", "sentiment": {"score": -0.624842, "label": "negative"}, "relevance": 0.523898}, {"text": "market capitalization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523792}, {"text": "research note", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522884}, {"text": "trading volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517322}, {"text": "average volume", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516479}, {"text": "net margin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516431}, {"text": "52-week low", "sentiment": {"score": -0.717967, "label": "negative"}, "relevance": 0.516022}, {"text": "52-week high", "sentiment": {"score": -0.717967, "label": "negative"}, "relevance": 0.515761}, {"text": "pharmaceutical products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514896}, {"text": "legal version", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510352}, {"text": "Prescription Drug", "sentiment": {"score": -0.258, "label": "negative"}, "relevance": 0.509338}, {"text": "international copyright", "sentiment": {"score": -0.360129, "label": "negative"}, "relevance": 0.507632}, {"text": "trademark laws", "sentiment": {"score": -0.360129, "label": "negative"}, "relevance": 0.505818}, {"text": "Consumer Healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503448}, {"text": "shares", "sentiment": {"score": -0.228403, "label": "negative"}, "relevance": 0.46524}, {"text": "piece", "sentiment": {"score": 0.473215, "label": "positive"}, "relevance": 0.447096}, {"text": "stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440269}, {"text": "OTCMKTS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.440208}, {"text": "TKPYY", "sentiment": {"score": -0.265744, "label": "negative"}, "relevance": 0.440182}, {"text": "rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43841}, {"text": "finance.yahoo.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438381}, {"text": "ValuEngine", "sentiment": {"score": -0.228403, "label": "negative"}, "relevance": 0.438131}, {"text": "ratings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431536}, {"text": "27th", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426778}, {"text": "EPS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422541}, {"text": "OTC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421576}, {"text": "vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419742}, {"text": "beta", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419649}, {"text": "gastroenterology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419589}, {"text": "Thursday", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419521}, {"text": "business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419266}, {"text": "revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419161}, {"text": "Friday", "sentiment": {"score": -0.265744, "label": "negative"}, "relevance": 0.419095}, {"text": "segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418475}, {"text": "reagents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418348}, {"text": "publication", "sentiment": {"score": 0.473215, "label": "positive"}, "relevance": 0.418211}]}, "extracted_metadata": {"sha1": "c6e5a6e00d99d2606bd3abef139d94d34a7acaee", "filename": "1541901024380.zip-06bb359d43fc4261f1041ef42181db69.xml", "file_type": "json"}, "external_links": ["http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=TKPYY", "https://www.marketbeat.com/stocks/OTCMKTS/TKPYY/news/", "https://finance.yahoo.com/news/takeda-ceo-confident-investor-backing-150521900.html?.tsrc=rss"], "title": "Favorable Media Coverage Extremely Likely to Affect Takeda Pharmaceutical (TKPYY) Stock Price", "forum_title": "American Banking News"}, {"id": "rujxsuaRzOL11AA1uWH7hEjqE5z6gQXpPhQfQOtUsAahWKYnD-uXspAMvsNxneOZ", "result_metadata": {"score": 27.14921}, "author": "Ankush Nikam", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "DPP IV Inhibitors", "keywords": [{"text": "Inhibitors"}]}, "sentence": "DPP IV Inhibitors to Witness a Pronounce Growth During 2015 \u2013 2021", "object": {"text": "a Pronounce Growth", "keywords": [{"text": "Pronounce Growth"}]}, "action": {"verb": {"text": "Witness", "tense": "future"}, "text": "to Witness", "normalized": "to Witness"}}], "concepts": [], "categories": [{"score": 0.520926, "label": "/health and fitness"}, {"score": 0.497474, "label": "/health and fitness/disease/cancer"}, {"score": 0.481596, "label": "/society/crime/personal offense/homicide"}], "relations": [], "keywords": [{"text": "DPP IV Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.980512}, {"text": "Pronounce Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.791881}]}, "crawl_date": "2018-11-11T12:20:43Z", "url": "https://www.findmarketresearch.org/2018/07/dpp-iv-inhibitors-market-to-witness-a-pronounce-growth-during-2015-2021/", "host": "findmarketresearch.org", "text": "Various key players contributing to the global DPP IV inhibitors market comprises Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited and Novartis AG.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-07-04T09:36:00+05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.603436, "label": "negative"}, "text": "Diabetes", "relevance": 0.794533, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.392844, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.326126, "label": "negative"}, "text": "National Centre for Biotechnology Information", "relevance": 0.365846, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mitsubishi Tanabe Pharma Corporation", "relevance": 0.363969, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.330883, "label": "negative"}, "text": "nephropathy", "relevance": 0.36144, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease", "RiskFactor"], "name": "Nephropathy", "dbpedia_resource": "http://dbpedia.org/resource/Nephropathy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.360411, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.36004, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb", "relevance": 0.357122, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.344921, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly And Company", "relevance": 0.339369, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc", "relevance": 0.334431, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pacific", "relevance": 0.331017, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.326126, "label": "negative"}, "text": "U.S.", "relevance": 0.323689, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Arisaph Pharmaceuticals, Inc.", "relevance": 0.322798, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sitagliptin", "relevance": 0.320722, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.320134, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "saxagliptin", "relevance": 0.293292, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.3254, "label": "negative"}, "text": "Merck & Co, Inc.", "relevance": 0.284128, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "vildagliptin", "relevance": 0.279896, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.261674, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8%", "relevance": 0.261674, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.261674, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.703462, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "DPP IV inhibitors", "keywords": [{"text": "DPP IV inhibitors"}]}, "sentence": "DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV.", "object": {"text": "a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV", "keywords": [{"text": "hypoglycemic agents"}, {"text": "dipeptidyl peptidase"}, {"text": "enzyme"}, {"text": "class"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "hypoglycemic agents", "keywords": [{"text": "hypoglycemic agents"}]}, "sentence": "DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV.", "object": {"text": "the enzyme named dipeptidyl peptidase IV", "keywords": [{"text": "enzyme"}, {"text": "dipeptidyl peptidase"}]}, "action": {"verb": {"text": "block", "tense": "present"}, "text": "block", "normalized": "block"}}, {"subject": {"text": "the proteins", "keywords": [{"text": "proteins"}]}, "sentence": " Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion.", "object": {"text": "responsible for stimulating the insulin producing cells that slows down gastric secretion", "keywords": [{"text": "insulin producing cells"}, {"text": "gastric secretion"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the proteins", "keywords": [{"text": "proteins"}]}, "sentence": " Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion.", "object": {"text": "the insulin", "keywords": [{"text": "insulin"}]}, "action": {"verb": {"text": "stimulate", "tense": "present"}, "text": "stimulating", "normalized": "stimulate"}}, {"subject": {"text": "Proteins", "keywords": [{"text": "Proteins"}]}, "sentence": " Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body.", "object": {"text": "the release of insulin", "keywords": [{"text": "insulin"}, {"text": "release"}]}, "action": {"verb": {"text": "activate", "tense": "future"}, "text": "can activate", "normalized": "can activate"}}, {"subject": {"text": "Proteins", "keywords": [{"text": "Proteins"}]}, "sentence": " Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body.", "object": {"text": "the blood sugar level", "keywords": [{"text": "blood sugar level"}], "entities": []}, "action": {"verb": {"text": "control", "tense": "future"}, "text": "can control", "normalized": "can control"}}, {"subject": {"text": "DPP IV"}, "sentence": " Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body.", "object": {"text": "inhibited in our body", "keywords": [{"text": "body"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "DPP IV"}, "sentence": " Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body.", "action": {"verb": {"text": "inhibit", "tense": "past"}, "text": "is inhibited", "normalized": "be inhibit"}}, {"subject": {"text": "DPP IV inhibitors", "keywords": [{"text": "DPP IV inhibitors"}]}, "sentence": " Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body.", "object": {"text": "the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body", "keywords": [{"text": "blood glucose level"}, {"text": "glucose levels"}, {"text": "glucagon"}, {"text": "hormone"}], "entities": []}, "action": {"verb": {"text": "restrict", "tense": "present"}, "text": "restrict", "normalized": "restrict"}}, {"subject": {"text": "a hormone", "keywords": [{"text": "hormone"}]}, "sentence": " Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body.", "object": {"text": "blood glucose level", "keywords": [{"text": "blood glucose level"}], "entities": []}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increases", "normalized": "increase"}}, {"subject": {"text": "a hormone", "keywords": [{"text": "hormone"}]}, "sentence": " Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body.", "object": {"text": "the glucose levels in the body", "keywords": [{"text": "glucose levels"}, {"text": "body"}]}, "action": {"verb": {"text": "control", "tense": "present"}, "text": "thereby control", "normalized": "thereby control"}}, {"subject": {"text": "DPP IV inhibitors", "keywords": [{"text": "DPP IV inhibitors"}]}, "sentence": " DPP IV inhibitors are widely utilized as a treatment for type 2 diabetes.", "object": {"text": "as a treatment for type 2 diabetes", "keywords": [{"text": "diabetes"}, {"text": "treatment"}, {"text": "type"}]}, "action": {"verb": {"text": "utilize", "tense": "past"}, "text": "utilized", "normalized": "utilize"}}, {"subject": {"text": "Sitagliptin, vildagliptin, saxagliptin and linagliptin", "keywords": [{"text": "Sitagliptin"}, {"text": "vildagliptin"}, {"text": "saxagliptin"}, {"text": "linagliptin"}], "entities": [{"type": "Drug", "text": "Sitagliptin"}, {"type": "Drug", "text": "vildagliptin"}, {"type": "Drug", "text": "saxagliptin"}]}, "sentence": " Sitagliptin, vildagliptin, saxagliptin and linagliptin are included in the drug class DPP IV.", "object": {"text": "in the drug class DPP IV", "keywords": [{"text": "drug class DPP"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "are included", "normalized": "be include"}}, {"subject": {"text": "nausea and hypersensitivity", "keywords": [{"text": "hypersensitivity"}, {"text": "nausea"}]}, "sentence": " Nasopharyngitis, headache, nausea and hypersensitivity are some of the adverse effects due to the utilization of DPP IV.", "object": {"text": "some of the adverse effects due to the utilization of DPP IV", "keywords": [{"text": "adverse effects"}, {"text": "DPP"}, {"text": "utilization"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Increasing prevalence of type 2 diabetes", "keywords": [{"text": "prevalence"}, {"text": "diabetes"}, {"text": "type"}], "entities": [{"type": "HealthCondition", "text": "Diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Increasing prevalence of type 2 diabetes is a major public health concern worldwide.", "object": {"text": "a major public health concern worldwide", "keywords": [{"text": "public health concern"}], "entities": [{"type": "HealthCondition", "text": "Diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "National Centre for Biotechnology Information", "keywords": [{"text": "Biotechnology Information"}, {"text": "National Centre"}], "entities": [{"type": "Organization", "text": "National Centre for Biotechnology Information"}]}, "sentence": " National Centre for Biotechnology Information in 2011 stated that in the U.S. more than 8% of the total population is diagnosed with diabetes.", "object": {"text": "that in the U.S. more than 8% of the total population is diagnosed with diabetes", "keywords": [{"text": "total population"}, {"text": "diabetes"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "HealthCondition", "text": "Diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"type": "Quantity", "text": "8"}]}, "action": {"verb": {"text": "state", "tense": "past"}, "text": "stated", "normalized": "state"}}, {"subject": {"text": "Biotechnology Information in 2011 stated that in the U.S. more than 8% of the total population", "keywords": [{"text": "Biotechnology Information"}, {"text": "total population"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "8"}]}, "sentence": " National Centre for Biotechnology Information in 2011 stated that in the U.S. more than 8% of the total population is diagnosed with diabetes.", "object": {"text": "diagnosed with diabetes", "keywords": [{"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "Diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Diabetes", "keywords": [{"text": "Diabetes"}], "entities": [{"type": "HealthCondition", "text": "Diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Diabetes is associated with a number of complications that includes cardiovascular disease, nephropathy, retinopathy, and neuropathy.", "object": {"text": "associated with a number of complications that includes cardiovascular disease, nephropathy, retinopathy, and neuropathy", "keywords": [{"text": "cardiovascular disease"}, {"text": "complications"}, {"text": "number"}], "entities": [{"type": "HealthCondition", "text": "nephropathy", "disambiguation": {"subtype": ["Disease", "RiskFactor"], "name": "Nephropathy", "dbpedia_resource": "http://dbpedia.org/resource/Nephropathy"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Diabetes", "keywords": [{"text": "Diabetes"}], "entities": [{"type": "HealthCondition", "text": "Diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Diabetes is associated with a number of complications that includes cardiovascular disease, nephropathy, retinopathy, and neuropathy.", "object": {"text": "with a number of complications that includes cardiovascular disease, nephropathy, retinopathy, and neuropathy", "keywords": [{"text": "cardiovascular disease"}, {"text": "complications"}, {"text": "number"}], "entities": [{"type": "HealthCondition", "text": "nephropathy", "disambiguation": {"subtype": ["Disease", "RiskFactor"], "name": "Nephropathy", "dbpedia_resource": "http://dbpedia.org/resource/Nephropathy"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "is associated", "normalized": "be associate"}}, {"subject": {"text": "cardiovascular disease, nephropathy, retinopathy, and neuropathy", "keywords": [{"text": "cardiovascular disease"}], "entities": [{"type": "HealthCondition", "text": "nephropathy", "disambiguation": {"subtype": ["Disease", "RiskFactor"], "name": "Nephropathy", "dbpedia_resource": "http://dbpedia.org/resource/Nephropathy"}}]}, "sentence": " Diabetes is associated with a number of complications that includes cardiovascular disease, nephropathy, retinopathy, and neuropathy.", "object": {"text": "a number of complications", "keywords": [{"text": "complications"}, {"text": "number"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "the cost for DPP IV inhibitors", "keywords": [{"text": "DPP IV inhibitors"}, {"text": "cost"}]}, "sentence": " However, the cost for DPP IV inhibitors is very high that might hinder the global DPP IV inhibitors market.", "object": {"text": "very high that might hinder the global DPP IV inhibitors market", "keywords": [{"text": "DPP IV inhibitors"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "very high"}, "sentence": " However, the cost for DPP IV inhibitors is very high that might hinder the global DPP IV inhibitors market.", "object": {"text": "the global DPP IV inhibitors market", "keywords": [{"text": "DPP IV inhibitors"}], "entities": []}, "action": {"verb": {"text": "hinder", "tense": "present"}, "text": "might hinder", "normalized": "might hinder"}}, {"subject": {"text": "North America and Europe", "keywords": [{"text": "North America"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Geographically, North America and Europe dominates the global market for DPP IV inhibitors due to high prevalence rate and rising awareness among people about the DPP IV inhibitors.", "object": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "Asia \u2013 Pacific", "keywords": [{"text": "Asia \u2013 Pacific"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " Asia \u2013 Pacific is considered as a fastest growing market due to increasing obese population.", "object": {"text": "considered as a fastest growing market due to increasing obese population", "keywords": [{"text": "fastest growing market"}, {"text": "obese population"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Asia \u2013 Pacific", "keywords": [{"text": "Asia \u2013 Pacific"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " Asia \u2013 Pacific is considered as a fastest growing market due to increasing obese population.", "object": {"text": "as a fastest growing market due to increasing obese population", "keywords": [{"text": "fastest growing market"}, {"text": "obese population"}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "is considered", "normalized": "be consider"}}, {"subject": {"text": "the global DPP IV inhibitors market", "keywords": [{"text": "DPP IV inhibitors"}], "entities": []}, "sentence": " Various key players contributing to the global DPP IV inhibitors market comprises Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited and Novartis AG.", "object": {"text": "Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim GmbH", "keywords": [{"text": "Boehringer Ingelheim GmbH"}, {"text": "Arisaph Pharmaceuticals"}, {"text": "Inc."}], "entities": [{"type": "Company", "text": "Arisaph Pharmaceuticals, Inc."}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprises", "normalized": "comprise"}}], "concepts": [{"text": "Blood sugar", "relevance": 0.947382, "dbpedia_resource": "http://dbpedia.org/resource/Blood_sugar"}, {"text": "Diabetes mellitus", "relevance": 0.942925, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}, {"text": "Insulin", "relevance": 0.777197, "dbpedia_resource": "http://dbpedia.org/resource/Insulin"}, {"text": "Enzyme", "relevance": 0.728022, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme"}, {"text": "Metabolism", "relevance": 0.6261, "dbpedia_resource": "http://dbpedia.org/resource/Metabolism"}, {"text": "Hyperglycemia", "relevance": 0.570964, "dbpedia_resource": "http://dbpedia.org/resource/Hyperglycemia"}, {"text": "Carbohydrate", "relevance": 0.55674, "dbpedia_resource": "http://dbpedia.org/resource/Carbohydrate"}, {"text": "Sugar", "relevance": 0.555322, "dbpedia_resource": "http://dbpedia.org/resource/Sugar"}, {"text": "Glucose tolerance test", "relevance": 0.523582, "dbpedia_resource": "http://dbpedia.org/resource/Glucose_tolerance_test"}, {"text": "Insulinoma", "relevance": 0.514533, "dbpedia_resource": "http://dbpedia.org/resource/Insulinoma"}, {"text": "Diabetes", "relevance": 0.481584, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes"}, {"text": "Hypopituitarism", "relevance": 0.471071, "dbpedia_resource": "http://dbpedia.org/resource/Hypopituitarism"}, {"text": "Cortisol", "relevance": 0.467154, "dbpedia_resource": "http://dbpedia.org/resource/Cortisol"}, {"text": "Saxagliptin", "relevance": 0.451258, "dbpedia_resource": "http://dbpedia.org/resource/Saxagliptin"}, {"text": "Boehringer Ingelheim", "relevance": 0.448915, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Hypoglycemia", "relevance": 0.445786, "dbpedia_resource": "http://dbpedia.org/resource/Hypoglycemia"}, {"text": "Dipeptidyl peptidase-4", "relevance": 0.445635, "dbpedia_resource": "http://dbpedia.org/resource/Dipeptidyl_peptidase-4"}, {"text": "Glucose", "relevance": 0.443039, "dbpedia_resource": "http://dbpedia.org/resource/Glucose"}, {"text": "Bristol-Myers Squibb", "relevance": 0.441057, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Hemoglobin", "relevance": 0.432999, "dbpedia_resource": "http://dbpedia.org/resource/Hemoglobin"}, {"text": "Diabetes mellitus type 2", "relevance": 0.431282, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus_type_2"}, {"text": "Multinational companies", "relevance": 0.413802, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Obesity", "relevance": 0.407447, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Glycogen", "relevance": 0.403277, "dbpedia_resource": "http://dbpedia.org/resource/Glycogen"}], "categories": [{"score": 0.946751, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "employedBy", "sentence": "DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV.", "score": 0.417224, "arguments": [{"text": "inhibitors", "location": [7, 17], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "DPP IV", "location": [0, 6], "entities": [{"type": "Organization", "text": "DPP IV"}]}]}, {"type": "employedBy", "sentence": "Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body.", "score": 0.484584, "arguments": [{"text": "inhibitors", "location": [397, 407], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "DPP IV", "location": [390, 396], "entities": [{"type": "Organization", "text": "DPP IV"}]}]}, {"type": "employedBy", "sentence": "DPP IV inhibitors are widely utilized as a treatment for type 2 diabetes.", "score": 0.423519, "arguments": [{"text": "inhibitors", "location": [548, 558], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "DPP IV", "location": [541, 547], "entities": [{"type": "Organization", "text": "DPP IV"}]}]}, {"type": "timeOf", "sentence": "National Centre for Biotechnology Information in 2011 stated that in the U.S. more than 8% of the total population is diagnosed with diabetes.", "score": 0.860446, "arguments": [{"text": "2011", "location": [964, 968], "entities": [{"type": "Date", "text": "2011"}]}, {"text": "stated", "location": [969, 975], "entities": [{"type": "EventCommunication", "text": "stated"}]}]}, {"type": "hasAttribute", "sentence": "National Centre for Biotechnology Information in 2011 stated that in the U.S. more than 8% of the total population is diagnosed with diabetes.", "score": 0.890164, "arguments": [{"text": "population", "location": [1019, 1029], "entities": [{"type": "Person", "text": "population"}]}, {"text": "diabetes", "location": [1048, 1056], "entities": [{"type": "HealthCondition", "text": "cardiovascular disease"}]}]}, {"type": "memberOf", "sentence": "Thus, the above mentioned factors derives the global DPP IV inhibitors market.", "score": 0.338176, "arguments": [{"text": "inhibitors", "location": [1252, 1262], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "DPP IV", "location": [1245, 1251], "entities": [{"type": "Organization", "text": "DPP IV"}]}]}, {"type": "locatedAt", "sentence": "Asia - Pacific is considered as a fastest growing market due to increasing obese population.", "score": 0.431235, "arguments": [{"text": "Asia", "location": [1561, 1565], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [1568, 1575], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "educatedAt", "sentence": "Various key players contributing to the global DPP IV inhibitors market comprises Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited and Novartis AG.", "score": 0.348773, "arguments": [{"text": "inhibitors", "location": [1708, 1718], "entities": [{"type": "Person", "text": "inhibitors"}]}, {"text": "DPP IV", "location": [1701, 1707], "entities": [{"type": "Organization", "text": "DPP IV"}]}]}, {"type": "hasAttribute", "sentence": "Request to Sample Report @ https://www.persistencemarketresearch.com/samples/5453", "score": 0.448214, "arguments": [{"text": "Sample Report @", "location": [1978, 1993], "entities": [{"type": "Organization", "text": "Sample Report @", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.persistencemarketresearch.com/samples/", "location": [1994, 2044], "entities": [{"type": "Web", "text": "https://www.persistencemarketresearch.com/samples/"}]}]}], "keywords": [{"text": "DPP IV inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.994826}, {"text": "drug class DPP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.747193}, {"text": "global DPP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.728998}, {"text": "inhibitors market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61506}, {"text": "insulin producing cells", "sentiment": {"score": -0.740764, "label": "negative"}, "relevance": 0.534768}, {"text": "dipeptidyl peptidase", "sentiment": {"score": -0.740764, "label": "negative"}, "relevance": 0.534688}, {"text": "blood glucose level", "sentiment": {"score": -0.496431, "label": "negative"}, "relevance": 0.528304}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523678}, {"text": "Mitsubishi Tanabe Pharma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519061}, {"text": "blood sugar level", "sentiment": {"score": -0.818226, "label": "negative"}, "relevance": 0.517668}, {"text": "public health concern", "sentiment": {"score": -0.685616, "label": "negative"}, "relevance": 0.512266}, {"text": "high prevalence rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511553}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511297}, {"text": "fastest growing market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509619}, {"text": "Various key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507776}, {"text": "gastric secretion", "sentiment": {"score": -0.740764, "label": "negative"}, "relevance": 0.47827}, {"text": "glucose levels", "sentiment": {"score": -0.496431, "label": "negative"}, "relevance": 0.474696}, {"text": "hypoglycemic agents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470291}, {"text": "Bristol-Myers Squibb", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468846}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464481}, {"text": "adverse effects", "sentiment": {"score": -0.594797, "label": "negative"}, "relevance": 0.463267}, {"text": "Eli Lilly", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.461922}, {"text": "AstraZeneca Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.46129}, {"text": "obese population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460989}, {"text": "total population", "sentiment": {"score": -0.326126, "label": "negative"}, "relevance": 0.460797}, {"text": "National Centre", "sentiment": {"score": -0.326126, "label": "negative"}, "relevance": 0.460448}, {"text": "Novartis AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459791}, {"text": "cardiovascular disease", "sentiment": {"score": -0.716387, "label": "negative"}, "relevance": 0.459421}, {"text": "Biotechnology Information", "sentiment": {"score": -0.326126, "label": "negative"}, "relevance": 0.458621}, {"text": "Arisaph Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458594}, {"text": "Sample Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457731}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457266}, {"text": "diabetes", "sentiment": {"score": -0.576043, "label": "negative"}, "relevance": 0.456626}, {"text": "Asia \u2013 Pacific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45634}, {"text": "proteins", "sentiment": {"score": -0.779495, "label": "negative"}, "relevance": 0.426347}, {"text": "body", "sentiment": {"score": -0.657329, "label": "negative"}, "relevance": 0.42018}, {"text": "glucagon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419994}, {"text": "enzyme", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419835}, {"text": "type", "sentiment": {"score": -0.685616, "label": "negative"}, "relevance": 0.419492}, {"text": "hypersensitivity", "sentiment": {"score": -0.594797, "label": "negative"}, "relevance": 0.416544}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.415998}, {"text": "nausea", "sentiment": {"score": -0.594797, "label": "negative"}, "relevance": 0.414047}, {"text": "headache", "sentiment": {"score": -0.679096, "label": "negative"}, "relevance": 0.411271}, {"text": "hormone", "sentiment": {"score": -0.496431, "label": "negative"}, "relevance": 0.410949}, {"text": "Merck", "sentiment": {"score": -0.3254, "label": "negative"}, "relevance": 0.410782}, {"text": "utilization", "sentiment": {"score": -0.594797, "label": "negative"}, "relevance": 0.410566}, {"text": "release", "sentiment": {"score": -0.818226, "label": "negative"}, "relevance": 0.410436}, {"text": "treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410123}, {"text": "Sitagliptin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410039}, {"text": "vildagliptin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.410032}]}, "extracted_metadata": {"sha1": "5f7cde8114ded667ac0b8c15f50d7c165d1189e6", "filename": "1541938843964.zip-97fdbe15221c3d1e75821a5374e43ee0.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/dpp-iv-inhibitors-market.asp", "https://www.persistencemarketresearch.com/samples/5453"], "title": "DPP IV Inhibitors to Witness a Pronounce Growth During 2015 \u2013 2021", "forum_title": "Business \u2013 Page 50 \u2013 Find Market Research"}, {"id": "XmlRPvrhRHG_bmTJnc5__woVzA0saPLFjoykryOhKxJ7rQI69uPQ48FodjFVTHvC", "result_metadata": {"score": 25.287497}, "author": "Healthcare Intelligence Markets", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.266582, "label": "negative"}, "text": "Merck", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SK Chemicals", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.448315, "label": "negative"}, "text": "Valeant Pharmaceuticals", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hualan Biological Engineering", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Multinational companies", "relevance": 0.984882, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.959641, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Pharmaceutical industry", "relevance": 0.909498, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Medicine", "relevance": 0.880179, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Biotechnology companies", "relevance": 0.660818, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Companies listed on the New York Stock Exchange", "relevance": 0.632383, "dbpedia_resource": "http://dbpedia.org/resource/Companies_listed_on_the_New_York_Stock_Exchange"}], "categories": [{"score": 0.667185, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.555488, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Travel Vaccines Market", "sentiment": {"score": -0.386019, "label": "negative"}, "relevance": 0.903126}, {"text": "Hualan Biological Engineering", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.759999}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.687557}, {"text": "SK Chemicals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.645953}, {"text": "Valeant Pharmaceuticals", "sentiment": {"score": -0.448315, "label": "negative"}, "relevance": 0.617455}, {"text": "Sanofi", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481562}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451491}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.450089}, {"text": "GlaxoSmithKline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.446694}, {"text": "Merck", "sentiment": {"score": -0.266582, "label": "negative"}, "relevance": 0.42372}, {"text": "Roche", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422338}, {"text": "Abbott", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419711}, {"text": "Forecast", "sentiment": {"score": -0.386019, "label": "negative"}, "relevance": 0.410242}, {"text": "Vendors", "sentiment": {"score": -0.386019, "label": "negative"}, "relevance": 0.392102}]}, "crawl_date": "2018-11-10T15:10:11Z", "url": "https://www.openpr.com/news/1359970/Report-Covers-Top-Vendors-of-Travel-Vaccines-Market-2018-Forecast-to-2025-Merck-Pfizer-Abbott-Sanofi-Takeda-Pharmaceutical-GlaxoSmithKline-SK-Chemicals-AstraZeneca-Roche-Valeant-Pharmaceuticals-Hualan-Biological-Engineering.html", "host": "openpr.com", "text": "Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-10T14:50:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Healthcare Intelligence Markets PR Agency", "relevance": 0.367085, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.681847, "label": "negative"}, "text": "South America", "relevance": 0.228518, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IT industries", "relevance": 0.208008, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Serum Institute of IndiaAfter", "relevance": 0.203465, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.681847, "label": "negative"}, "text": "Africa", "relevance": 0.202478, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.183163, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.181955, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.427234, "label": "negative"}, "text": "Valeant Pharmaceuticals", "relevance": 0.180429, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.178971, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.176876, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.176462, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.176381, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hualan Biological Engineering", "relevance": 0.170347, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SK Chemicals", "relevance": 0.160774, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche", "relevance": 0.157053, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott", "relevance": 0.156729, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.156729, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.395091, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "HealthCare Intelligence Markets Travel vaccine", "keywords": [{"text": "Markets Travel vaccine"}]}, "sentence": "Press release from: Healthcare Intelligence Markets PR Agency: HealthCare Intelligence Markets Travel vaccine is the first step towards smart and healthy travel.", "object": {"text": "the first step towards smart and healthy travel", "keywords": [{"text": "healthy travel"}, {"text": "step"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "travel vaccine shots", "keywords": [{"text": "travel vaccine shots"}]}, "sentence": " Nowadays along with the passport, travel vaccine shots are a must have before a person embarks on international travel.", "object": {"text": "a must have"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "a person", "keywords": [{"text": "person"}]}, "sentence": " Nowadays along with the passport, travel vaccine shots are a must have before a person embarks on international travel.", "object": {"text": "on international travel", "keywords": [{"text": "international travel"}]}, "action": {"verb": {"text": "embark", "tense": "future"}, "text": "embarks", "normalized": "embark"}}, {"subject": {"text": "Travel vaccines", "keywords": [{"text": "Travel vaccines"}]}, "sentence": " Travel vaccines provide immunisation by reducing the risk of getting sick while travelling abroad.", "object": {"text": "immunisation", "keywords": [{"text": "immunisation"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "sick"}, "sentence": " Travel vaccines provide immunisation by reducing the risk of getting sick while travelling abroad.", "action": {"verb": {"text": "get", "tense": "future"}, "text": "getting", "normalized": "get"}}, {"subject": {"text": "Tourists traveling to South America and central countries of Africa", "keywords": [{"text": "South America"}, {"text": "central countries"}, {"text": "Tourists"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Tourists traveling to South America and central countries of Africa should get vaccinated for Yellow Fever.", "object": {"text": "vaccinated for Yellow Fever", "keywords": [{"text": "Yellow Fever"}]}, "action": {"verb": {"text": "get", "tense": "future"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "different countries", "keywords": [{"text": "different countries"}]}, "sentence": " Likewise, different countries have different diseases existing or prevailing within the region.", "object": {"text": "different diseases existing or prevailing within the region", "keywords": [{"text": "different diseases"}, {"text": "region"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "different countries", "keywords": [{"text": "different countries"}]}, "sentence": " Likewise, different countries have different diseases existing or prevailing within the region.", "action": {"verb": {"text": "prevail", "tense": "present"}, "text": "prevailing", "normalized": "prevail"}}, {"subject": {"text": "Travel vaccines", "keywords": [{"text": "Travel vaccines"}]}, "sentence": " Travel vaccines are recommended by health organisations especially to tourists who travel to developing or endemic countries.", "object": {"text": "recommended by health organisations especially to tourists who travel to developing or endemic countries", "keywords": [{"text": "endemic countries"}, {"text": "health organisations"}, {"text": "tourists"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by health organisations especially to tourists who travel to developing or endemic countries", "keywords": [{"text": "endemic countries"}, {"text": "health organisations"}, {"text": "tourists"}]}, "sentence": " Travel vaccines are recommended by health organisations especially to tourists who travel to developing or endemic countries.", "object": {"text": "Travel vaccines", "keywords": [{"text": "Travel vaccines"}]}, "action": {"verb": {"text": "recommend", "tense": "past"}, "text": "are recommended", "normalized": "be recommend"}}, {"subject": {"text": "tourists", "keywords": [{"text": "tourists"}]}, "sentence": " Travel vaccines are recommended by health organisations especially to tourists who travel to developing or endemic countries.", "object": {"text": "to developing or endemic countries", "keywords": [{"text": "endemic countries"}]}, "action": {"verb": {"text": "travel", "tense": "present"}, "text": "travel", "normalized": "travel"}}, {"subject": {"text": "Sample Copy", "keywords": [{"text": "Sample Copy"}]}, "sentence": " Get Sample Copy of this Report@: www.healthcareintelligencemarkets.com/request_sample.php?...", "object": {"text": "of this Report@: www.healthcareintelligencemarkets.com/request_sample.php?", "keywords": [{"text": "Report www.healthcareintelligencemarkets.com/request_sample.php"}]}, "action": {"verb": {"text": "Get", "tense": "present"}, "text": "Get", "normalized": "Get"}}, {"subject": {"text": "Travel Vaccines market research", "keywords": [{"text": "Travel Vaccines market"}]}, "sentence": " Travel Vaccines market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information.", "object": {"text": "an intelligence report", "keywords": [{"text": "intelligence report"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The data", "keywords": [{"text": "data"}]}, "sentence": " The data which has been looked upon is done considering both, the existing top players and the upcoming competitors.", "object": {"text": "done considering both"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Business strategies of the key players and the new entering market industries", "keywords": [{"text": "new entering market"}, {"text": "Business strategies"}, {"text": "key players"}, {"text": "industries"}]}, "sentence": " Business strategies of the key players and the new entering market industries are studied in detail.", "object": {"text": "studied in detail"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "SWOT analysis, revenue share and contact information", "keywords": [{"text": "SWOT analysis"}, {"text": "revenue share"}, {"text": "contact information"}]}, "sentence": " Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market.", "object": {"text": "shared"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "SWOT analysis, revenue share and contact information", "keywords": [{"text": "SWOT analysis"}, {"text": "revenue share"}, {"text": "contact information"}]}, "sentence": " Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market.", "action": {"verb": {"text": "share", "tense": "past"}, "text": "are shared", "normalized": "be share"}}, {"subject": {"text": "analysis.Top Companies", "keywords": [{"text": "analysis.Top Companies"}]}, "sentence": " Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market.", "action": {"verb": {"text": "Profiled", "tense": "past"}, "text": "Profiled", "normalized": "Profiled"}}, {"subject": {"text": "Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market", "keywords": [{"text": "Hualan Biological Engineering"}, {"text": "Takeda Pharmaceutical"}, {"text": "Serum Institute"}, {"text": "SK Chemicals"}], "entities": [{"type": "Company", "text": "Merck"}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Abbott"}, {"type": "Company", "text": "Sanofi", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "SK Chemicals"}, {"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Roche"}, {"type": "Company", "text": "Valeant Pharmaceuticals", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"type": "Company", "text": "Hualan Biological Engineering"}, {"type": "Organization", "text": "Serum Institute of IndiaAfter"}]}, "sentence": " Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market.", "object": {"text": "analysis.Top Companies Profiled in this Report", "keywords": [{"text": "analysis.Top Companies"}, {"text": "Report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter", "keywords": [{"text": "Hualan Biological Engineering"}, {"text": "Serum Institute"}, {"text": "Valeant Pharmaceuticals"}, {"text": "Roche"}], "entities": [{"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Roche"}, {"type": "Company", "text": "Valeant Pharmaceuticals", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"type": "Company", "text": "Hualan Biological Engineering"}, {"type": "Organization", "text": "Serum Institute of IndiaAfter"}]}, "sentence": " Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market.", "object": {"text": "key companies", "keywords": [{"text": "key companies"}]}, "action": {"verb": {"text": "study", "tense": "present"}, "text": "studying", "normalized": "study"}}, {"subject": {"text": "Possible mergers and acquisitions among the startups and key organizations", "keywords": [{"text": "Possible mergers"}, {"text": "startups"}, {"text": "key organizations"}, {"text": "acquisitions"}]}, "sentence": " Possible mergers and acquisitions among the startups and key organizations are identified by the report's authors in the study.", "object": {"text": "identified by the report's authors in the study", "keywords": [{"text": "report"}, {"text": "authors"}, {"text": "study"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by the report's authors in the study", "keywords": [{"text": "report"}, {"text": "authors"}, {"text": "study"}]}, "sentence": " Possible mergers and acquisitions among the startups and key organizations are identified by the report's authors in the study.", "object": {"text": "Possible mergers and acquisitions among the startups and key organizations", "keywords": [{"text": "Possible mergers"}, {"text": "startups"}, {"text": "key organizations"}, {"text": "acquisitions"}]}, "action": {"verb": {"text": "identify", "tense": "past"}, "text": "are identified", "normalized": "be identify"}}, {"subject": {"text": "leading companies", "keywords": [{"text": "leading companies"}]}, "sentence": " As leading companies take efforts to maintain their dominance in the global Travel Vaccines market, the right way to do so is by adopting new technologies and strategies.", "object": {"text": "efforts to maintain their dominance in the global Travel Vaccines market", "keywords": [{"text": "global Travel Vaccines"}, {"text": "dominance"}, {"text": "efforts"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "take", "normalized": "take"}}, {"subject": {"text": "leading companies", "keywords": [{"text": "leading companies"}]}, "sentence": " As leading companies take efforts to maintain their dominance in the global Travel Vaccines market, the right way to do so is by adopting new technologies and strategies.", "object": {"text": "their dominance", "keywords": [{"text": "dominance"}]}, "action": {"verb": {"text": "maintain", "tense": "future"}, "text": "to maintain", "normalized": "to maintain"}}, {"subject": {"text": "the right way", "keywords": [{"text": "right way"}]}, "sentence": " As leading companies take efforts to maintain their dominance in the global Travel Vaccines market, the right way to do so is by adopting new technologies and strategies.", "object": {"text": "by adopting new technologies and strategies", "keywords": [{"text": "new technologies"}, {"text": "strategies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report highlights major technological developments and changing trends adopted by key companies over a period of time.", "object": {"text": "major technological developments and changing trends adopted by key companies", "keywords": [{"text": "major technological developments"}, {"text": "key companies"}, {"text": "trends"}]}, "action": {"verb": {"text": "highlight", "tense": "present"}, "text": "highlights", "normalized": "highlight"}}, {"subject": {"text": "trends adopted by key companies", "keywords": [{"text": "key companies"}, {"text": "trends"}]}, "sentence": " The report highlights major technological developments and changing trends adopted by key companies over a period of time.", "action": {"verb": {"text": "change", "tense": "present"}, "text": "changing", "normalized": "change"}}, {"subject": {"text": "by key companies", "keywords": [{"text": "key companies"}]}, "sentence": " The report highlights major technological developments and changing trends adopted by key companies over a period of time.", "object": {"text": "changing trends", "keywords": [{"text": "trends"}]}, "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "adopted", "normalized": "adopt"}}, {"subject": {"text": "For a stronger and more stable business outlook, the report on the global market", "keywords": [{"text": "stable business outlook"}, {"text": "global market"}, {"text": "report"}], "entities": []}, "sentence": " For a stronger and more stable business outlook, the report on the global market carries key projections that can be practically studied.Get Reasonable Discount on this Premium Report @: www.healthcareintelligencemarkets.com/ask_for_discount.ph...", "object": {"text": "key projections that can be practically studied.Get Reasonable Discount on this Premium Report @: www.healthcareintelligencemarkets.com/ask_for_discount.ph", "keywords": [{"text": "Reasonable Discount"}, {"text": "key projections"}, {"text": "Premium Report"}, {"text": "www.healthcareintelligencemarkets.com/ask_for_discount.ph"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carries", "normalized": "carry"}}, {"subject": {"text": "key projections", "keywords": [{"text": "key projections"}]}, "sentence": " For a stronger and more stable business outlook, the report on the global market carries key projections that can be practically studied.Get Reasonable Discount on this Premium Report @: www.healthcareintelligencemarkets.com/ask_for_discount.ph...", "object": {"text": "practically studied.Get Reasonable Discount", "keywords": [{"text": "Reasonable Discount"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Reasonable Discount", "keywords": [{"text": "Reasonable Discount"}]}, "sentence": " For a stronger and more stable business outlook, the report on the global market carries key projections that can be practically studied.Get Reasonable Discount on this Premium Report @: www.healthcareintelligencemarkets.com/ask_for_discount.ph...", "action": {"verb": {"text": "studied.Get", "tense": "future"}, "text": "studied.Get", "normalized": "studied.Get"}}, {"subject": {"text": "Travel Vaccines market", "keywords": [{"text": "Travel Vaccines"}, {"text": "market"}], "entities": []}, "sentence": " Travel Vaccines market is segmented on the basis of various parameters.", "object": {"text": "segmented on the basis of various parameters", "keywords": [{"text": "various parameters"}, {"text": "basis"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The factors", "keywords": [{"text": "factors"}]}, "sentence": " The factors which are impacting the market\u00e2s growth are studied in detail.", "object": {"text": "impacting the market\u00e2s growth", "keywords": [{"text": "market\u00e2s growth"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The factors", "keywords": [{"text": "factors"}]}, "sentence": " The factors which are impacting the market\u00e2s growth are studied in detail.", "object": {"text": "the market\u00e2s growth", "keywords": [{"text": "market\u00e2s growth"}]}, "action": {"verb": {"text": "impact", "tense": "present"}, "text": "are impacting", "normalized": "be impact"}}, {"subject": {"text": "the market\u00e2s growth", "keywords": [{"text": "market\u00e2s growth"}]}, "sentence": " The factors which are impacting the market\u00e2s growth are studied in detail.", "object": {"text": "studied in detail"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report also presents a overall weaknesses which companies operating in the market must avoid in order to enjoy sustainable growth through the course of the forecast period.", "object": {"text": "a overall weaknesses which companies operating in the market must avoid in order to enjoy sustainable growth through the course of the forecast period", "keywords": [{"text": "overall weaknesses"}, {"text": "forecast period"}, {"text": "sustainable growth"}, {"text": "companies"}], "entities": []}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "a overall weaknesses which companies operating in the market", "keywords": [{"text": "overall weaknesses"}, {"text": "companies"}, {"text": "market"}], "entities": []}, "sentence": " The report also presents a overall weaknesses which companies operating in the market must avoid in order to enjoy sustainable growth through the course of the forecast period.", "action": {"verb": {"text": "avoid", "tense": "future"}, "text": "must avoid", "normalized": "must avoid"}}, {"subject": {"text": "companies operating in the market", "keywords": [{"text": "companies"}, {"text": "market"}], "entities": []}, "sentence": " The report also presents a overall weaknesses which companies operating in the market must avoid in order to enjoy sustainable growth through the course of the forecast period.", "object": {"text": "sustainable growth", "keywords": [{"text": "sustainable growth"}]}, "action": {"verb": {"text": "enjoy", "tense": "future"}, "text": "to enjoy", "normalized": "to enjoy"}}, {"subject": {"text": "profiles of some of the leading players operating and encouraging in the growth of the global market", "keywords": [{"text": "global market"}, {"text": "profiles"}, {"text": "players"}, {"text": "growth"}], "entities": []}, "sentence": " Besides this, profiles of some of the leading players operating and encouraging in the growth of the global market are included in the study.", "object": {"text": "in the study", "keywords": [{"text": "study"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "are included", "normalized": "be include"}}, {"subject": {"text": "markets weaknesses and strengths", "keywords": [{"text": "markets weaknesses"}, {"text": "strengths"}]}, "sentence": " Additionally, using SWOT analysis, markets weaknesses and strengths are analyzed.", "object": {"text": "analyzed"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It also helps the report provide insights into the opportunities and threats that these companies may face during the forecast period.", "object": {"text": "the report provide insights into the opportunities and threats that these companies may face during the forecast period", "keywords": [{"text": "forecast period"}, {"text": "threats"}, {"text": "insights"}, {"text": "report"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "these companies", "keywords": [{"text": "companies"}]}, "sentence": " It also helps the report provide insights into the opportunities and threats that these companies may face during the forecast period.", "object": {"text": "the opportunities and threats", "keywords": [{"text": "threats"}, {"text": "opportunities"}]}, "action": {"verb": {"text": "face", "tense": "future"}, "text": "may face", "normalized": "may face"}}, {"subject": {"text": "you"}, "sentence": " If you have any special requirements, please let us know and we will offer you the report as you want.About us: HealthCare Intelligence Markets HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "object": {"text": "any special requirements", "keywords": [{"text": "special requirements"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "you"}, "sentence": " If you have any special requirements, please let us know and we will offer you the report as you want.About us: HealthCare Intelligence Markets HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "object": {"text": "us"}, "action": {"verb": {"text": "want.About", "tense": "present"}, "text": "want.About", "normalized": "want.About"}}, {"subject": {"text": "HealthCare Intelligence Markets HealthCare Intelligence Markets Reports", "keywords": [{"text": "Intelligence Markets"}, {"text": "HealthCare Intelligence Markets"}, {"text": "Reports"}]}, "sentence": " If you have any special requirements, please let us know and we will offer you the report as you want.About us: HealthCare Intelligence Markets HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "object": {"text": "market intelligence & consulting services", "keywords": [{"text": "market intelligence"}, {"text": "services"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "services", "keywords": [{"text": "services"}]}, "sentence": " If you have any special requirements, please let us know and we will offer you the report as you want.About us: HealthCare Intelligence Markets HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "object": {"text": "to a global clientele spread over 145 countries", "keywords": [{"text": "global clientele"}, {"text": "countries"}]}, "action": {"verb": {"text": "consult", "tense": "present"}, "text": "consulting", "normalized": "consult"}}, {"subject": {"text": "a global clientele", "keywords": [{"text": "global clientele"}]}, "sentence": " If you have any special requirements, please let us know and we will offer you the report as you want.About us: HealthCare Intelligence Markets HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "action": {"verb": {"text": "spread", "tense": "past"}, "text": "spread", "normalized": "spread"}}, {"subject": {"text": "we"}, "sentence": " Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence.", "object": {"text": "businesses to meet the challenges of an ever evolving market with unbridled confidence", "keywords": [{"text": "unbridled confidence"}, {"text": "challenges"}, {"text": "businesses"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "market", "keywords": [{"text": "market"}]}, "sentence": " Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence.", "action": {"verb": {"text": "evolve", "tense": "present"}, "text": "evolving", "normalized": "evolve"}}, {"subject": {"text": "We"}, "sentence": " We craft customized and syndicated market research reports that help market players to build game changing strategies.", "object": {"text": "customized and syndicated market research reports", "keywords": [{"text": "market research reports"}]}, "action": {"verb": {"text": "craft", "tense": "present"}, "text": "craft", "normalized": "craft"}}], "concepts": [{"text": "Marketing", "relevance": 0.961617, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Vaccination", "relevance": 0.795986, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination"}, {"text": "Bankruptcy in the United States", "relevance": 0.5589, "dbpedia_resource": "http://dbpedia.org/resource/Bankruptcy_in_the_United_States"}, {"text": "Market research", "relevance": 0.55702, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Strategic management", "relevance": 0.542943, "dbpedia_resource": "http://dbpedia.org/resource/Strategic_management"}, {"text": "Vaccine", "relevance": 0.505065, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "Business intelligence", "relevance": 0.498166, "dbpedia_resource": "http://dbpedia.org/resource/Business_intelligence"}, {"text": "Immune system", "relevance": 0.488187, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "United States bankruptcy law", "relevance": 0.46351, "dbpedia_resource": "http://dbpedia.org/resource/United_States_bankruptcy_law"}, {"text": "Abbas Kiarostami", "relevance": 0.442216, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}, {"text": "Ribavirin", "relevance": 0.441847, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}], "categories": [{"score": 0.569894, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.522932, "label": "/finance/financial news"}, {"score": 0.407766, "label": "/education/studying business"}], "relations": [{"type": "locatedAt", "sentence": "Tourists traveling to South America and central countries of Africa should get vaccinated for Yellow Fever.", "score": 0.346374, "arguments": [{"text": "countries", "location": [429, 438], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Africa", "location": [442, 448], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them.", "score": 0.699581, "arguments": [{"text": "clients", "location": [4450, 4457], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [4446, 4449], "entities": [{"type": "Organization", "text": "B2B"}]}]}, {"type": "employedBy", "sentence": "We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "score": 0.720447, "arguments": [{"text": "clients", "location": [4561, 4568], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [4557, 4560], "entities": [{"type": "Organization", "text": "B2B"}]}]}, {"type": "participantIn", "sentence": "We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "score": 0.914205, "arguments": [{"text": "them", "location": [4597, 4601], "entities": [{"type": "Person", "text": "their"}]}, {"text": "sessions", "location": [4602, 4610], "entities": [{"type": "EventMeeting", "text": "sessions"}]}]}, {"type": "participantIn", "sentence": "We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "score": 0.86777, "arguments": [{"text": "analysts", "location": [4629, 4637], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "sessions", "location": [4602, 4610], "entities": [{"type": "EventMeeting", "text": "sessions"}]}]}, {"type": "agentOf", "sentence": "Travel vaccines are recommended by health organisations especially to tourists who travel to developing or endemic countries.", "score": 0.613613, "arguments": [{"text": "Travel", "location": [585, 591], "entities": [{"type": "Organization", "text": "HealthCare Intelligence Markets Travel"}]}, {"text": "recommended", "location": [605, 616], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Get Reasonable Discount on this Premium Report @: www.healthcareintelligencemarkets.com/ask_for_discount.ph... Travel Vaccines market is segmented on the basis of various parameters.", "score": 0.609107, "arguments": [{"text": "Travel Vaccines", "location": [2279, 2294], "entities": [{"type": "Organization", "text": "HealthCare Intelligence Markets Travel"}]}, {"text": "Report", "location": [2208, 2214], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.", "score": 0.377481, "arguments": [{"text": "SWOT", "location": [1176, 1180], "entities": [{"type": "Organization", "text": "SWOT"}]}, {"text": "explained", "location": [1166, 1175], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Top Companies Profiled in this Report includes, Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering, Serum Institute of IndiaAfter studying key companies, the report focuses on the startups contributing towards the growth of the market.", "score": 0.923685, "arguments": [{"text": "Companies", "location": [1268, 1277], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "Report", "location": [1295, 1301], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOf", "sentence": "Table of Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions Chapter 6 Global Production, Revenue (Value), Price Trend by Type Chapter 7 Global Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Global Travel Vaccines Market ForecastFor More Information: www.healthcareintelligencemarkets.com/enquiry_before_buyi... If you have any special requirements, please let us know and we will offer you the report as you want.", "score": 0.739975, "arguments": [{"text": "Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition", "location": [2971, 3148], "entities": [{"type": "Organization", "text": "Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition"}]}, {"text": "Manufacturers Chapter 4 Global Production", "location": [3152, 3193], "entities": [{"type": "Organization", "text": "Manufacturers Chapter 4 Global Production"}]}]}, {"type": "locatedAt", "sentence": "Table of Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions Chapter 6 Global Production, Revenue (Value), Price Trend by Type Chapter 7 Global Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Global Travel Vaccines Market ForecastFor More Information: www.healthcareintelligencemarkets.com/enquiry_before_buyi... If you have any special requirements, please let us know and we will offer you the report as you want.", "score": 0.617186, "arguments": [{"text": "Consumption", "location": [3259, 3270], "entities": [{"type": "GeopoliticalEntity", "text": "Consumption"}]}, {"text": "Export", "location": [3272, 3278], "entities": [{"type": "GeopoliticalEntity", "text": "Export"}]}]}, {"type": "locatedAt", "sentence": "Table of Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions Chapter 6 Global Production, Revenue (Value), Price Trend by Type Chapter 7 Global Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Global Travel Vaccines Market ForecastFor More Information: www.healthcareintelligencemarkets.com/enquiry_before_buyi... If you have any special requirements, please let us know and we will offer you the report as you want.", "score": 0.605572, "arguments": [{"text": "Export", "location": [3272, 3278], "entities": [{"type": "GeopoliticalEntity", "text": "Export"}]}, {"text": "Import", "location": [3280, 3286], "entities": [{"type": "GeopoliticalEntity", "text": "Import"}]}]}, {"type": "employedBy", "sentence": "Table of Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions Chapter 6 Global Production, Revenue (Value), Price Trend by Type Chapter 7 Global Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Global Travel Vaccines Market ForecastFor More Information: www.healthcareintelligencemarkets.com/enquiry_before_buyi... If you have any special requirements, please let us know and we will offer you the report as you want.", "score": 0.672221, "arguments": [{"text": "Price Trend", "location": [3344, 3355], "entities": [{"type": "Person", "text": "Price Trend"}]}, {"text": "Type Chapter 7 Global Market Analysis", "location": [3359, 3396], "entities": [{"type": "Organization", "text": "Type Chapter 7 Global Market Analysis"}]}]}, {"type": "partOf", "sentence": "Table of Contents Global Travel Vaccines Market Research Report Chapter 1 Travel Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions Chapter 6 Global Production, Revenue (Value), Price Trend by Type Chapter 7 Global Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Global Travel Vaccines Market ForecastFor More Information: www.healthcareintelligencemarkets.com/enquiry_before_buyi... If you have any special requirements, please let us know and we will offer you the report as you want.", "score": 0.509037, "arguments": [{"text": "Marketing Strategy Analysis", "location": [3529, 3556], "entities": [{"type": "Organization", "text": "Marketing Strategy Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Sourcing Strategy and Downstream Buyers Chapter", "location": [3478, 3525], "entities": [{"type": "Organization", "text": "Sourcing Strategy and Downstream Buyers Chapter"}]}]}], "keywords": [{"text": "travel vaccines market", "sentiment": {"score": 0.721477, "label": "positive"}, "relevance": 0.915404}, {"text": "healthcare intelligence markets", "sentiment": {"score": 0.624842, "label": "positive"}, "relevance": 0.720483}, {"text": "global travel vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.674152}, {"text": "vaccines market research", "sentiment": {"score": 0.721477, "label": "positive"}, "relevance": 0.638436}, {"text": "global market", "sentiment": {"score": 0.487889, "label": "positive"}, "relevance": 0.561207}, {"text": "Vaccines Market Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556439}, {"text": "Vaccines Market ForecastFor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554107}, {"text": "Intelligence Markets Travel", "sentiment": {"score": 0.624842, "label": "positive"}, "relevance": 0.551785}, {"text": "Market Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543819}, {"text": "Global Market Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542892}, {"text": "Global Market Competition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536667}, {"text": "travel vaccine shots", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533597}, {"text": "new entering market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529481}, {"text": "report analysis.Top Companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529209}, {"text": "Contents Global Travel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528092}, {"text": "Intelligence Markets PR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525146}, {"text": "help market players", "sentiment": {"score": 0.555621, "label": "positive"}, "relevance": 0.517762}, {"text": "future market prospects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517434}, {"text": "SWOT analysis", "sentiment": {"score": 0.359333, "label": "positive"}, "relevance": 0.514955}, {"text": "Market Effect Factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511744}, {"text": "Global Economic Impact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507995}, {"text": "Intelligence Markets HealthCare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50727}, {"text": "Downstream Buyers Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504575}, {"text": "Intelligence Markets Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503654}, {"text": "key companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503433}, {"text": "Hualan Biological Engineering", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.497468}, {"text": "forecast period", "sentiment": {"score": -0.788284, "label": "negative"}, "relevance": 0.496514}, {"text": "Marketing Strategy Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496277}, {"text": "Manufacturing Cost Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496216}, {"text": "major technological developments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492844}, {"text": "Global Production", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.49036}, {"text": "stable business outlook", "sentiment": {"score": 0.733541, "label": "positive"}, "relevance": 0.48945}, {"text": "intelligence report", "sentiment": {"score": 0.721477, "label": "positive"}, "relevance": 0.488384}, {"text": "game changing strategies", "sentiment": {"score": 0.555621, "label": "positive"}, "relevance": 0.486561}, {"text": "market intelligence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484748}, {"text": "international travel", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483168}, {"text": "healthy travel", "sentiment": {"score": 0.624842, "label": "positive"}, "relevance": 0.480257}, {"text": "Analysis Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473258}, {"text": "Premium Report", "sentiment": {"score": 0.573456, "label": "positive"}, "relevance": 0.471021}, {"text": "Region Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467026}, {"text": "Industry Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466924}, {"text": "Manufacturers Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466851}, {"text": "Global Supply", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466705}, {"text": "Type Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466434}, {"text": "Application Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466362}, {"text": "Distributors/Traders Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466133}, {"text": "global clientele", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464652}, {"text": "Regions Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463728}, {"text": "key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463359}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459755}]}, "extracted_metadata": {"sha1": "532a0a3592b8a3d464962968a0eb83f2c2b6048e", "filename": "1541862611367.zip-e0d9b6dff079765a9dad7ca85b704573.xml", "file_type": "json"}, "external_links": ["https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=5488", "https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=5488", "https://www.healthcareintelligencemarkets.com/request_sample.php?id=5488"], "title": "Report Covers Top Vendors of Travel Vaccines Market 2018 Forecast to 2025: Merck, Pfizer, Abbott, Sanofi, Takeda Pharmaceutical, GlaxoSmithKline, SK Chemicals, AstraZeneca, Roche, Valeant Pharmaceuticals, Hualan Biological Engineering", "forum_title": "openPR.com - Newsfeed"}, {"id": "giB3b2DG32x9NbUeC17KJ9YmGBpsSbVfNcM8Y23JYjuAkZl94uqejbj0DnFxfVWC", "result_metadata": {"score": 24.409876}, "author": "Ram", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hyperuricemia Market", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Years in the future", "relevance": 0.8526, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}], "categories": [{"score": 0.542624, "label": "/news"}, {"score": 0.520259, "label": "/finance/financial news"}, {"score": 0.437334, "label": "/finance/investing/day trading"}], "relations": [], "keywords": [{"text": "Hyperuricemia Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.930787}, {"text": "Research Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.677209}, {"text": "Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564265}]}, "crawl_date": "2018-11-11T06:24:06Z", "url": "https://www.findmarketresearch.org/2017/09/research-report-and-overview-on-hyperuricemia-market-2016-2024/", "host": "findmarketresearch.org", "text": "Currently ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals is widely prescribed for treating hyperuricemia.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2017-09-14T06:59:00+05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.562797, "label": "negative"}, "text": "obesity", "relevance": 0.739807, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 3, "sentiment": {"score": -0.667951, "label": "negative"}, "text": "U.S.", "relevance": 0.47567, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals", "relevance": 0.37598, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.565874, "label": "negative"}, "text": "BMC Cardiovascular Disorders", "relevance": 0.370165, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": -0.537074, "label": "negative"}, "text": "Arthritis Care & Research", "relevance": 0.368252, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "World Health Organization", "relevance": 0.359938, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": -0.358029, "label": "negative"}, "text": "diabetes", "relevance": 0.353897, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ardea Biosciences, Inc.", "relevance": 0.343636, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.656979, "label": "negative"}, "text": "Hebei Medical University", "relevance": 0.343497, "type": "Organization", "disambiguation": {"subtype": ["University"], "name": "Hebei Medical University", "dbpedia_resource": "http://dbpedia.org/resource/Hebei_Medical_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "dyslipidemia", "relevance": 0.342974, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Dyslipidemia", "dbpedia_resource": "http://dbpedia.org/resource/Dyslipidemia"}}, {"count": 1, "sentiment": {"score": -0.498936, "label": "negative"}, "text": "Alcoholism", "relevance": 0.342111, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Alcoholism", "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Journal of", "relevance": 0.34005, "type": "PrintMedia", "disambiguation": {"subtype": [], "name": "Journal of Applied Social Psychology", "dbpedia_resource": "http://dbpedia.org/resource/Journal_of_Applied_Social_Psychology"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TWi Biotechnology, Inc.", "relevance": 0.330007, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.498936, "label": "negative"}, "text": "National Institute", "relevance": 0.32065, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America College of Cardiology", "relevance": 0.320648, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.317762, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.498562, "label": "negative"}, "text": "metabolic syndrome", "relevance": 0.313123, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Metabolic syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.299475, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.2973, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.656979, "label": "negative"}, "text": "prednisone", "relevance": 0.289261, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.656979, "label": "negative"}, "text": "allopurinol", "relevance": 0.279387, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.259282, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "15 years", "relevance": 0.259282, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6 liters", "relevance": 0.259282, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "70%", "relevance": 0.259282, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.259282, "type": "TwitterHandle"}], "sentiment": {"document": {"score": -0.149834, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "the level of uric acid in the blood", "keywords": [{"text": "uric acid"}, {"text": "level"}, {"text": "blood"}]}, "sentence": " Hyperuricemia is condition in which the level of uric acid in the blood increases to abnormally high levels.", "object": {"text": "to abnormally high levels", "keywords": [{"text": "abnormally high levels"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increases", "normalized": "increase"}}, {"subject": {"text": "Various factors", "keywords": [{"text": "Various factors"}]}, "sentence": " Various factors are responsible for hyperuricemia, which include insulin resistance, renal failure, obesity and alcohol consumption which is found to be the most prevalent factor.", "object": {"text": "responsible for hyperuricemia", "keywords": [{"text": "hyperuricemia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "insulin resistance", "keywords": [{"text": "insulin resistance"}]}, "sentence": " Various factors are responsible for hyperuricemia, which include insulin resistance, renal failure, obesity and alcohol consumption which is found to be the most prevalent factor.", "object": {"text": "hyperuricemia", "keywords": [{"text": "hyperuricemia"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "renal failure, obesity and alcohol consumption", "keywords": [{"text": "renal failure"}, {"text": "alcohol consumption"}, {"text": "obesity"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " Various factors are responsible for hyperuricemia, which include insulin resistance, renal failure, obesity and alcohol consumption which is found to be the most prevalent factor.", "object": {"text": "found"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "renal failure, obesity and alcohol consumption", "keywords": [{"text": "renal failure"}, {"text": "alcohol consumption"}, {"text": "obesity"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " Various factors are responsible for hyperuricemia, which include insulin resistance, renal failure, obesity and alcohol consumption which is found to be the most prevalent factor.", "object": {"text": "the most prevalent factor", "keywords": [{"text": "prevalent factor"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is found to be", "normalized": "be find to be"}}, {"subject": {"text": "Scientists", "keywords": [{"text": "Scientists"}]}, "sentence": " Scientists are still trying to confirm obesity as a predisposing factor for hyperuricemia,", "object": {"text": "still trying to confirm obesity as a predisposing factor for hyperuricemia,", "keywords": [{"text": "hyperuricemia"}, {"text": "obesity"}, {"text": "factor"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Scientists", "keywords": [{"text": "Scientists"}]}, "sentence": " Scientists are still trying to confirm obesity as a predisposing factor for hyperuricemia,", "object": {"text": "to confirm obesity as a predisposing factor for hyperuricemia,", "keywords": [{"text": "hyperuricemia"}, {"text": "obesity"}, {"text": "factor"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "try", "tense": "present"}, "text": "trying", "normalized": "try"}}, {"subject": {"text": "Scientists", "keywords": [{"text": "Scientists"}]}, "sentence": " Scientists are still trying to confirm obesity as a predisposing factor for hyperuricemia,", "object": {"text": "obesity", "keywords": [{"text": "obesity"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "confirm", "tense": "future"}, "text": "are still trying to confirm", "normalized": "be still try to confirm"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " According to data published in National Institute on Alcohol Abuse and Alcoholism, U.S. an average of 17 million U.S. citizens suffered from alcohol use disorder in 2011.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by World Health Organization (WHO) global alcohol consumption in 2010 was around 6 liters of pure alcohol per person aged 15 years above", "keywords": [{"text": "global alcohol consumption"}, {"text": "World Health Organization"}, {"text": "pure alcohol"}, {"text": "liters"}], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"type": "Quantity", "text": "15 years"}, {"type": "Quantity", "text": "6 liters"}]}, "sentence": " In another statistics published by World Health Organization (WHO) global alcohol consumption in 2010 was around 6 liters of pure alcohol per person aged 15 years above.", "object": {"text": "another statistics", "keywords": [{"text": "statistics"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "person", "keywords": [{"text": "person"}]}, "sentence": " In another statistics published by World Health Organization (WHO) global alcohol consumption in 2010 was around 6 liters of pure alcohol per person aged 15 years above.", "object": {"text": "15 years above", "entities": [{"type": "Quantity", "text": "15 years"}]}, "action": {"verb": {"text": "age", "tense": "past"}, "text": "aged", "normalized": "age"}}, {"subject": {"text": "The incidences of alcohol abuse", "keywords": [{"text": "incidences"}, {"text": "alcohol abuse"}]}, "sentence": " The incidences of alcohol abuse are increasing across the globe and also act as a major contributing factor to disorders such as liver cirrhosis, and hyperuricemia.", "object": {"text": "increasing across the globe", "keywords": [{"text": "globe"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The incidences of alcohol abuse", "keywords": [{"text": "incidences"}, {"text": "alcohol abuse"}]}, "sentence": " The incidences of alcohol abuse are increasing across the globe and also act as a major contributing factor to disorders such as liver cirrhosis, and hyperuricemia.", "object": {"text": "across the globe", "keywords": [{"text": "globe"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "are increasing", "normalized": "be increase"}}, {"subject": {"text": "the uric acid", "keywords": [{"text": "uric acid"}]}, "sentence": " Approximately 70% of the uric acid produced in the body is filtered by the kidneys, while the remaining amount is eliminated by intestine.", "action": {"verb": {"text": "produce", "tense": "past"}, "text": "produced", "normalized": "produce"}}, {"subject": {"text": "Approximately 70% of the uric acid produced in the body", "keywords": [{"text": "uric acid"}, {"text": "body"}], "entities": [{"type": "Quantity", "text": "70"}]}, "sentence": " Approximately 70% of the uric acid produced in the body is filtered by the kidneys, while the remaining amount is eliminated by intestine.", "object": {"text": "filtered by the kidneys", "keywords": [{"text": "kidneys"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the kidneys", "keywords": [{"text": "kidneys"}]}, "sentence": " Approximately 70% of the uric acid produced in the body is filtered by the kidneys, while the remaining amount is eliminated by intestine.", "object": {"text": "Approximately 70% of the uric acid produced in the body", "keywords": [{"text": "uric acid"}, {"text": "body"}], "entities": [{"type": "Quantity", "text": "70"}]}, "action": {"verb": {"text": "filter", "tense": "past"}, "text": "is filtered", "normalized": "be filter"}}, {"subject": {"text": "the remaining amount"}, "sentence": " Approximately 70% of the uric acid produced in the body is filtered by the kidneys, while the remaining amount is eliminated by intestine.", "object": {"text": "eliminated by intestine"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by intestine"}, "sentence": " Approximately 70% of the uric acid produced in the body is filtered by the kidneys, while the remaining amount is eliminated by intestine.", "object": {"text": "the remaining amount"}, "action": {"verb": {"text": "eliminate", "tense": "past"}, "text": "is eliminated", "normalized": "be eliminate"}}, {"subject": {"text": "individuals", "keywords": [{"text": "individuals"}]}, "sentence": " In individuals suffering from renal failure, the elimination of uric acid by the kidney decreases, leading to increased uric acid levels in blood.", "object": {"text": "from renal failure, the elimination of uric acid by the kidney decreases", "keywords": [{"text": "uric acid"}, {"text": "renal failure"}, {"text": "elimination"}, {"text": "kidney"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "an article", "keywords": [{"text": "article"}]}, "sentence": " Further, an article published in the Journal of the America College of Cardiology in the year 2012 suggests that hyperuricemia is found to be associated with dyslipidemia of insulin resistance, systemic inflammation, and hepatic steatosis independent of obesity and metabolic syndrome.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "an article published in the Journal of the America College of Cardiology in the year 2012", "keywords": [{"text": "Cardiology"}, {"text": "article"}, {"text": "Journal"}, {"text": "America"}], "entities": [{"type": "PrintMedia", "text": "Journal of", "disambiguation": {"subtype": [], "name": "Journal of Applied Social Psychology", "dbpedia_resource": "http://dbpedia.org/resource/Journal_of_Applied_Social_Psychology"}}, {"type": "Organization", "text": "America College of Cardiology"}]}, "sentence": " Further, an article published in the Journal of the America College of Cardiology in the year 2012 suggests that hyperuricemia is found to be associated with dyslipidemia of insulin resistance, systemic inflammation, and hepatic steatosis independent of obesity and metabolic syndrome.", "object": {"text": "that hyperuricemia is found to be associated with dyslipidemia of insulin resistance, systemic inflammation, and hepatic steatosis independent of obesity and metabolic syndrome", "keywords": [{"text": "hepatic steatosis"}, {"text": "systemic inflammation"}, {"text": "insulin resistance"}, {"text": "metabolic syndrome"}], "entities": [{"type": "HealthCondition", "text": "dyslipidemia", "disambiguation": {"subtype": ["Disease"], "name": "Dyslipidemia", "dbpedia_resource": "http://dbpedia.org/resource/Dyslipidemia"}}, {"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "HealthCondition", "text": "metabolic syndrome", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "RiskFactor"], "name": "Metabolic syndrome", "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}}]}, "action": {"verb": {"text": "suggest", "tense": "present"}, "text": "suggests", "normalized": "suggest"}}, {"subject": {"text": "Another article", "keywords": [{"text": "article"}]}, "sentence": " Another article published in the journal Arthritis Care & Research in 2013 also suggests further confirmation of obesity as a factor leading to hyperuricemia.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Another article published in the journal Arthritis Care & Research in 2013", "keywords": [{"text": "journal Arthritis Care"}, {"text": "article"}, {"text": "Research"}], "entities": [{"type": "PrintMedia", "text": "Arthritis Care & Research"}]}, "sentence": " Another article published in the journal Arthritis Care & Research in 2013 also suggests further confirmation of obesity as a factor leading to hyperuricemia.", "object": {"text": "further confirmation of obesity as a factor leading to hyperuricemia", "keywords": [{"text": "hyperuricemia"}, {"text": "confirmation"}, {"text": "obesity"}, {"text": "factor"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "action": {"verb": {"text": "suggest", "tense": "present"}, "text": "suggests", "normalized": "suggest"}}, {"subject": {"text": "pre diabetes and insulin resistance", "keywords": [{"text": "insulin resistance"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " However pre diabetes and insulin resistance are found to be one of the factors leading to hyperuricemia.", "object": {"text": "one of the factors leading to hyperuricemia", "keywords": [{"text": "hyperuricemia"}, {"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are found to be", "normalized": "be find to be"}}, {"subject": {"text": "Articles", "keywords": [{"text": "Articles"}]}, "sentence": " Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders published in 2013 and 2012 have confirmed the factors.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Rheumatology and BMC Cardiovascular Disorders", "keywords": [{"text": "BMC Cardiovascular Disorders"}, {"text": "Rheumatology"}], "entities": [{"type": "PrintMedia", "text": "BMC Cardiovascular Disorders"}]}, "sentence": " Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders published in 2013 and 2012 have confirmed the factors.", "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders", "keywords": [{"text": "BMC Cardiovascular Disorders"}, {"text": "Current Opinion"}, {"text": "Rheumatology"}, {"text": "Articles"}], "entities": [{"type": "PrintMedia", "text": "BMC Cardiovascular Disorders"}]}, "sentence": " Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders published in 2013 and 2012 have confirmed the factors.", "object": {"text": "confirmed the factors", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders published in 2013 and 2012", "keywords": [{"text": "BMC Cardiovascular Disorders"}, {"text": "Current Opinion"}, {"text": "Rheumatology"}, {"text": "Articles"}], "entities": [{"type": "PrintMedia", "text": "BMC Cardiovascular Disorders"}]}, "sentence": " Articles published in Current Opinion in Rheumatology and BMC Cardiovascular Disorders published in 2013 and 2012 have confirmed the factors.", "object": {"text": "the factors", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "confirm", "tense": "past"}, "text": "have confirmed", "normalized": "have confirm"}}, {"subject": {"text": "Various drugs especially cancer drugs", "keywords": [{"text": "Various drugs"}, {"text": "cancer drugs"}]}, "sentence": " Various drugs especially cancer drugs are also found to cause hyperuricemia.", "object": {"text": "hyperuricemia", "keywords": [{"text": "hyperuricemia"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "are also found to cause", "normalized": "be also find to cause"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors will increase the prevalence of hyperuricemia as drive the market in the future.", "object": {"text": "the prevalence of hyperuricemia", "keywords": [{"text": "hyperuricemia"}, {"text": "prevalence"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "will increase", "normalized": "will increase"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors will increase the prevalence of hyperuricemia as drive the market in the future.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "by Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Currently ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals is widely prescribed for treating hyperuricemia.", "object": {"text": "ULORIC"}, "action": {"verb": {"text": "manufacture", "tense": "past"}, "text": "manufactured", "normalized": "manufacture"}}, {"subject": {"text": "ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "ULORIC"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Currently ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals is widely prescribed for treating hyperuricemia.", "object": {"text": "widely prescribed for treating hyperuricemia", "keywords": [{"text": "hyperuricemia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals", "keywords": [{"text": "Takeda Pharmaceuticals"}, {"text": "ULORIC"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Currently ULORIC (febuxostat) manufactured by Takeda Pharmaceuticals is widely prescribed for treating hyperuricemia.", "action": {"verb": {"text": "prescribe", "tense": "past"}, "text": "prescribed", "normalized": "prescribe"}}, {"subject": {"text": "the drug", "keywords": [{"text": "drug"}]}, "sentence": " However the drug is not prescribed for treatment of high uric acid without a history of gout.", "object": {"text": "not prescribed for treatment of high uric acid without a history of gout", "keywords": [{"text": "high uric acid"}, {"text": "gout"}, {"text": "treatment"}, {"text": "history"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Various clinical trials", "keywords": [{"text": "Various clinical trials"}]}, "sentence": " Various clinical trials are carried out by research institutes and companies in order to discover most efficient drug for rearming the disorder.", "object": {"text": "carried out by research institutes and companies", "keywords": [{"text": "research institutes"}, {"text": "companies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "by research institutes and companies in order to discover most efficient drug for rearming the disorder", "keywords": [{"text": "research institutes"}, {"text": "efficient drug"}, {"text": "companies"}, {"text": "disorder"}]}, "sentence": " Various clinical trials are carried out by research institutes and companies in order to discover most efficient drug for rearming the disorder.", "object": {"text": "Various clinical trials", "keywords": [{"text": "Various clinical trials"}]}, "action": {"verb": {"text": "carry", "tense": "past"}, "text": "are carried", "normalized": "be carry"}}, {"subject": {"text": "Ardea Biosciences, Inc.", "keywords": [{"text": "Ardea Biosciences"}], "entities": [{"type": "Company", "text": "Ardea Biosciences, Inc."}]}, "sentence": " Ardea Biosciences, Inc. is conducting phase 2 clinical trials for testing efficiency of RDEA806 for treatment of hyperuricemia.", "object": {"text": "conducting phase 2 clinical trials for testing efficiency of RDEA806 for treatment of hyperuricemia", "keywords": [{"text": "clinical trials"}, {"text": "hyperuricemia"}, {"text": "phase"}, {"text": "efficiency"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Ardea Biosciences, Inc.", "keywords": [{"text": "Ardea Biosciences"}], "entities": [{"type": "Company", "text": "Ardea Biosciences, Inc."}]}, "sentence": " Ardea Biosciences, Inc. is conducting phase 2 clinical trials for testing efficiency of RDEA806 for treatment of hyperuricemia.", "object": {"text": "phase 2 clinical trials for testing efficiency of RDEA806 for treatment of hyperuricemia", "keywords": [{"text": "clinical trials"}, {"text": "hyperuricemia"}, {"text": "phase"}, {"text": "efficiency"}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "is conducting", "normalized": "be conduct"}}, {"subject": {"text": "Hebei Medical University", "keywords": [{"text": "Hebei Medical University"}], "entities": [{"type": "Organization", "text": "Hebei Medical University", "disambiguation": {"subtype": ["University"], "name": "Hebei Medical University", "dbpedia_resource": "http://dbpedia.org/resource/Hebei_Medical_University"}}]}, "sentence": " Hebei Medical University is conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia.", "object": {"text": "conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia", "keywords": [{"text": "renal function improvement"}, {"text": "heart failure"}, {"text": "allopurinol"}, {"text": "hyperuricemia"}], "entities": [{"type": "Drug", "text": "prednisone"}, {"type": "Drug", "text": "allopurinol"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Hebei Medical University", "keywords": [{"text": "Hebei Medical University"}], "entities": [{"type": "Organization", "text": "Hebei Medical University", "disambiguation": {"subtype": ["University"], "name": "Hebei Medical University", "dbpedia_resource": "http://dbpedia.org/resource/Hebei_Medical_University"}}]}, "sentence": " Hebei Medical University is conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia.", "object": {"text": "phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia", "keywords": [{"text": "renal function improvement"}, {"text": "heart failure"}, {"text": "allopurinol"}, {"text": "hyperuricemia"}], "entities": [{"type": "Drug", "text": "prednisone"}, {"type": "Drug", "text": "allopurinol"}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "is conducting", "normalized": "be conduct"}}, {"subject": {"text": "with U.S. patent", "keywords": [{"text": "U.S. patent"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " TWi Biotechnology, Inc. was awarded with U.S. patent in 2014 for AC \u2013 201 which is effective in treating hyperuricemia.", "object": {"text": "TWi Biotechnology, Inc.", "keywords": [{"text": "TWi Biotechnology"}], "entities": [{"type": "Company", "text": "TWi Biotechnology, Inc."}]}, "action": {"verb": {"text": "award", "tense": "past"}, "text": "was awarded", "normalized": "be award"}}, {"subject": {"text": "Similar research and development activities", "keywords": [{"text": "Similar research"}, {"text": "development activities"}]}, "sentence": " Similar research and development activities will add more products to the market and expand its reach globally.", "object": {"text": "more products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "add", "tense": "future"}, "text": "will add", "normalized": "will add"}}, {"subject": {"text": "Similar research and development activities", "keywords": [{"text": "Similar research"}, {"text": "development activities"}]}, "sentence": " Similar research and development activities will add more products to the market and expand its reach globally.", "object": {"text": "its reach", "keywords": [{"text": "reach"}]}, "action": {"verb": {"text": "expand", "tense": "present"}, "text": "expand", "normalized": "expand"}}, {"subject": {"text": "Lesser competition and wide scope for research and development activities", "keywords": [{"text": "Lesser competition"}, {"text": "wide scope"}, {"text": "development activities"}, {"text": "research"}]}, "sentence": " Lesser competition and wide scope for research and development activities have made the market more attractive.", "object": {"text": "made the market more attractive", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Lesser competition and wide scope for research and development activities", "keywords": [{"text": "Lesser competition"}, {"text": "wide scope"}, {"text": "development activities"}, {"text": "research"}]}, "sentence": " Lesser competition and wide scope for research and development activities have made the market more attractive.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "have made", "normalized": "have make"}}, {"subject": {"text": "newer drugs", "keywords": [{"text": "newer drugs"}]}, "sentence": " As newer drugs receive regulatory approvals, the market is expected to boost in the near future.", "object": {"text": "regulatory approvals", "keywords": [{"text": "regulatory approvals"}]}, "action": {"verb": {"text": "receive", "tense": "present"}, "text": "receive", "normalized": "receive"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " As newer drugs receive regulatory approvals, the market is expected to boost in the near future.", "action": {"verb": {"text": "boost", "tense": "future"}, "text": "is expected to boost", "normalized": "be expect to boost"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.", "object": {"text": "a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies", "keywords": [{"text": "restricted growth"}, {"text": "Asia Pacific"}, {"text": "Latin America"}, {"text": "Middle East"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "will have", "normalized": "will have"}}, {"subject": {"text": "the Middle East and Africa", "keywords": [{"text": "Middle East"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.", "object": {"text": "of under developed and developing economies", "keywords": [{"text": "economies"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprise", "normalized": "comprise"}}], "concepts": [{"text": "Uric acid", "relevance": 0.943711, "dbpedia_resource": "http://dbpedia.org/resource/Uric_acid"}, {"text": "Gout", "relevance": 0.833697, "dbpedia_resource": "http://dbpedia.org/resource/Gout"}, {"text": "Metabolic syndrome", "relevance": 0.812651, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Obesity", "relevance": 0.642763, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Alcohol", "relevance": 0.585687, "dbpedia_resource": "http://dbpedia.org/resource/Alcohol"}, {"text": "Hyperuricemia", "relevance": 0.529856, "dbpedia_resource": "http://dbpedia.org/resource/Hyperuricemia"}, {"text": "Wine", "relevance": 0.509044, "dbpedia_resource": "http://dbpedia.org/resource/Wine"}, {"text": "Kidney", "relevance": 0.460005, "dbpedia_resource": "http://dbpedia.org/resource/Kidney"}, {"text": "Alcoholism", "relevance": 0.459335, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}, {"text": "Ethanol", "relevance": 0.438631, "dbpedia_resource": "http://dbpedia.org/resource/Ethanol"}, {"text": "Insulin resistance", "relevance": 0.425751, "dbpedia_resource": "http://dbpedia.org/resource/Insulin_resistance"}, {"text": "Hypertension", "relevance": 0.418746, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Non-alcoholic fatty liver disease", "relevance": 0.416799, "dbpedia_resource": "http://dbpedia.org/resource/Non-alcoholic_fatty_liver_disease"}, {"text": "Kidney stone", "relevance": 0.413381, "dbpedia_resource": "http://dbpedia.org/resource/Kidney_stone"}, {"text": "Fructose", "relevance": 0.401925, "dbpedia_resource": "http://dbpedia.org/resource/Fructose"}, {"text": "Hypouricemia", "relevance": 0.400625, "dbpedia_resource": "http://dbpedia.org/resource/Hypouricemia"}, {"text": "Renal failure", "relevance": 0.396445, "dbpedia_resource": "http://dbpedia.org/resource/Renal_failure"}, {"text": "Insulin", "relevance": 0.396139, "dbpedia_resource": "http://dbpedia.org/resource/Insulin"}, {"text": "Ammonia", "relevance": 0.3937, "dbpedia_resource": "http://dbpedia.org/resource/Ammonia"}, {"text": "Arthritis", "relevance": 0.391537, "dbpedia_resource": "http://dbpedia.org/resource/Arthritis"}, {"text": "Diabetes mellitus", "relevance": 0.366874, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}, {"text": "Hyperuricosuria", "relevance": 0.3645, "dbpedia_resource": "http://dbpedia.org/resource/Hyperuricosuria"}, {"text": "Fatty liver", "relevance": 0.357271, "dbpedia_resource": "http://dbpedia.org/resource/Fatty_liver"}, {"text": "Alcoholic beverage", "relevance": 0.355166, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholic_beverage"}, {"text": "Fermentation", "relevance": 0.3455, "dbpedia_resource": "http://dbpedia.org/resource/Fermentation_(wine)"}, {"text": "Clinical trial", "relevance": 0.343291, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Urea", "relevance": 0.337502, "dbpedia_resource": "http://dbpedia.org/resource/Urea"}, {"text": "Xanthine oxidase", "relevance": 0.328826, "dbpedia_resource": "http://dbpedia.org/resource/Xanthine_oxidase"}, {"text": "Nephrology", "relevance": 0.3238, "dbpedia_resource": "http://dbpedia.org/resource/Nephrology"}, {"text": "Heart failure", "relevance": 0.322799, "dbpedia_resource": "http://dbpedia.org/resource/Heart_failure"}, {"text": "Urine", "relevance": 0.322321, "dbpedia_resource": "http://dbpedia.org/resource/Urine"}, {"text": "Beer", "relevance": 0.3173, "dbpedia_resource": "http://dbpedia.org/resource/Beer"}, {"text": "SLC2A9", "relevance": 0.312395, "dbpedia_resource": "http://dbpedia.org/resource/SLC2A9"}, {"text": "Acetic acid", "relevance": 0.307217, "dbpedia_resource": "http://dbpedia.org/resource/Acetic_acid"}, {"text": "Alcohol abuse", "relevance": 0.305632, "dbpedia_resource": "http://dbpedia.org/resource/Alcohol_abuse"}, {"text": "Cirrhosis", "relevance": 0.303474, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Vodka", "relevance": 0.302895, "dbpedia_resource": "http://dbpedia.org/resource/Vodka"}, {"text": "Scientific method", "relevance": 0.301861, "dbpedia_resource": "http://dbpedia.org/resource/Scientific_method"}, {"text": "Yeast", "relevance": 0.300926, "dbpedia_resource": "http://dbpedia.org/resource/Yeast"}, {"text": "Sevelamer", "relevance": 0.288823, "dbpedia_resource": "http://dbpedia.org/resource/Sevelamer"}, {"text": "Atherosclerosis", "relevance": 0.287867, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Acid", "relevance": 0.286389, "dbpedia_resource": "http://dbpedia.org/resource/Acid"}, {"text": "Organic acids", "relevance": 0.283974, "dbpedia_resource": "http://dbpedia.org/resource/Organic_acids"}, {"text": "Distilled beverage", "relevance": 0.282909, "dbpedia_resource": "http://dbpedia.org/resource/Distilled_beverage"}, {"text": "Research and development", "relevance": 0.272216, "dbpedia_resource": "http://dbpedia.org/resource/Research_and_development"}, {"text": "Purine metabolism", "relevance": 0.271894, "dbpedia_resource": "http://dbpedia.org/resource/Purine_metabolism"}, {"text": "Ethanol fermentation", "relevance": 0.270994, "dbpedia_resource": "http://dbpedia.org/resource/Ethanol_fermentation"}], "categories": [{"score": 0.713788, "label": "/health and fitness"}, {"score": 0.407314, "label": "/health and fitness/disorders"}, {"score": 0.368472, "label": "/health and fitness/disease/diabetes"}], "relations": [{"type": "citizenOf", "sentence": "Scientists are still trying to confirm obesity as a predisposing factor for hyperuricemia, According to data published in National Institute on Alcohol Abuse and Alcoholism, U.S. an average of 17 million U.S. citizens suffered from alcohol use disorder in 2011.", "score": 0.360182, "arguments": [{"text": "citizens", "location": [558, 566], "entities": [{"type": "Person", "text": "citizens"}]}, {"text": "U.S.", "location": [553, 557], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "TWi Biotechnology, Inc. was awarded with U.S. patent in 2014 for AC - 201 which is effective in treating hyperuricemia.", "score": 0.907824, "arguments": [{"text": "2014", "location": [2934, 2938], "entities": [{"type": "Date", "text": "2014"}]}, {"text": "awarded", "location": [2906, 2913], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "locatedAt", "sentence": "Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.", "score": 0.883322, "arguments": [{"text": "regions", "location": [3402, 3409], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia Pacific", "location": [3413, 3425], "entities": [{"type": "GeopoliticalEntity", "text": "Asia Pacific"}]}]}, {"type": "locatedAt", "sentence": "Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.", "score": 0.8643, "arguments": [{"text": "regions", "location": [3402, 3409], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [3427, 3440], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.", "score": 0.843553, "arguments": [{"text": "regions", "location": [3402, 3409], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Middle East", "location": [3446, 3457], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Due to high cost of branded drugs, the market will have a restricted growth in the regions of Asia Pacific, Latin America, the Middle East and Africa which majorly comprise of under developed and developing economies.", "score": 0.908245, "arguments": [{"text": "regions", "location": [3402, 3409], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Africa", "location": [3462, 3468], "entities": [{"type": "GeopoliticalEntity", "text": "Africa", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "In another statistics published by World Health Organization (WHO) global alcohol consumption in 2010 was around 6 liters of pure alcohol per person aged 15 years above.", "score": 0.554256, "arguments": [{"text": "WHO", "location": [673, 676], "entities": [{"type": "Person", "text": "person"}]}, {"text": "World Health Organization", "location": [646, 671], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "hasAttribute", "sentence": "The incidences of alcohol abuse are increasing across the globe and also act as a major contributing factor to disorders such as liver cirrhosis, and hyperuricemia.", "score": 0.849854, "arguments": [{"text": "disorders", "location": [892, 901], "entities": [{"type": "Person", "text": "disorders"}]}, {"text": "liver cirrhosis", "location": [910, 925], "entities": [{"type": "HealthCondition", "text": "liver cirrhosis"}]}]}, {"type": "hasAttribute", "sentence": "In individuals suffering from renal failure, the elimination of uric acid by the kidney decreases, leading to increased uric acid levels in blood.", "score": 0.663723, "arguments": [{"text": "individuals", "location": [1088, 1099], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "renal failure", "location": [1115, 1128], "entities": [{"type": "HealthCondition", "text": "renal failure"}]}]}, {"type": "hasAttribute", "sentence": "In individuals suffering from renal failure, the elimination of uric acid by the kidney decreases, leading to increased uric acid levels in blood.", "score": 0.511812, "arguments": [{"text": "individuals", "location": [1088, 1099], "entities": [{"type": "Person", "text": "individuals"}]}, {"text": "kidney decreases", "location": [1166, 1182], "entities": [{"type": "HealthCondition", "text": "kidney decreases"}]}]}, {"type": "partOf", "sentence": "Further, an article published in the Journal of the America College of Cardiology in the year 2012 suggests that hyperuricemia is found to be associated with dyslipidemia of insulin resistance, systemic inflammation, and hepatic steatosis independent of obesity and metabolic syndrome.", "score": 0.748038, "arguments": [{"text": "the America College of Cardiology", "location": [1280, 1313], "entities": [{"type": "Organization", "text": "the America College of Cardiology"}]}, {"text": "Journal of", "location": [1269, 1279], "entities": [{"type": "Organization", "text": "Journal of", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Further, an article published in the Journal of the America College of Cardiology in the year 2012 suggests that hyperuricemia is found to be associated with dyslipidemia of insulin resistance, systemic inflammation, and hepatic steatosis independent of obesity and metabolic syndrome.", "score": 0.823809, "arguments": [{"text": "year 2012", "location": [1321, 1330], "entities": [{"type": "Date", "text": "year 2012"}]}, {"text": "suggests", "location": [1331, 1339], "entities": [{"type": "EventCommunication", "text": "suggests"}]}]}, {"type": "hasAttribute", "sentence": "Hebei Medical University is conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia.", "score": 0.850872, "arguments": [{"text": "patients", "location": [2849, 2857], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "heart failure", "location": [2835, 2848], "entities": [{"type": "HealthCondition", "text": "heart failure"}]}]}, {"type": "agentOf", "sentence": "TWi Biotechnology, Inc. was awarded with U.S. patent in 2014 for AC - 201 which is effective in treating hyperuricemia.", "score": 0.837663, "arguments": [{"text": "TWi Biotechnology, Inc.", "location": [2878, 2901], "entities": [{"type": "Organization", "text": "TWi Biotechnology, Inc."}]}, {"text": "awarded", "location": [2906, 2913], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}], "keywords": [{"text": "hyperuricemia", "sentiment": {"score": -0.559863, "label": "negative"}, "relevance": 0.983544}, {"text": "uric acid", "sentiment": {"score": -0.691121, "label": "negative"}, "relevance": 0.963057}, {"text": "Global Hyperuricemia Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.825616}, {"text": "insulin resistance", "sentiment": {"score": -0.358029, "label": "negative"}, "relevance": 0.514007}, {"text": "uric acid levels", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511259}, {"text": "high uric acid", "sentiment": {"score": -0.513192, "label": "negative"}, "relevance": 0.49273}, {"text": "alcohol consumption", "sentiment": {"score": -0.631599, "label": "negative"}, "relevance": 0.405957}, {"text": "renal failure", "sentiment": {"score": -0.638863, "label": "negative"}, "relevance": 0.398886}, {"text": "abnormally high levels", "sentiment": {"score": -0.796152, "label": "negative"}, "relevance": 0.395786}, {"text": "alcohol abuse", "sentiment": {"score": -0.510973, "label": "negative"}, "relevance": 0.394625}, {"text": "global alcohol consumption", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.389837}, {"text": "major contributing factor", "sentiment": {"score": -0.52301, "label": "negative"}, "relevance": 0.378053}, {"text": "World Health Organization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363279}, {"text": "journal Arthritis Care", "sentiment": {"score": -0.537074, "label": "negative"}, "relevance": 0.34851}, {"text": "renal function improvement", "sentiment": {"score": -0.656979, "label": "negative"}, "relevance": 0.345192}, {"text": "BMC Cardiovascular Disorders", "sentiment": {"score": -0.565874, "label": "negative"}, "relevance": 0.345069}, {"text": "Various clinical trials", "sentiment": {"score": -0.619653, "label": "negative"}, "relevance": 0.341093}, {"text": "Hebei Medical University", "sentiment": {"score": -0.656979, "label": "negative"}, "relevance": 0.339948}, {"text": "development activities", "sentiment": {"score": 0.559465, "label": "positive"}, "relevance": 0.325133}, {"text": "in-depth qualitative insights", "sentiment": {"score": 0.451751, "label": "positive"}, "relevance": 0.312356}, {"text": "prevalent factor", "sentiment": {"score": -0.631599, "label": "negative"}, "relevance": 0.277364}, {"text": "alcohol use disorder", "sentiment": {"score": -0.667951, "label": "negative"}, "relevance": 0.271867}, {"text": "pure alcohol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265073}, {"text": "Various factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262347}, {"text": "hepatic steatosis", "sentiment": {"score": -0.498562, "label": "negative"}, "relevance": 0.253585}, {"text": "Various drugs", "sentiment": {"score": -0.426994, "label": "negative"}, "relevance": 0.245579}, {"text": "cancer drugs", "sentiment": {"score": -0.426994, "label": "negative"}, "relevance": 0.24464}, {"text": "National Institute", "sentiment": {"score": -0.498936, "label": "negative"}, "relevance": 0.244563}, {"text": "market size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244244}, {"text": "research report", "sentiment": {"score": 0.364448, "label": "positive"}, "relevance": 0.243009}, {"text": "systemic inflammation", "sentiment": {"score": -0.446848, "label": "negative"}, "relevance": 0.240471}, {"text": "U.S. citizens", "sentiment": {"score": -0.667951, "label": "negative"}, "relevance": 0.23906}, {"text": "liver cirrhosis", "sentiment": {"score": -0.52301, "label": "negative"}, "relevance": 0.238943}, {"text": "Similar research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238557}, {"text": "prolonged period", "sentiment": {"score": -0.76056, "label": "negative"}, "relevance": 0.237899}, {"text": "research institutes", "sentiment": {"score": -0.619653, "label": "negative"}, "relevance": 0.237888}, {"text": "metabolic syndrome", "sentiment": {"score": -0.498562, "label": "negative"}, "relevance": 0.237183}, {"text": "research methodologies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237116}, {"text": "Takeda Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234721}, {"text": "newer drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233418}, {"text": "Ardea Biosciences", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232916}, {"text": "heart failure", "sentiment": {"score": -0.656979, "label": "negative"}, "relevance": 0.231301}, {"text": "branded drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23109}, {"text": "verifiable projections", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230288}, {"text": "Current Opinion", "sentiment": {"score": -0.565874, "label": "negative"}, "relevance": 0.2296}, {"text": "U.S. patent", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.228991}, {"text": "high cost", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.228841}, {"text": "pre diabetes", "sentiment": {"score": -0.358029, "label": "negative"}, "relevance": 0.228546}, {"text": "Regional markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.227389}, {"text": "TWi Biotechnology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.227358}]}, "extracted_metadata": {"sha1": "f157a567b48d5f1d75b855d07249149164f7b617", "filename": "1541917446734.zip-6693b5a780010e68bece945b4ec7096b.xml", "file_type": "json"}, "external_links": ["http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=17141", "http://www.transparencymarketresearch.com/hyperuricemia-market.html"], "title": "Research Report and Overview on Hyperuricemia Market, 2016 \u2013 2024", "forum_title": "Research Insights \u2013 Page 97 \u2013 Find Market Research"}, {"id": "aEgfgrloQABxsY5VcafaM1jw62Ui3s_7i7eCDqg1-TAuxFnOr0lMUhIlCeofyDM5", "result_metadata": {"score": 22.187733}, "author": "seekingalpha.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H Lundbeck A/S", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Deborah Dunsire", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Lundbeck", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}], "categories": [{"score": 0.552422, "label": "/business and industrial/company"}, {"score": 0.479622, "label": "/business and industrial/company/earnings"}, {"score": 0.467818, "label": "/finance/investing/options"}], "relations": [{"type": "employedBy", "sentence": "H Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q3 2018 Results - Earnings Call Transcript", "score": 0.412309, "arguments": [{"text": "CEO", "location": [23, 26], "entities": [{"type": "Person", "text": "Deborah Dunsire"}]}, {"text": "HLUKF", "location": [16, 21], "entities": [{"type": "Organization", "text": "Lundbeck A/S", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "CEO Deborah Dunsire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.964676}, {"text": "Lundbeck A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.876948}, {"text": "Q3", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371675}, {"text": "Earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.30925}, {"text": "Transcript", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252238}]}, "crawl_date": "2018-11-11T12:20:43Z", "url": "https://seekingalpha.com/article/4220966-h-lundbeck-s-hlukf-ceo-deborah-dunsire-q3-2018-results-earnings-call-transcript", "host": "seekingalpha.com", "text": "Bernstein & Co.", "main_image_url": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-11T07:11:00Z", "enriched_text": {"entities": [{"count": 26, "sentiment": {"score": 0.719693, "label": "positive"}, "text": "Deborah Dunsire", "relevance": 0.820661, "type": "Person", "disambiguation": {"subtype": ["ReligiousLeader"], "name": "Deborah", "dbpedia_resource": "http://dbpedia.org/resource/Deborah"}}, {"count": 20, "sentiment": {"score": 0.531839, "label": "positive"}, "text": "Anders G\u00f6tzsche", "relevance": 0.802967, "type": "Person"}, {"count": 25, "sentiment": {"score": 0.356727, "label": "positive"}, "text": "Lundbeck", "relevance": 0.777447, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 9, "sentiment": {"score": 0.473752, "label": "positive"}, "text": "Anders Pedersen", "relevance": 0.582124, "type": "Person", "disambiguation": {"subtype": ["Boxer", "OlympicAthlete"], "name": "Anders Petersen (boxer)", "dbpedia_resource": "http://dbpedia.org/resource/Anders_Petersen_(boxer)"}}, {"count": 8, "sentiment": {"score": -0.495502, "label": "negative"}, "text": "Anders", "relevance": 0.517051, "type": "Person"}, {"count": 11, "sentiment": {"score": -0.121649, "label": "negative"}, "text": "U.S.", "relevance": 0.411313, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 10, "sentiment": {"score": 0.399633, "label": "positive"}, "text": "Northera", "relevance": 0.405804, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 11, "sentiment": {"score": 0, "label": "neutral"}, "text": "Rexulti", "relevance": 0.400759, "type": "Company"}, {"count": 8, "sentiment": {"score": 0.437888, "label": "positive"}, "text": "Peter Anastasiou", "relevance": 0.399746, "type": "Person"}, {"count": 3, "sentiment": {"score": 0.509903, "label": "positive"}, "text": "Anders Gersel", "relevance": 0.389844, "type": "Person"}, {"count": 11, "sentiment": {"score": 0.270234, "label": "positive"}, "text": "Europe", "relevance": 0.369042, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 11, "sentiment": {"score": 0, "label": "neutral"}, "text": "Onfi", "relevance": 0.362501, "type": "Company"}, {"count": 4, "sentiment": {"score": -0.286035, "label": "negative"}, "text": "Peter", "relevance": 0.349604, "type": "Person"}, {"count": 6, "sentiment": {"score": 0.52585, "label": "positive"}, "text": "Wimal Kapadia", "relevance": 0.340329, "type": "Person"}, {"count": 6, "sentiment": {"score": 0.308356, "label": "positive"}, "text": "Michael Novod", "relevance": 0.339529, "type": "Person"}, {"count": 6, "sentiment": {"score": -0.219024, "label": "negative"}, "text": "schizophrenia", "relevance": 0.338459, "type": "HealthCondition"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.338264, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 6, "sentiment": {"score": 0.434087, "label": "positive"}, "text": "James Gordon", "relevance": 0.330956, "type": "Person"}, {"count": 7, "sentiment": {"score": -0.55083, "label": "negative"}, "text": "depression", "relevance": 0.325747, "type": "HealthCondition"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nordea Markets", "relevance": 0.323567, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H Lundbeck A/S", "relevance": 0.318641, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.587049, "label": "positive"}, "text": "Trintellix", "relevance": 0.314897, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.20187, "label": "positive"}, "text": "Executive Vice President and CFO", "relevance": 0.306451, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.234308, "label": "positive"}, "text": "President and CEO", "relevance": 0.304089, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cr\u00e9dit Suisse", "relevance": 0.298841, "type": "Company", "disambiguation": {"subtype": [], "name": "Credit Suisse", "dbpedia_resource": "http://dbpedia.org/resource/Credit_Suisse"}}, {"count": 7, "sentiment": {"score": 0.452642, "label": "positive"}, "text": "Martin Parkh\u00f8i", "relevance": 0.297993, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Trung Huynh", "relevance": 0.295232, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "JPMorgan Chase & Co", "relevance": 0.292011, "type": "Company", "disambiguation": {"subtype": [], "name": "JPMorgan Chase", "dbpedia_resource": "http://dbpedia.org/resource/JPMorgan_Chase"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Marietta Miemietz", "relevance": 0.288907, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Research and Development", "relevance": 0.287743, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Danske Bank", "relevance": 0.287697, "type": "Company", "disambiguation": {"subtype": [], "name": "Danske Bank", "dbpedia_resource": "http://dbpedia.org/resource/Danske_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anders Gotzsche", "relevance": 0.286591, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jacob Tolstrup", "relevance": 0.284557, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Australia", "relevance": 0.283833, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Handelsbanken", "relevance": 0.282518, "type": "Company", "disambiguation": {"subtype": [], "name": "Handelsbanken", "dbpedia_resource": "http://dbpedia.org/resource/Handelsbanken"}}, {"count": 3, "sentiment": {"score": 0.403854, "label": "positive"}, "text": "Peter Sehested", "relevance": 0.281103, "type": "Person"}, {"count": 5, "sentiment": {"score": 0.3687, "label": "positive"}, "text": "China", "relevance": 0.280755, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 3, "sentiment": {"score": 0.521128, "label": "positive"}, "text": "International Markets", "relevance": 0.279003, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Northera", "relevance": 0.278514, "type": "Person"}, {"count": 3, "sentiment": {"score": 0.441814, "label": "positive"}, "text": "Onfi", "relevance": 0.275353, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Timothy Race", "relevance": 0.274683, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Deutsche Bank", "relevance": 0.27372, "type": "Company", "disambiguation": {"subtype": ["Person", "BoardMember"], "name": "Deutsche Bank", "dbpedia_resource": "http://dbpedia.org/resource/Deutsche_Bank"}}, {"count": 6, "sentiment": {"score": 0.350874, "label": "positive"}, "text": "EVP", "relevance": 0.269768, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.266652, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.248826, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 2, "sentiment": {"score": -0.463401, "label": "negative"}, "text": "Sabril", "relevance": 0.247244, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Financial Officer", "relevance": 0.245772, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Saudi Arabia", "relevance": 0.245505, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0.331746, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "I"}, "sentence": " Today, I am pleased to present Deborah Dunsire, President and CEO; Anders G\u00f6tzsche, the Executive Vice President and CFO; and Anders Pedersen, Executive Vice President, Research and Development.", "object": {"text": "pleased to present Deborah Dunsire, President and CEO", "keywords": [{"text": "Deborah Dunsire"}, {"text": "CEO"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Deborah Dunsire"}, {"type": "JobTitle", "text": "President and CEO"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "I"}, "sentence": " Today, I am pleased to present Deborah Dunsire, President and CEO; Anders G\u00f6tzsche, the Executive Vice President and CFO; and Anders Pedersen, Executive Vice President, Research and Development.", "object": {"text": "to present Deborah Dunsire, President and CEO", "keywords": [{"text": "Deborah Dunsire"}, {"text": "CEO"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Deborah Dunsire"}, {"type": "JobTitle", "text": "President and CEO"}]}, "action": {"verb": {"text": "please", "tense": "past"}, "text": "pleased", "normalized": "please"}}, {"subject": {"text": "I"}, "sentence": " Today, I am pleased to present Deborah Dunsire, President and CEO; Anders G\u00f6tzsche, the Executive Vice President and CFO; and Anders Pedersen, Executive Vice President, Research and Development.", "object": {"text": "Deborah Dunsire, President and CEO", "keywords": [{"text": "Deborah Dunsire"}, {"text": "CEO"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Deborah Dunsire"}, {"type": "JobTitle", "text": "President and CEO"}]}, "action": {"verb": {"text": "present", "tense": "future"}, "text": "am pleased to present", "normalized": "be please to present"}}, {"subject": {"text": "you"}, "sentence": " Thank you very much, operator, and thank you all for your interest in Lundbeck.", "object": {"text": "very much"}, "action": {"verb": {"text": "Thank", "tense": "present"}, "text": "Thank", "normalized": "Thank"}}, {"subject": {"text": "our financial report for the first nine months of 2018", "keywords": [{"text": "financial report"}], "entities": [{"type": "Quantity", "text": "nine months"}]}, "sentence": " Welcome to this Lundbeck teleconference covering our financial report for the first nine months of 2018.", "object": {"text": "Welcome to this Lundbeck teleconference", "keywords": [{"text": "Lundbeck teleconference"}], "entities": [{"type": "Company", "text": "Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covering", "normalized": "cover"}}, {"subject": {"text": "me"}, "sentence": " Together with me are our Chief Financial Officer, Anders G\u00f6tzsche; our head of R&D, Anders Pedersen; Peter Anastasiou, EVP of North America; Jacob Tolstrup, EVP of commercial operations.", "object": {"text": "our Chief Financial Officer, Anders G\u00f6tzsche", "keywords": [{"text": "Chief Financial Officer"}, {"text": "Anders G\u00f6tzsche"}], "entities": [{"type": "JobTitle", "text": "Chief Financial Officer"}, {"type": "Person", "text": "Anders G\u00f6tzsche"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "you"}, "sentence": " On Slide 2, you can see the company's disclaimer, which I know you've read many times before, so I won't read it out.", "object": {"text": "the company's disclaimer, which I know you've read many times before", "keywords": [{"text": "company"}, {"text": "times"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "can see", "normalized": "can see"}}, {"subject": {"text": "you"}, "sentence": " On Slide 2, you can see the company's disclaimer, which I know you've read many times before, so I won't read it out.", "object": {"text": "read many times before", "keywords": [{"text": "times"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "you"}, "sentence": " On Slide 2, you can see the company's disclaimer, which I know you've read many times before, so I won't read it out.", "object": {"text": "many times", "keywords": [{"text": "times"}]}, "action": {"verb": {"text": "read", "tense": "past"}, "text": "read", "normalized": "read"}}, {"subject": {"text": "I"}, "sentence": " On Slide 2, you can see the company's disclaimer, which I know you've read many times before, so I won't read it out.", "object": {"text": "it"}, "action": {"verb": {"text": "read", "tense": "future", "negated": true}, "text": "read", "normalized": "read"}}, {"subject": {"text": "this"}, "sentence": " Firstly, as this is the first time we are talking since I joined Lundbeck on September 3, let me start with some comments on why I chose to join Lundbeck and how I see the future.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " Firstly, as this is the first time we are talking since I joined Lundbeck on September 3, let me start with some comments on why I chose to join Lundbeck and how I see the future.", "action": {"verb": {"text": "talk", "tense": "present"}, "text": "are talking", "normalized": "be talk"}}, {"subject": {"text": "I"}, "sentence": " Firstly, as this is the first time we are talking since I joined Lundbeck on September 3, let me start with some comments on why I chose to join Lundbeck and how I see the future.", "object": {"text": "Lundbeck", "keywords": [{"text": "Lundbeck"}], "entities": [{"type": "Company", "text": "Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "action": {"verb": {"text": "join", "tense": "past"}, "text": "joined", "normalized": "join"}}, {"subject": {"text": "I"}, "sentence": " Firstly, as this is the first time we are talking since I joined Lundbeck on September 3, let me start with some comments on why I chose to join Lundbeck and how I see the future.", "object": {"text": "me start with some comments on why I chose to join Lundbeck and how I see the future", "keywords": [{"text": "Lundbeck"}, {"text": "comments"}, {"text": "future"}], "entities": [{"type": "Person", "text": "Jacob Tolstrup"}, {"type": "Company", "text": "Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "action": {"verb": {"text": "let", "tense": "present"}, "text": "let", "normalized": "let"}}, {"subject": {"text": "Lundbeck", "keywords": [{"text": "Lundbeck"}], "entities": [{"type": "Company", "text": "Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "sentence": " Lundbeck has had a long and successful history of bringing new medicines forward in the fields of neurology and psychiatry to drive better outcomes for people living with these diseases.", "object": {"text": "a long and successful history of bringing new medicines forward in the fields of neurology and psychiatry to drive better outcomes for people living with these diseases", "keywords": [{"text": "new medicines"}, {"text": "successful history"}, {"text": "better outcomes"}, {"text": "psychiatry"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "has had", "normalized": "have have"}}, {"subject": {"text": "Lundbeck", "keywords": [{"text": "Lundbeck"}], "entities": [{"type": "Company", "text": "Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}]}, "sentence": " Lundbeck has had a long and successful history of bringing new medicines forward in the fields of neurology and psychiatry to drive better outcomes for people living with these diseases.", "object": {"text": "new medicines", "keywords": [{"text": "new medicines"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "bringing", "normalized": "bring"}}, {"subject": {"text": "It"}, "sentence": " It is a company that's held in high regard by physicians and investigators in the field for our commitment to advancing care in these fields.", "object": {"text": "a company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "care", "keywords": [{"text": "care"}]}, "sentence": " It is a company that's held in high regard by physicians and investigators in the field for our commitment to advancing care in these fields.", "action": {"verb": {"text": "advance", "tense": "future"}, "text": "advancing", "normalized": "advance"}}, {"subject": {"text": "It"}, "sentence": " It's also a company with a strong reputation for integrity, both in science and business practices.", "object": {"text": "a company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "It"}, "sentence": " It's a privilege to be invited to lead such a company.", "object": {"text": "a privilege to be invited to lead such a company", "keywords": [{"text": "privilege"}, {"text": "company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "It"}, "sentence": " It's a privilege to be invited to lead such a company.", "object": {"text": "to lead such a company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "invite", "tense": "past"}, "text": "to be invited", "normalized": "to be invite"}}, {"subject": {"text": "a physician", "keywords": [{"text": "physician"}]}, "sentence": " It also fits with my personal objective as a physician working in this industry to spend my energies to tackle the areas of highest unmet need and bring forward transformative medicines.", "action": {"verb": {"text": "work", "tense": "present"}, "text": "working", "normalized": "work"}}, {"subject": {"text": "a physician", "keywords": [{"text": "physician"}]}, "sentence": " It also fits with my personal objective as a physician working in this industry to spend my energies to tackle the areas of highest unmet need and bring forward transformative medicines.", "object": {"text": "my energies", "keywords": [{"text": "energies"}]}, "action": {"verb": {"text": "spend", "tense": "future"}, "text": "to spend", "normalized": "to spend"}}, {"subject": {"text": "a physician", "keywords": [{"text": "physician"}]}, "sentence": " It also fits with my personal objective as a physician working in this industry to spend my energies to tackle the areas of highest unmet need and bring forward transformative medicines.", "object": {"text": "forward transformative medicines", "keywords": [{"text": "transformative medicines"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "bring", "normalized": "bring"}}, {"subject": {"text": "The patients with diseases in the area of neurology and psychiatry", "keywords": [{"text": "neurology"}, {"text": "psychiatry"}, {"text": "patients"}, {"text": "diseases"}]}, "sentence": " The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "object": {"text": "an enormous burden", "keywords": [{"text": "enormous burden"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carry", "normalized": "carry"}}, {"subject": {"text": "the numbers of people affected", "keywords": [{"text": "numbers"}, {"text": "people"}]}, "sentence": " The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "object": {"text": "growing around the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the numbers of people affected", "keywords": [{"text": "numbers"}, {"text": "people"}]}, "sentence": " The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "object": {"text": "around the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "are growing", "normalized": "be grow"}}, {"subject": {"text": "The first two months with Lundbeck", "keywords": [{"text": "Lundbeck"}], "entities": [{"type": "Company", "text": "Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Quantity", "text": "two months"}]}, "sentence": " The first two months with Lundbeck have confirmed that I've joined a passionate, committed and highly skilled team of colleagues around the world.", "object": {"text": "that I've joined a passionate, committed and highly skilled team of colleagues around the world", "keywords": [{"text": "colleagues"}, {"text": "team"}, {"text": "world"}]}, "action": {"verb": {"text": "confirm", "tense": "past"}, "text": "have confirmed", "normalized": "have confirm"}}, {"subject": {"text": "I"}, "sentence": " The first two months with Lundbeck have confirmed that I've joined a passionate, committed and highly skilled team of colleagues around the world.", "object": {"text": "joined a passionate"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "I"}, "sentence": " The first two months with Lundbeck have confirmed that I've joined a passionate, committed and highly skilled team of colleagues around the world.", "object": {"text": "a passionate"}, "action": {"verb": {"text": "join", "tense": "past"}, "text": "joined", "normalized": "join"}}, {"subject": {"text": "We"}, "sentence": " We have a very strong foundation for developing the company further as we pursue our vision to bring new medicines to people with -- living with diseases of the brain and by doing so, deliver long-term sustainable growth.", "object": {"text": "a very strong foundation for developing the company further as we pursue our vision to bring new medicines to people with -- living with diseases of the brain and by doing so", "keywords": [{"text": "new medicines"}, {"text": "strong foundation"}, {"text": "company"}, {"text": "vision"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "We"}, "sentence": " We have a very strong foundation for developing the company further as we pursue our vision to bring new medicines to people with -- living with diseases of the brain and by doing so, deliver long-term sustainable growth.", "object": {"text": "the company further as we pursue our vision to bring new medicines to people with -- living with diseases of the brain and by doing so, deliver long-term sustainable growth", "keywords": [{"text": "long-term sustainable growth"}, {"text": "new medicines"}, {"text": "company"}, {"text": "vision"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "we"}, "sentence": " We have a very strong foundation for developing the company further as we pursue our vision to bring new medicines to people with -- living with diseases of the brain and by doing so, deliver long-term sustainable growth.", "object": {"text": "new medicines", "keywords": [{"text": "new medicines"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "to bring", "normalized": "to bring"}}, {"subject": {"text": "I"}, "sentence": " I'd like to thank Anders G\u00f6tzsche for his steady leadership during the transition, which helped the company deliver a very strong first nine months.", "object": {"text": "to thank Anders G\u00f6tzsche", "keywords": [{"text": "Anders"}, {"text": "G\u00f6tzsche"}], "entities": [{"type": "Person", "text": "Anders G\u00f6tzsche"}]}, "action": {"verb": {"text": "like", "tense": "present", "negated": true}, "text": "like", "normalized": "like"}}, {"subject": {"text": "I"}, "sentence": " I'd like to thank Anders G\u00f6tzsche for his steady leadership during the transition, which helped the company deliver a very strong first nine months.", "object": {"text": "Anders G\u00f6tzsche", "keywords": [{"text": "Anders"}], "entities": [{"type": "Person", "text": "Anders G\u00f6tzsche"}]}, "action": {"verb": {"text": "thank", "tense": "future"}, "text": "like to thank", "normalized": "like to thank"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " I'd like to thank Anders G\u00f6tzsche for his steady leadership during the transition, which helped the company deliver a very strong first nine months.", "object": {"text": "a very strong"}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "deliver", "normalized": "deliver"}}, {"subject": {"text": "you"}, "sentence": " As you might expect with the arrival of a new leader, we're currently conducting a strategic review within the company and will be able to speak more about that the next time we talk at the time of our full year results in February.", "object": {"text": "with the arrival of a new leader", "keywords": [{"text": "arrival"}, {"text": "new leader"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "might expect", "normalized": "might expect"}}, {"subject": {"text": "we"}, "sentence": " As you might expect with the arrival of a new leader, we're currently conducting a strategic review within the company and will be able to speak more about that the next time we talk at the time of our full year results in February.", "object": {"text": "a strategic review", "keywords": [{"text": "strategic review"}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducting", "normalized": "conduct"}}, {"subject": {"text": "we"}, "sentence": " As you might expect with the arrival of a new leader, we're currently conducting a strategic review within the company and will be able to speak more about that the next time we talk at the time of our full year results in February.", "action": {"verb": {"text": "talk", "tense": "present"}, "text": "talk", "normalized": "talk"}}, {"subject": {"text": "I"}, "sentence": " What I can say right now is that the company has an ambition to create sustainable, profitable growth through delivering new medicines to patients.", "object": {"text": "right now is that the company has an ambition to create sustainable", "keywords": [{"text": "ambition"}, {"text": "company"}]}, "action": {"verb": {"text": "say", "tense": "future"}, "text": "can say", "normalized": "can say"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " What I can say right now is that the company has an ambition to create sustainable, profitable growth through delivering new medicines to patients.", "object": {"text": "an ambition to create sustainable, profitable growth through delivering new medicines to patients", "keywords": [{"text": "profitable growth"}, {"text": "new medicines"}, {"text": "ambition"}, {"text": "patients"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " What I can say right now is that the company has an ambition to create sustainable, profitable growth through delivering new medicines to patients.", "object": {"text": "sustainable, profitable growth", "keywords": [{"text": "profitable growth"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "to create", "normalized": "to create"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " What I can say right now is that the company has an ambition to create sustainable, profitable growth through delivering new medicines to patients.", "object": {"text": "new medicines", "keywords": [{"text": "new medicines"}]}, "action": {"verb": {"text": "deliver", "tense": "present"}, "text": "delivering", "normalized": "deliver"}}, {"subject": {"text": "We"}, "sentence": " We will look to maximize the opportunity with our currently available brands on the market, look to our internal pipeline for acceleration opportunities and the potential for transformative approaches and will continue to seek to supplement the pipeline with external innovation that fits our strategy and core strengths in the central nervous system.", "object": {"text": "to maximize the opportunity with our currently available brands on the market, look to our internal pipeline for acceleration opportunities and the potential for transformative approaches and will continue to seek to supplement the pipeline with external innovation that fits our strategy and core strengths in the central nervous system", "keywords": [{"text": "currently available brands"}, {"text": "transformative approaches"}, {"text": "internal pipeline"}, {"text": "acceleration opportunities"}], "entities": [{"type": "Company", "text": "International Markets"}]}, "action": {"verb": {"text": "look", "tense": "future"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "We"}, "sentence": " We will look to maximize the opportunity with our currently available brands on the market, look to our internal pipeline for acceleration opportunities and the potential for transformative approaches and will continue to seek to supplement the pipeline with external innovation that fits our strategy and core strengths in the central nervous system.", "object": {"text": "the opportunity", "keywords": [{"text": "opportunity"}]}, "action": {"verb": {"text": "maximize", "tense": "future"}, "text": "will look to maximize", "normalized": "will look to maximize"}}, {"subject": {"text": "We"}, "sentence": " We will look to maximize the opportunity with our currently available brands on the market, look to our internal pipeline for acceleration opportunities and the potential for transformative approaches and will continue to seek to supplement the pipeline with external innovation that fits our strategy and core strengths in the central nervous system.", "object": {"text": "to supplement the pipeline with external innovation that fits our strategy and core strengths in the central nervous system", "keywords": [{"text": "external innovation"}, {"text": "core strengths"}, {"text": "pipeline"}, {"text": "strategy"}], "entities": []}, "action": {"verb": {"text": "seek", "tense": "future"}, "text": "seek", "normalized": "seek"}}, {"subject": {"text": "We"}, "sentence": " We will look to maximize the opportunity with our currently available brands on the market, look to our internal pipeline for acceleration opportunities and the potential for transformative approaches and will continue to seek to supplement the pipeline with external innovation that fits our strategy and core strengths in the central nervous system.", "object": {"text": "the pipeline", "keywords": [{"text": "pipeline"}]}, "action": {"verb": {"text": "supplement", "tense": "future"}, "text": "will continue to seek to supplement", "normalized": "will continue to seek to supplement"}}, {"subject": {"text": "we"}, "sentence": " In the first nine months of the year, we've seen continued improvements in our revenue and profitability.", "object": {"text": "seen continued improvements in our revenue and profitability", "keywords": [{"text": "continued improvements"}, {"text": "profitability"}, {"text": "revenue"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "we"}, "sentence": " In the first nine months of the year, we've seen continued improvements in our revenue and profitability.", "object": {"text": "continued improvements in our revenue and profitability", "keywords": [{"text": "continued improvements"}, {"text": "profitability"}, {"text": "revenue"}]}, "action": {"verb": {"text": "see", "tense": "past"}, "text": "seen", "normalized": "see"}}, {"subject": {"text": "Revenue growth", "keywords": [{"text": "Revenue growth"}]}, "sentence": " Revenue growth has been solid despite headwinds from exchange rate and generic erosion, as well as coming from a continued focus on cost and disciplined investment.", "object": {"text": "solid"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}], "concepts": [{"text": "Revenue", "relevance": 0.920016, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Lundbeck", "relevance": 0.918555, "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}], "categories": [{"score": 0.546074, "label": "/finance/financial news"}, {"score": 0.476914, "label": "/finance/investing"}, {"score": 0.476914, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "H Lundbeck A/S ( OTC:HLUKF ) Q3 2018 Earnings Conference Call November 7, 2018 7:00 AM ET Executives Deborah Dunsire - CEO & President Anders G\u00f6tzsche - EVP & CFO Anders Pedersen - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial Operations Analysts Trung Huynh - Cr\u00e9dit Suisse James Gordon - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Michael Novod - Nordea Markets Martin Parkh\u00e6i - Danske Bank Timothy Race - Deutsche Bank Peter Sehested - Handelsbanken Marietta Miemietz - Primavenue Advisory Services Limited Operator Ladies and gentlemen, welcome to the H. Lundbeck interim report for the third quarter, first nine months of 2018.", "score": 0.476123, "arguments": [{"text": "Executives", "location": [90, 100], "entities": [{"type": "Person", "text": "Executives"}]}, {"text": "Earnings Conference Call", "location": [37, 61], "entities": [{"type": "Organization", "text": "Earnings Conference Call"}]}]}, {"type": "hasAttribute", "sentence": "The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "score": 0.890981, "arguments": [{"text": "patients", "location": [2342, 2350], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diseases", "location": [2356, 2364], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "employedBy", "sentence": "Operator Our next question comes from the line of James Gordon of JPMorgan.", "score": 0.5662, "arguments": [{"text": "James Gordon", "location": [24551, 24563], "entities": [{"type": "Person", "text": "James Gordon"}]}, {"text": "JPMorgan", "location": [24567, 24575], "entities": [{"type": "Organization", "text": "JPMorgan"}]}]}, {"type": "agentOf", "sentence": "Can we say something like how many patients are in the backlog relative to how many patients are on therapy?", "score": 0.975753, "arguments": [{"text": "we", "location": [25587, 25589], "entities": [{"type": "Person", "text": "we"}]}, {"text": "say", "location": [25590, 25593], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "ownerOf", "sentence": "So within our own pipeline, we'll be looking for those acceleration opportunities and products that we bring in from external innovation may need development resources.", "score": 0.67363, "arguments": [{"text": "our", "location": [26087, 26090], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [26095, 26103], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "agentOf", "sentence": "Along these lines, what Deborah is illustrating, what we have said earlier is I think what I can hear from Deborah is she's very much in alignment with that.", "score": 0.462933, "arguments": [{"text": "Deborah", "location": [26594, 26601], "entities": [{"type": "Person", "text": "Deborah"}]}, {"text": "said", "location": [26632, 26636], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "If we find good opportunities where we can see value creation, we have also said in the past, would we be scared to death to go to 20% of revenue on nominal value beyond DKK3 billion, which is kind of the magnitude of the investments?", "score": 0.96911, "arguments": [{"text": "we", "location": [26791, 26793], "entities": [{"type": "Person", "text": "we"}]}, {"text": "said", "location": [26804, 26808], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "But, of course, as Deborah also described, we will, of course, make proof testing of, is it something that creates value in the long run?", "score": 0.986451, "arguments": [{"text": "Deborah", "location": [26998, 27005], "entities": [{"type": "Person", "text": "Deborah"}]}, {"text": "described", "location": [27011, 27020], "entities": [{"type": "EventCommunication", "text": "described"}]}]}, {"type": "agentOf", "sentence": "And it's always good to have kind of a threshold or a bar where we say, if we want to go above that, then we need to internally to discuss thoroughly what are we investing in.", "score": 0.96753, "arguments": [{"text": "we", "location": [27274, 27276], "entities": [{"type": "Person", "text": "we"}]}, {"text": "say", "location": [27277, 27280], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "But I will say that the backlog is expected to be resolved in Q4.", "score": 0.934666, "arguments": [{"text": "I", "location": [28513, 28514], "entities": [{"type": "Person", "text": "I"}]}, {"text": "say", "location": [28520, 28523], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "And I reiterate that this backlog issue is a temporary phenomenon.", "score": 0.965986, "arguments": [{"text": "I", "location": [28724, 28725], "entities": [{"type": "Person", "text": "I"}]}, {"text": "reiterate", "location": [28726, 28735], "entities": [{"type": "EventCommunication", "text": "reiterate"}]}]}, {"type": "managerOf", "sentence": "Operator Our next question comes from the line of Wimal Kapadia of Bernstein.", "score": 0.461704, "arguments": [{"text": "Bernstein", "location": [28854, 28863], "entities": [{"type": "Person", "text": "Bernstein"}]}, {"text": "Wimal Kapadia", "location": [28837, 28850], "entities": [{"type": "Organization", "text": "Wimal Kapadia"}]}]}, {"type": "residesIn", "sentence": "The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "score": 0.633193, "arguments": [{"text": "patients", "location": [2342, 2350], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "area", "location": [2372, 2376], "entities": [{"type": "Location", "text": "area"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire Wimal, I'm going to hand over to Anders G\u00f6tzsche to take the question on contract manufacturing, and then Anders Pedersen will respond on 35700.", "score": 0.982386, "arguments": [{"text": "Anders Pedersen", "location": [29778, 29793], "entities": [{"type": "Person", "text": "Anders Pedersen"}]}, {"text": "respond", "location": [29799, 29806], "entities": [{"type": "EventCommunication", "text": "respond"}]}]}, {"type": "timeOf", "sentence": "Deborah Dunsire Wimal, I'm going to hand over to Anders G\u00f6tzsche to take the question on contract manufacturing, and then Anders Pedersen will respond on 35700.", "score": 0.971228, "arguments": [{"text": "35700", "location": [29810, 29815], "entities": [{"type": "Date", "text": "35700"}]}, {"text": "respond", "location": [29799, 29806], "entities": [{"type": "EventCommunication", "text": "respond"}]}]}, {"type": "agentOf", "sentence": "Peter Anastasiou will respond on Northera.", "score": 0.976022, "arguments": [{"text": "Peter Anastasiou", "location": [29817, 29833], "entities": [{"type": "Person", "text": "Peter Anastasiou"}]}, {"text": "respond", "location": [29839, 29846], "entities": [{"type": "EventCommunication", "text": "respond"}]}]}, {"type": "agentOf", "sentence": "First, I just want to point out that the questions you asked about, about high cost and administrative burden, are not new phenomenon.", "score": 0.78341, "arguments": [{"text": "I", "location": [31976, 31977], "entities": [{"type": "Person", "text": "I"}]}, {"text": "point out", "location": [31991, 32000], "entities": [{"type": "EventCommunication", "text": "point out"}]}]}, {"type": "agentOf", "sentence": "First, I just want to point out that the questions you asked about, about high cost and administrative burden, are not new phenomenon.", "score": 0.958845, "arguments": [{"text": "you", "location": [32020, 32023], "entities": [{"type": "Person", "text": "you"}]}, {"text": "asked", "location": [32024, 32029], "entities": [{"type": "EventCommunication", "text": "asked"}]}]}, {"type": "employedBy", "sentence": "You implicitly gave for Q4 on EBIT, somewhere around DKK650 million to DKK1 billion and that includes approximately DKK100 million one- off.", "score": 0.780058, "arguments": [{"text": "Q4", "location": [32817, 32819], "entities": [{"type": "Person", "text": "Q4"}]}, {"text": "EBIT", "location": [32823, 32827], "entities": [{"type": "Organization", "text": "EBIT"}]}]}, {"type": "hasAttribute", "sentence": "You implicitly gave for Q4 on EBIT, somewhere around DKK650 million to DKK1 billion and that includes approximately DKK100 million one- off.", "score": 0.724754, "arguments": [{"text": "EBIT", "location": [32823, 32827], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "DKK1 billion", "location": [32864, 32876], "entities": [{"type": "Money", "text": "DKK1 billion"}]}]}, {"type": "agentOf", "sentence": "You've seen the pricing, of course, which you also mentioned.", "score": 0.878135, "arguments": [{"text": "you", "location": [33258, 33261], "entities": [{"type": "Person", "text": "you"}]}, {"text": "mentioned", "location": [33267, 33276], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "partOfMany", "sentence": "Deborah Dunsire So I think on the fourth quarter, I'm going to ask Anders G\u00f6tzsche to comment on how we're thinking about the fourth quarter cost structure going forward.", "score": 0.879722, "arguments": [{"text": "Deborah Dunsire", "location": [33726, 33741], "entities": [{"type": "Person", "text": "Deborah Dunsire"}]}, {"text": "we", "location": [33827, 33829], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire So I think on the fourth quarter, I'm going to ask Anders G\u00f6tzsche to comment on how we're thinking about the fourth quarter cost structure going forward.", "score": 0.624727, "arguments": [{"text": "I", "location": [33776, 33777], "entities": [{"type": "Person", "text": "I"}]}, {"text": "ask", "location": [33789, 33792], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "hasAttribute", "sentence": "The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "score": 0.658216, "arguments": [{"text": "their", "location": [2435, 2440], "entities": [{"type": "Person", "text": "their"}]}, {"text": "disease", "location": [2441, 2448], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "partOfMany", "sentence": "Deborah Dunsire So I think on the fourth quarter, I'm going to ask Anders G\u00f6tzsche to comment on how we're thinking about the fourth quarter cost structure going forward.", "score": 0.910598, "arguments": [{"text": "Anders G\u00f6tzsche", "location": [33793, 33808], "entities": [{"type": "Person", "text": "Anders G\u00f6tzsche"}]}, {"text": "we", "location": [33827, 33829], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "agentOf", "sentence": "And then Peter will take the Onfi and the Epidiolex questions.", "score": 0.577882, "arguments": [{"text": "Onfi", "location": [34088, 34092], "entities": [{"type": "Person", "text": "Onfi"}]}, {"text": "questions", "location": [34111, 34120], "entities": [{"type": "EventCommunication", "text": "questions"}]}]}, {"type": "agentOf", "sentence": "And then Peter will take the Onfi and the Epidiolex questions.", "score": 0.988216, "arguments": [{"text": "Epidiolex", "location": [34101, 34110], "entities": [{"type": "Organization", "text": "Epidiolex"}]}, {"text": "questions", "location": [34111, 34120], "entities": [{"type": "EventCommunication", "text": "questions"}]}]}, {"type": "locatedAt", "sentence": "You have also seen that in the past we have a high activity level ongoing in the commercial business, actually starting in September after coming back from holiday in the southern part of Europe and also other places.", "score": 0.918157, "arguments": [{"text": "southern part", "location": [34337, 34350], "entities": [{"type": "Location", "text": "southern part"}]}, {"text": "Europe", "location": [34354, 34360], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}]}, {"type": "affectedBy", "sentence": "In the case of Epidiolex, it's an adjunct treatment to Onfi.", "score": 0.609465, "arguments": [{"text": "Epidiolex", "location": [35665, 35674], "entities": [{"type": "Organization", "text": "Epidiolex"}]}, {"text": "case", "location": [35657, 35661], "entities": [{"type": "EventLegal", "text": "case"}]}]}, {"type": "affectedBy", "sentence": "Actually the trials were done in utilization with Onfi.", "score": 0.650558, "arguments": [{"text": "Onfi", "location": [35761, 35765], "entities": [{"type": "Person", "text": "Onfi"}]}, {"text": "trials", "location": [35724, 35730], "entities": [{"type": "EventLegal", "text": "trials"}]}]}, {"type": "partOf", "sentence": "Isn't this just the nature of operating within the central nervous system that it's very product driven so you will have to live with that you come to this very rough time some time and it would be misleading to direct the company with CNS to be a sustainable growth company?", "score": 0.719884, "arguments": [{"text": "company", "location": [36527, 36534], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "CNS", "location": [36540, 36543], "entities": [{"type": "Organization", "text": "CNS"}]}]}, {"type": "partOf", "sentence": "Isn't this just the nature of operating within the central nervous system that it's very product driven so you will have to live with that you come to this very rough time some time and it would be misleading to direct the company with CNS to be a sustainable growth company?", "score": 0.329726, "arguments": [{"text": "company", "location": [36571, 36578], "entities": [{"type": "Organization", "text": "company"}]}, {"text": "CNS", "location": [36540, 36543], "entities": [{"type": "Organization", "text": "CNS"}]}]}, {"type": "hasAttribute", "sentence": "I think it's a couple years back you made this rather rigid pipeline strategy, meaning that you only had these four core areas, where one of them is depression where you don't have 1 single product in your pipeline.", "score": 0.843887, "arguments": [{"text": "them", "location": [36773, 36777], "entities": [{"type": "Person", "text": "them"}]}, {"text": "depression", "location": [36781, 36791], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "I think it's a couple years back you made this rather rigid pipeline strategy, meaning that you only had these four core areas, where one of them is depression where you don't have 1 single product in your pipeline.", "score": 0.840117, "arguments": [{"text": "you", "location": [36798, 36801], "entities": [{"type": "Person", "text": "you"}]}, {"text": "depression", "location": [36781, 36791], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "The patients with diseases in the area of neurology and psychiatry carry an enormous burden with their disease, and the numbers of people affected are growing around the world.", "score": 0.72774, "arguments": [{"text": "people", "location": [2469, 2475], "entities": [{"type": "Person", "text": "people"}]}, {"text": "disease", "location": [2441, 2448], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "ownerOf", "sentence": "I think it's a couple years back you made this rather rigid pipeline strategy, meaning that you only had these four core areas, where one of them is depression where you don't have 1 single product in your pipeline.", "score": 0.501876, "arguments": [{"text": "your", "location": [36833, 36837], "entities": [{"type": "Person", "text": "your"}]}, {"text": "pipeline", "location": [36838, 36846], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "hasAttribute", "sentence": "And I don't know if you can see any external candidates which are interesting within depression.", "score": 0.880955, "arguments": [{"text": "candidates", "location": [36893, 36903], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "depression", "location": [36933, 36943], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "locatedAt", "sentence": "But is there any chance that you believe that there will be more proper now to maybe divert a bit of this strategy and maybe also look at external candidates, which are outside your four core areas?", "score": 0.73904, "arguments": [{"text": "which", "location": [37104, 37109], "entities": [{"type": "Person", "text": "which"}]}, {"text": "areas", "location": [37137, 37142], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "agentOf", "sentence": "What we have said is that we will build on Lundbeck's core strengths in knowledge and understanding in psychiatry and neurology.", "score": 0.890337, "arguments": [{"text": "we", "location": [38260, 38262], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "said", "location": [38268, 38272], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "And so let's talk about that more in February when we come together.", "score": 0.530859, "arguments": [{"text": "February", "location": [38421, 38429], "entities": [{"type": "Date", "text": "February"}]}, {"text": "talk", "location": [38397, 38401], "entities": [{"type": "EventCommunication", "text": "talk"}]}]}, {"type": "employedBy", "sentence": "When I think about growth strategies, I think about building for on our sources of competitive strength, and our competitive strength is really in the central nervous system area.", "score": 0.829422, "arguments": [{"text": "sources", "location": [38525, 38532], "entities": [{"type": "Person", "text": "sources"}]}, {"text": "our", "location": [38521, 38524], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "agentOf", "sentence": "And Anders, now you talked about speeding up your own pipeline.", "score": 0.597091, "arguments": [{"text": "Anders", "location": [38712, 38718], "entities": [{"type": "Person", "text": "Anders"}]}, {"text": "talked", "location": [38728, 38734], "entities": [{"type": "EventCommunication", "text": "talked"}]}]}, {"type": "agentOf", "sentence": "And Anders, now you talked about speeding up your own pipeline.", "score": 0.56151, "arguments": [{"text": "you", "location": [38724, 38727], "entities": [{"type": "Person", "text": "you"}]}, {"text": "talked", "location": [38728, 38734], "entities": [{"type": "EventCommunication", "text": "talked"}]}]}, {"type": "residesIn", "sentence": "And Anders, now you talked about speeding up your own pipeline.", "score": 0.193028, "arguments": [{"text": "your", "location": [38753, 38757], "entities": [{"type": "Person", "text": "your"}]}, {"text": "pipeline", "location": [38762, 38770], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "hasAttribute", "sentence": "And I think with respect to your particular question about depression, then I think it is quite clear that, that is a very tough area because of the very generic label that currently exists across that area.", "score": 0.872961, "arguments": [{"text": "your", "location": [39499, 39503], "entities": [{"type": "Person", "text": "your"}]}, {"text": "depression", "location": [39530, 39540], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "agentOf", "sentence": "The first two months with Lundbeck have confirmed that I've joined a passionate, committed and highly skilled team of colleagues around the world.", "score": 0.861362, "arguments": [{"text": "Lundbeck", "location": [2608, 2616], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "confirmed", "location": [2622, 2631], "entities": [{"type": "EventCommunication", "text": "confirmed"}]}]}, {"type": "hasAttribute", "sentence": "And I think with respect to your particular question about depression, then I think it is quite clear that, that is a very tough area because of the very generic label that currently exists across that area.", "score": 0.793923, "arguments": [{"text": "I", "location": [39547, 39548], "entities": [{"type": "Person", "text": "I"}]}, {"text": "depression", "location": [39530, 39540], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "hasAttribute", "sentence": "We do still have, as you full well know, the Trintellix on the market for depression for quite some years with data and patent protection on that.", "score": 0.918934, "arguments": [{"text": "Trintellix", "location": [40022, 40032], "entities": [{"type": "Person", "text": "Trintellix"}]}, {"text": "depression", "location": [40051, 40061], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "agentOf", "sentence": "So it's not that we are abandoning the depression per se, but we don't want to take molecules into an area if we don't see a clear differential position there.", "score": 0.844465, "arguments": [{"text": "we", "location": [40325, 40327], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "abandoning", "location": [40332, 40342], "entities": [{"type": "EventCommunication", "text": "abandoning"}]}]}, {"type": "agentOf", "sentence": "Anders G\u00f6tzsche In theory, you could say yes.", "score": 0.861199, "arguments": [{"text": "you", "location": [40914, 40917], "entities": [{"type": "Person", "text": "you"}]}, {"text": "say", "location": [40924, 40927], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "employedBy", "sentence": "Operator Our next question comes from the line of Tim Race of Deutsche Bank.", "score": 0.952946, "arguments": [{"text": "Tim Race", "location": [41922, 41930], "entities": [{"type": "Person", "text": "Tim Race"}]}, {"text": "Deutsche Bank", "location": [41934, 41947], "entities": [{"type": "Organization", "text": "Deutsche Bank"}]}]}, {"type": "partOfMany", "sentence": "Deborah Dunsire So I think your question going into 2019 with respect to Onfi and Sabril, I'm going to actually turn it over to Anders G\u00f6tzsche to comment.", "score": 0.879575, "arguments": [{"text": "Deborah Dunsire", "location": [42635, 42650], "entities": [{"type": "Person", "text": "Deborah Dunsire"}]}, {"text": "your", "location": [42662, 42666], "entities": [{"type": "Person", "text": "your"}]}]}, {"type": "partOfMany", "sentence": "Anders G\u00f6tzsche So Tim, what you should expect and that is totally consistent with what we have also said during the last year is that you should expect SG&A to be pretty much at the same level as we have this year.", "score": 0.707478, "arguments": [{"text": "Anders G\u00f6tzsche", "location": [42791, 42806], "entities": [{"type": "Person", "text": "Anders G\u00f6tzsche"}]}, {"text": "we", "location": [42879, 42881], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "partOfMany", "sentence": "Anders G\u00f6tzsche So Tim, what you should expect and that is totally consistent with what we have also said during the last year is that you should expect SG&A to be pretty much at the same level as we have this year.", "score": 0.969631, "arguments": [{"text": "Tim", "location": [42810, 42813], "entities": [{"type": "Person", "text": "Tim"}]}, {"text": "we", "location": [42879, 42881], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "agentOf", "sentence": "Anders G\u00f6tzsche So Tim, what you should expect and that is totally consistent with what we have also said during the last year is that you should expect SG&A to be pretty much at the same level as we have this year.", "score": 0.937026, "arguments": [{"text": "we", "location": [42879, 42881], "entities": [{"type": "Person", "text": "we"}]}, {"text": "said", "location": [42892, 42896], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Anders G\u00f6tzsche So Tim, what you should expect and that is totally consistent with what we have also said during the last year is that you should expect SG&A to be pretty much at the same level as we have this year.", "score": 0.931379, "arguments": [{"text": "last year", "location": [42908, 42917], "entities": [{"type": "Date", "text": "last year"}]}, {"text": "said", "location": [42892, 42896], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOfMany", "sentence": "The first two months with Lundbeck have confirmed that I've joined a passionate, committed and highly skilled team of colleagues around the world.", "score": 0.457929, "arguments": [{"text": "team", "location": [2692, 2696], "entities": [{"type": "Person", "text": "team"}]}, {"text": "colleagues", "location": [2700, 2710], "entities": [{"type": "Person", "text": "colleagues"}]}]}, {"type": "locatedAt", "sentence": "Deborah Dunsire Jake, would you like to comment at I think Tim had raised Rexulti in Europe as we go through the launches there?", "score": 0.539836, "arguments": [{"text": "Rexulti", "location": [43869, 43876], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "Europe", "location": [43880, 43886], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}]}, {"type": "locatedAt", "sentence": "We have the approval, Tim, of Rexulti in Europe.", "score": 0.463176, "arguments": [{"text": "Rexulti", "location": [43989, 43996], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "Europe", "location": [44000, 44006], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}]}, {"type": "locatedAt", "sentence": "And I think also the last quarter, we said that the growth will take place -- sorry, launch will take place of Rexulti in Europe in the spring of '19, and that is still the case.", "score": 0.633699, "arguments": [{"text": "Rexulti", "location": [44119, 44126], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "Europe", "location": [44130, 44136], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}]}, {"type": "timeOf", "sentence": "And I think also the last quarter, we said that the growth will take place -- sorry, launch will take place of Rexulti in Europe in the spring of '19, and that is still the case.", "score": 0.654919, "arguments": [{"text": "last quarter", "location": [44029, 44041], "entities": [{"type": "Date", "text": "last quarter"}]}, {"text": "said", "location": [44046, 44050], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "And I think also the last quarter, we said that the growth will take place -- sorry, launch will take place of Rexulti in Europe in the spring of '19, and that is still the case.", "score": 0.99234, "arguments": [{"text": "we", "location": [44043, 44045], "entities": [{"type": "Person", "text": "we"}]}, {"text": "said", "location": [44046, 44050], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "And I think also the last quarter, we said that the growth will take place -- sorry, launch will take place of Rexulti in Europe in the spring of '19, and that is still the case.", "score": 0.679793, "arguments": [{"text": "Rexulti", "location": [44119, 44126], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "19", "location": [44155, 44157], "entities": [{"type": "Age", "text": "19"}]}]}, {"type": "locatedAt", "sentence": "We'll be launching in Saudi Arabia this month, and then in early '19 in Mexico and then the first launch will take place in Europe.", "score": 0.544481, "arguments": [{"text": "We", "location": [44245, 44247], "entities": [{"type": "Person", "text": "We"}]}, {"text": "Saudi Arabia", "location": [44267, 44279], "entities": [{"type": "GeopoliticalEntity", "text": "Saudi Arabia"}]}]}, {"type": "partOfMany", "sentence": "Anders G\u00f6tzsche Please hold on, it seems like we have a small technical issue, and we hope that the remaining questions will very fast come through.", "score": 0.662845, "arguments": [{"text": "Anders G\u00f6tzsche", "location": [44500, 44515], "entities": [{"type": "Person", "text": "Anders G\u00f6tzsche"}]}, {"text": "we", "location": [44546, 44548], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire We can see that there were questions and what we can say is that Palle will follow up by phone to make sure that we get your questions answered.", "score": 0.870923, "arguments": [{"text": "we", "location": [44711, 44713], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "say", "location": [44718, 44721], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire We can see that there were questions and what we can say is that Palle will follow up by phone to make sure that we get your questions answered.", "score": 0.636985, "arguments": [{"text": "your", "location": [44785, 44789], "entities": [{"type": "Person", "text": "your"}]}, {"text": "answered", "location": [44800, 44808], "entities": [{"type": "EventCommunication", "text": "answered"}]}]}, {"type": "agentOf", "sentence": "Peter Sehested I guess most of my questions have already been answered, so I will be so polite as to jump back out of the queue.", "score": 0.987674, "arguments": [{"text": "my", "location": [45043, 45045], "entities": [{"type": "Person", "text": "my"}]}, {"text": "questions", "location": [45046, 45055], "entities": [{"type": "EventCommunication", "text": "questions"}]}]}, {"type": "employedBy", "sentence": "We now go to Marietta Miemietz of Prime Avenue.", "score": 0.932664, "arguments": [{"text": "Marietta Miemietz", "location": [45188, 45205], "entities": [{"type": "Person", "text": "Marietta Miemietz"}]}, {"text": "Prime Avenue", "location": [45209, 45221], "entities": [{"type": "Organization", "text": "Prime Avenue"}]}]}, {"type": "locatedAt", "sentence": "The first two months with Lundbeck have confirmed that I've joined a passionate, committed and highly skilled team of colleagues around the world.", "score": 0.46312, "arguments": [{"text": "colleagues", "location": [2700, 2710], "entities": [{"type": "Person", "text": "colleagues"}]}, {"text": "world", "location": [2722, 2727], "entities": [{"type": "GeopoliticalEntity", "text": "world"}]}]}, {"type": "hasAttribute", "sentence": "Because if I remember correctly, Lundbeck also never really thought it made a lot of sense to take such a potent antipsychotic into depression.", "score": 0.661525, "arguments": [{"text": "Lundbeck", "location": [46051, 46059], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "depression", "location": [46150, 46160], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "agentOf", "sentence": "And that's what makes us say, we wouldn't get a treatment-resistant label with the product.", "score": 0.978061, "arguments": [{"text": "us", "location": [46855, 46857], "entities": [{"type": "Person", "text": "us"}]}, {"text": "say", "location": [46858, 46861], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "At this stage, we would say that treatment-resistant schizophrenia sort of indication as such is not one that we will pursue.", "score": 0.946837, "arguments": [{"text": "we", "location": [48264, 48266], "entities": [{"type": "Person", "text": "we"}]}, {"text": "say", "location": [48273, 48276], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "We heard Takeda say that they reported softer Q for that Q1 or Q2 for them, equal to your Q3, due to a true-up or a prior period adjustment on the rebate.", "score": 0.524242, "arguments": [{"text": "We", "location": [48800, 48802], "entities": [{"type": "Person", "text": "We"}]}, {"text": "say", "location": [48816, 48819], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "agentOf", "sentence": "We heard Takeda say that they reported softer Q for that Q1 or Q2 for them, equal to your Q3, due to a true-up or a prior period adjustment on the rebate.", "score": 0.7785, "arguments": [{"text": "Takeda", "location": [48809, 48815], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "say", "location": [48816, 48819], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "partOfMany", "sentence": "We heard Takeda say that they reported softer Q for that Q1 or Q2 for them, equal to your Q3, due to a true-up or a prior period adjustment on the rebate.", "score": 0.519288, "arguments": [{"text": "Takeda", "location": [48809, 48815], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "them", "location": [48870, 48874], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "agentOf", "sentence": "We heard Takeda say that they reported softer Q for that Q1 or Q2 for them, equal to your Q3, due to a true-up or a prior period adjustment on the rebate.", "score": 0.987191, "arguments": [{"text": "they", "location": [48825, 48829], "entities": [{"type": "Person", "text": "they"}]}, {"text": "reported", "location": [48830, 48838], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "partOfMany", "sentence": "We heard Takeda say that they reported softer Q for that Q1 or Q2 for them, equal to your Q3, due to a true-up or a prior period adjustment on the rebate.", "score": 0.945285, "arguments": [{"text": "Q1", "location": [48857, 48859], "entities": [{"type": "Person", "text": "Q1"}]}, {"text": "them", "location": [48870, 48874], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "partOfMany", "sentence": "We heard Takeda say that they reported softer Q for that Q1 or Q2 for them, equal to your Q3, due to a true-up or a prior period adjustment on the rebate.", "score": 0.81037, "arguments": [{"text": "Q2", "location": [48863, 48865], "entities": [{"type": "Person", "text": "Q2"}]}, {"text": "them", "location": [48870, 48874], "entities": [{"type": "Person", "text": "them"}]}]}, {"type": "residesIn", "sentence": "Is that something we then should model in for Q4 in your numbers, because there's no real correlation between Takeda numbers and Trintellix U.S. sales and your royalties in the U.S.?", "score": 0.46695, "arguments": [{"text": "Trintellix", "location": [49084, 49094], "entities": [{"type": "Person", "text": "Trintellix"}]}, {"text": "U.S.", "location": [49095, 49099], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "residesIn", "sentence": "So what you have -- what you can see from -- we don't normally comment on Takeda's numbers, but they have their expectation for Trintellix in the U.S. is double-digit growth continued, which you are also seeing that we are delivering.", "score": 0.47059, "arguments": [{"text": "Trintellix", "location": [49420, 49430], "entities": [{"type": "Person", "text": "Trintellix"}]}, {"text": "U.S.", "location": [49438, 49442], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "hasAttribute", "sentence": "We have a very strong foundation for developing the company further as we pursue our vision to bring new medicines to people with -- living with diseases of the brain and by doing so, deliver long-term sustainable growth.", "score": 0.788543, "arguments": [{"text": "people", "location": [2847, 2853], "entities": [{"type": "Person", "text": "people"}]}, {"text": "diseases", "location": [2874, 2882], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire I'd ask Anders to take that question.", "score": 0.591418, "arguments": [{"text": "Deborah Dunsire", "location": [49138, 49153], "entities": [{"type": "Person", "text": "Deborah Dunsire"}]}, {"text": "ask", "location": [49158, 49161], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire I'd ask Anders to take that question.", "score": 0.644589, "arguments": [{"text": "I", "location": [49154, 49155], "entities": [{"type": "Person", "text": "I"}]}, {"text": "ask", "location": [49158, 49161], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "affectedBy", "sentence": "Deborah Dunsire I'd ask Anders to take that question.", "score": 0.758508, "arguments": [{"text": "Anders", "location": [49162, 49168], "entities": [{"type": "Person", "text": "Anders"}]}, {"text": "ask", "location": [49158, 49161], "entities": [{"type": "EventCommunication", "text": "ask"}]}]}, {"type": "partOfMany", "sentence": "So what you have -- what you can see from -- we don't normally comment on Takeda's numbers, but they have their expectation for Trintellix in the U.S. is double-digit growth continued, which you are also seeing that we are delivering.", "score": 0.825248, "arguments": [{"text": "Takeda", "location": [49366, 49372], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "they", "location": [49388, 49392], "entities": [{"type": "Person", "text": "they"}]}]}, {"type": "partOf", "sentence": "So we expect that our U.S. organization will continue together with Takeda to deliver a stellar performance with Trintellix.", "score": 0.596817, "arguments": [{"text": "organization", "location": [49625, 49637], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "our", "location": [49616, 49619], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "partOf", "sentence": "So we expect that our U.S. organization will continue together with Takeda to deliver a stellar performance with Trintellix.", "score": 0.975815, "arguments": [{"text": "organization", "location": [49625, 49637], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "U.S.", "location": [49620, 49624], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "managerOf", "sentence": "So we expect that our U.S. organization will continue together with Takeda to deliver a stellar performance with Trintellix.", "score": 0.272154, "arguments": [{"text": "Takeda", "location": [49666, 49672], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "organization", "location": [49625, 49637], "entities": [{"type": "Organization", "text": "organization"}]}]}, {"type": "agentOf", "sentence": "As you might expect with the arrival of a new leader, we're currently conducting a strategic review within the company and will be able to speak more about that the next time we talk at the time of our full year results in February.", "score": 0.979984, "arguments": [{"text": "we", "location": [3275, 3277], "entities": [{"type": "Person", "text": "we"}]}, {"text": "talk", "location": [3278, 3282], "entities": [{"type": "EventCommunication", "text": "talk"}]}]}, {"type": "agentOf", "sentence": "What I can say right now is that the company has an ambition to create sustainable, profitable growth through delivering new medicines to patients.", "score": 0.653857, "arguments": [{"text": "I", "location": [3338, 3339], "entities": [{"type": "Person", "text": "I"}]}, {"text": "say", "location": [3344, 3347], "entities": [{"type": "EventCommunication", "text": "say"}]}]}, {"type": "partOfMany", "sentence": "H Lundbeck A/S ( OTC:HLUKF ) Q3 2018 Earnings Conference Call November 7, 2018 7:00 AM ET Executives Deborah Dunsire - CEO & President Anders G\u00f6tzsche - EVP & CFO Anders Pedersen - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial Operations Analysts Trung Huynh - Cr\u00e9dit Suisse James Gordon - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Michael Novod - Nordea Markets Martin Parkh\u00e6i - Danske Bank Timothy Race - Deutsche Bank Peter Sehested - Handelsbanken Marietta Miemietz - Primavenue Advisory Services Limited Operator Ladies and gentlemen, welcome to the H. Lundbeck interim report for the third quarter, first nine months of 2018.", "score": 0.945333, "arguments": [{"text": "Deborah Dunsire", "location": [101, 116], "entities": [{"type": "Person", "text": "Deborah Dunsire"}]}, {"text": "Executives", "location": [90, 100], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "locatedAt", "sentence": "Our key products continued growing strongly across all regions of the world, achieving 29% growth in local currencies.", "score": 0.674635, "arguments": [{"text": "Our", "location": [4576, 4579], "entities": [{"type": "Person", "text": "Our"}]}, {"text": "regions", "location": [4631, 4638], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Our key products continued growing strongly across all regions of the world, achieving 29% growth in local currencies.", "score": 0.968735, "arguments": [{"text": "regions", "location": [4631, 4638], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "world", "location": [4646, 4651], "entities": [{"type": "GeopoliticalEntity", "text": "world"}]}]}, {"type": "affectedBy", "sentence": "In parallel with the sales growth, we have managed our costs very effectively, thus reported EBIT increased by 28%, reaching DKK4.5 billion and the reported EBIT margin reached 32%.", "score": 0.690952, "arguments": [{"text": "EBIT", "location": [4788, 4792], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "reported", "location": [4779, 4787], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "hasAttribute", "sentence": "In parallel with the sales growth, we have managed our costs very effectively, thus reported EBIT increased by 28%, reaching DKK4.5 billion and the reported EBIT margin reached 32%.", "score": 0.631942, "arguments": [{"text": "EBIT", "location": [4788, 4792], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "DKK4.5 billion", "location": [4820, 4834], "entities": [{"type": "Money", "text": "DKK4.5 billion"}]}]}, {"type": "participantIn", "sentence": "Anders Gotzsche will discuss the financial performance in more detail and Anders Gersel will provide a brief pipeline update towards the end of the call.", "score": 0.840703, "arguments": [{"text": "Anders Gotzsche", "location": [4944, 4959], "entities": [{"type": "Person", "text": "Anders Gotzsche"}]}, {"text": "discuss", "location": [4965, 4972], "entities": [{"type": "EventMeeting", "text": "discuss"}]}]}, {"type": "timeOf", "sentence": "Before we go on, I would just acknowledge that the Phase III outcome for 35700 announced two weeks ago was a tremendous disappointment for patients whose schizophrenia is not adequately treated with current therapy, as well as for us here at Lundbeck.", "score": 0.981715, "arguments": [{"text": "two weeks ago", "location": [5187, 5200], "entities": [{"type": "Date", "text": "two weeks ago"}]}, {"text": "announced", "location": [5177, 5186], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOfMany", "sentence": "Before we go on, I would just acknowledge that the Phase III outcome for 35700 announced two weeks ago was a tremendous disappointment for patients whose schizophrenia is not adequately treated with current therapy, as well as for us here at Lundbeck.", "score": 0.752048, "arguments": [{"text": "whose", "location": [5246, 5251], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "patients", "location": [5237, 5245], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "partOfMany", "sentence": "Before we go on, I would just acknowledge that the Phase III outcome for 35700 announced two weeks ago was a tremendous disappointment for patients whose schizophrenia is not adequately treated with current therapy, as well as for us here at Lundbeck.", "score": 0.401877, "arguments": [{"text": "schizophrenia", "location": [5252, 5265], "entities": [{"type": "Person", "text": "schizophrenia"}]}, {"text": "patients", "location": [5237, 5245], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "agentOf", "sentence": "The results from the DAYBREAK trial demonstrated that 35700 is a safe and well-tolerated antipsychotic medication, having a similar efficacy as conventional therapy in this treatment-resistant indication, thus not achieving the goal we set out for superior performance against current standards of care.", "score": 0.858842, "arguments": [{"text": "DAYBREAK", "location": [5371, 5379], "entities": [{"type": "GeopoliticalEntity", "text": "DAYBREAK"}]}, {"text": "trial", "location": [5380, 5385], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "agentOf", "sentence": "The growth in these key brands is a testament to the excellence and execution by the organization, both in development and in sales and marketing around the world.", "score": 0.730041, "arguments": [{"text": "organization", "location": [6588, 6600], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "execution", "location": [6571, 6580], "entities": [{"type": "EventLegal", "text": "execution"}]}]}, {"type": "partOfMany", "sentence": "H Lundbeck A/S ( OTC:HLUKF ) Q3 2018 Earnings Conference Call November 7, 2018 7:00 AM ET Executives Deborah Dunsire - CEO & President Anders G\u00f6tzsche - EVP & CFO Anders Pedersen - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial Operations Analysts Trung Huynh - Cr\u00e9dit Suisse James Gordon - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Michael Novod - Nordea Markets Martin Parkh\u00e6i - Danske Bank Timothy Race - Deutsche Bank Peter Sehested - Handelsbanken Marietta Miemietz - Primavenue Advisory Services Limited Operator Ladies and gentlemen, welcome to the H. Lundbeck interim report for the third quarter, first nine months of 2018.", "score": 0.685969, "arguments": [{"text": "CEO", "location": [119, 122], "entities": [{"type": "Person", "text": "CEO"}]}, {"text": "Executives", "location": [90, 100], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "hasAttribute", "sentence": "Europe has seen a nice turnaround and is now growing by 7% to DKK2.3 billion, driven by our key products, which constitute 43% of sales.", "score": 0.875995, "arguments": [{"text": "our", "location": [7152, 7155], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "DKK2.3 billion", "location": [7126, 7140], "entities": [{"type": "Money", "text": "DKK2.3 billion"}]}]}, {"type": "locatedAt", "sentence": "The largest market for Lundbeck in Europe are France, Italy and Spain, which constitute around 45% of sales in the region.", "score": 0.578453, "arguments": [{"text": "Lundbeck", "location": [7224, 7232], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "Europe", "location": [7236, 7242], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}]}, {"type": "locatedAt", "sentence": "Rexulti has now been formally approved for schizophrenia in Europe, including Switzerland, and we expect to start launching it from the first half of 2019.", "score": 0.666633, "arguments": [{"text": "schizophrenia", "location": [7367, 7380], "entities": [{"type": "Person", "text": "schizophrenia"}]}, {"text": "Europe", "location": [7384, 7390], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}]}, {"type": "partOfMany", "sentence": "Rexulti has now been formally approved for schizophrenia in Europe, including Switzerland, and we expect to start launching it from the first half of 2019.", "score": 0.541628, "arguments": [{"text": "schizophrenia", "location": [7367, 7380], "entities": [{"type": "Person", "text": "schizophrenia"}]}, {"text": "we", "location": [7419, 7421], "entities": [{"type": "Person", "text": "we"}]}]}, {"type": "partOf", "sentence": "Japan is an investment area for Lundbeck as we will establish our own commercial organization here for the expected launch of Trintellix, pending approval next year.", "score": 0.581155, "arguments": [{"text": "organization", "location": [8004, 8016], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "our", "location": [7985, 7988], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "locatedAt", "sentence": "Japan is an investment area for Lundbeck as we will establish our own commercial organization here for the expected launch of Trintellix, pending approval next year.", "score": 0.637753, "arguments": [{"text": "organization", "location": [8004, 8016], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "here", "location": [8017, 8021], "entities": [{"type": "GeopoliticalEntity", "text": "here"}]}]}, {"type": "residesIn", "sentence": "Revenue from Brintellix -- or Trintellix, reached DKK1.5 billion in the period, of which 55% was generated in North America.", "score": 0.600447, "arguments": [{"text": "Brintellix", "location": [8271, 8281], "entities": [{"type": "Person", "text": "Brintellix"}]}, {"text": "Trintellix", "location": [8288, 8298], "entities": [{"type": "GeopoliticalEntity", "text": "Trintellix"}]}]}, {"type": "locatedAt", "sentence": "In the U.S., Trintellix has a volume share of 0.8% and the value share of 21% and both are still increasing.", "score": 0.596711, "arguments": [{"text": "Trintellix", "location": [8396, 8406], "entities": [{"type": "GeopoliticalEntity", "text": "Trintellix"}]}, {"text": "U.S.", "location": [8390, 8394], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "partOfMany", "sentence": "We also see a solid performance in countries, such as South Korea and Canada, and Brintellix has recently launched in China.", "score": 0.478152, "arguments": [{"text": "South Korea", "location": [8792, 8803], "entities": [{"type": "GeopoliticalEntity", "text": "South Korea"}]}, {"text": "countries", "location": [8773, 8782], "entities": [{"type": "GeopoliticalEntity", "text": "countries"}]}]}, {"type": "hasAttribute", "sentence": "Trintellix' strong continued growth 5 years post approval reflects the market's appreciation of the value it provides in addressing unmet needs for patients with depression.", "score": 0.895062, "arguments": [{"text": "patients", "location": [9011, 9019], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "depression", "location": [9025, 9035], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "H Lundbeck A/S ( OTC:HLUKF ) Q3 2018 Earnings Conference Call November 7, 2018 7:00 AM ET Executives Deborah Dunsire - CEO & President Anders G\u00f6tzsche - EVP & CFO Anders Pedersen - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial Operations Analysts Trung Huynh - Cr\u00e9dit Suisse James Gordon - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Michael Novod - Nordea Markets Martin Parkh\u00e6i - Danske Bank Timothy Race - Deutsche Bank Peter Sehested - Handelsbanken Marietta Miemietz - Primavenue Advisory Services Limited Operator Ladies and gentlemen, welcome to the H. Lundbeck interim report for the third quarter, first nine months of 2018.", "score": 0.754302, "arguments": [{"text": "President", "location": [125, 134], "entities": [{"type": "Person", "text": "President"}]}, {"text": "Executives", "location": [90, 100], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "locatedAt", "sentence": "As you are aware, we achieved revised labeling in the U.S. earlier in 2018 regarding the inclusion of processing speed, a key marker for cognition in depressed patients, most recently, that Trintellix benefit in tolerability versus some other medications, vis-\u00e0-vis treatment emergent sexual dysfunction, is now reflected in the Trintellix label.", "score": 0.576055, "arguments": [{"text": "we", "location": [9117, 9119], "entities": [{"type": "Person", "text": "we"}]}, {"text": "U.S.", "location": [9153, 9157], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "basedIn", "sentence": "As you are aware, we achieved revised labeling in the U.S. earlier in 2018 regarding the inclusion of processing speed, a key marker for cognition in depressed patients, most recently, that Trintellix benefit in tolerability versus some other medications, vis-\u00e0-vis treatment emergent sexual dysfunction, is now reflected in the Trintellix label.", "score": 0.937098, "arguments": [{"text": "label", "location": [9439, 9444], "entities": [{"type": "Organization", "text": "label"}]}, {"text": "Trintellix", "location": [9428, 9438], "entities": [{"type": "GeopoliticalEntity", "text": "Trintellix"}]}]}, {"type": "basedIn", "sentence": "Rexulti is still mainly a U.S. franchise and outside North America, it is only launched currently in Australia.", "score": 0.555917, "arguments": [{"text": "franchise", "location": [9497, 9506], "entities": [{"type": "Organization", "text": "franchise"}]}, {"text": "U.S.", "location": [9492, 9496], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}, {"type": "hasAttribute", "sentence": "In terms of revenue, Rexulti achieved DKK1.2 billion in sales for the period, representing a very strong growth of 42% in local currencies.", "score": 0.766332, "arguments": [{"text": "Rexulti", "location": [9834, 9841], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "DKK1.2 billion", "location": [9851, 9865], "entities": [{"type": "Money", "text": "DKK1.2 billion"}]}]}, {"type": "managerOf", "sentence": "The volume share is approaching 0.6% in Canada and 1% in Australia, both countries where Rexulti is only approved for schizophrenia.", "score": 0.446138, "arguments": [{"text": "Rexulti", "location": [10196, 10203], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "countries", "location": [10180, 10189], "entities": [{"type": "GeopoliticalEntity", "text": "countries"}]}]}, {"type": "hasAttribute", "sentence": "Abilify Maintena grew 23% in local currencies to approximately DKK1.2 billion through the 9 months, primarily driven by growth in Europe.", "score": 0.932529, "arguments": [{"text": "Abilify Maintena", "location": [10488, 10504], "entities": [{"type": "Organization", "text": "Abilify Maintena"}]}, {"text": "DKK1.2 billion", "location": [10551, 10565], "entities": [{"type": "Money", "text": "DKK1.2 billion"}]}]}, {"type": "hasAttribute", "sentence": "In the U.S., we have seen a positive effect from the approval of bipolar disorder last year and the value share has increased to 22%.", "score": 0.569482, "arguments": [{"text": "we", "location": [10820, 10822], "entities": [{"type": "Person", "text": "we"}]}, {"text": "bipolar disorder", "location": [10872, 10888], "entities": [{"type": "HealthCondition", "text": "bipolar disorder"}]}]}, {"type": "locatedAt", "sentence": "In local currencies, we see solid growth in all regions and strong growth for our key products.", "score": 0.656046, "arguments": [{"text": "we", "location": [12502, 12504], "entities": [{"type": "Person", "text": "we"}]}, {"text": "regions", "location": [12529, 12536], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "hasAttribute", "sentence": "The SG&A cost decreased from DKK4.8 billion to DKK4.4 billion, which is a decline of 7.6%.", "score": 0.607849, "arguments": [{"text": "SG&A", "location": [13552, 13556], "entities": [{"type": "Organization", "text": "SG&A"}]}, {"text": "DKK4.8 billion", "location": [13577, 13591], "entities": [{"type": "Money", "text": "DKK4.8 billion"}]}]}, {"type": "hasAttribute", "sentence": "The SG&A cost decreased from DKK4.8 billion to DKK4.4 billion, which is a decline of 7.6%.", "score": 0.576056, "arguments": [{"text": "SG&A", "location": [13552, 13556], "entities": [{"type": "Organization", "text": "SG&A"}]}, {"text": "DKK4.4 billion", "location": [13595, 13609], "entities": [{"type": "Money", "text": "DKK4.4 billion"}]}]}, {"type": "partOfMany", "sentence": "H Lundbeck A/S ( OTC:HLUKF ) Q3 2018 Earnings Conference Call November 7, 2018 7:00 AM ET Executives Deborah Dunsire - CEO & President Anders G\u00f6tzsche - EVP & CFO Anders Pedersen - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial Operations Analysts Trung Huynh - Cr\u00e9dit Suisse James Gordon - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Michael Novod - Nordea Markets Martin Parkh\u00e6i - Danske Bank Timothy Race - Deutsche Bank Peter Sehested - Handelsbanken Marietta Miemietz - Primavenue Advisory Services Limited Operator Ladies and gentlemen, welcome to the H. Lundbeck interim report for the third quarter, first nine months of 2018.", "score": 0.740602, "arguments": [{"text": "Anders G\u00f6tzsche", "location": [135, 150], "entities": [{"type": "Person", "text": "Anders G\u00f6tzsche"}]}, {"text": "Executives", "location": [90, 100], "entities": [{"type": "Person", "text": "Executives"}]}]}, {"type": "employedBy", "sentence": "Following the strong increase in company's operating profit and declining tax rate, Lundbeck has also showed a significant improvement in our return-on-invested capital.", "score": 0.403268, "arguments": [{"text": "Lundbeck", "location": [14404, 14412], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "company", "location": [14353, 14360], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "timeOf", "sentence": "Investments include the acquisition of Prexton as we did in March 2018 of \u20a0100 million and the EU approval milestone of Rexulti of $50 million.", "score": 0.735335, "arguments": [{"text": "March 2018", "location": [14689, 14699], "entities": [{"type": "Date", "text": "March 2018"}]}, {"text": "acquisition", "location": [14653, 14664], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "hasAttribute", "sentence": "Investments include the acquisition of Prexton as we did in March 2018 of \u20a0100 million and the EU approval milestone of Rexulti of $50 million.", "score": 0.757756, "arguments": [{"text": "Rexulti", "location": [14749, 14756], "entities": [{"type": "Person", "text": "Rexulti"}]}, {"text": "$50 million", "location": [14760, 14771], "entities": [{"type": "Money", "text": "$50 million"}]}]}, {"type": "hasAttribute", "sentence": "We expect net cash to be around DKK5.5 billion by the end of 2018.", "score": 0.816024, "arguments": [{"text": "We", "location": [14773, 14775], "entities": [{"type": "Organization", "text": "We"}]}, {"text": "DKK5.5 billion", "location": [14805, 14819], "entities": [{"type": "Money", "text": "DKK5.5 billion"}]}]}, {"type": "hasAttribute", "sentence": "We expect to see continued improvement in our profitability in '18, and EBIT is now expected to reach between DKK5.1 billion and DKK5.4 billion, compared to previously DKK4.9 billion to DKK5.2 billion for the year, which indicates that the EBIT margin will be of at least 28%.", "score": 0.732017, "arguments": [{"text": "EBIT", "location": [15464, 15468], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "DKK5.1 billion", "location": [15502, 15516], "entities": [{"type": "Money", "text": "DKK5.1 billion"}]}]}, {"type": "hasAttribute", "sentence": "We expect to see continued improvement in our profitability in '18, and EBIT is now expected to reach between DKK5.1 billion and DKK5.4 billion, compared to previously DKK4.9 billion to DKK5.2 billion for the year, which indicates that the EBIT margin will be of at least 28%.", "score": 0.568906, "arguments": [{"text": "EBIT", "location": [15464, 15468], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "DKK5.4 billion", "location": [15521, 15535], "entities": [{"type": "Money", "text": "DKK5.4 billion"}]}]}, {"type": "hasAttribute", "sentence": "We expect to see continued improvement in our profitability in '18, and EBIT is now expected to reach between DKK5.1 billion and DKK5.4 billion, compared to previously DKK4.9 billion to DKK5.2 billion for the year, which indicates that the EBIT margin will be of at least 28%.", "score": 0.531333, "arguments": [{"text": "EBIT", "location": [15464, 15468], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "DKK4.9 billion", "location": [15560, 15574], "entities": [{"type": "Money", "text": "DKK4.9 billion"}]}]}, {"type": "hasAttribute", "sentence": "We expect to see continued improvement in our profitability in '18, and EBIT is now expected to reach between DKK5.1 billion and DKK5.4 billion, compared to previously DKK4.9 billion to DKK5.2 billion for the year, which indicates that the EBIT margin will be of at least 28%.", "score": 0.629478, "arguments": [{"text": "EBIT", "location": [15464, 15468], "entities": [{"type": "Organization", "text": "EBIT"}]}, {"text": "DKK5.2 billion", "location": [15578, 15592], "entities": [{"type": "Money", "text": "DKK5.2 billion"}]}]}, {"type": "locatedAt", "sentence": "Please note that the EBIT in the fourth quarter will benefit from the gain from a settlement made in Australia.", "score": 0.587063, "arguments": [{"text": "settlement", "location": [15751, 15761], "entities": [{"type": "EventLegal", "text": "settlement"}]}, {"text": "Australia", "location": [15770, 15779], "entities": [{"type": "GeopoliticalEntity", "text": "Australia"}]}]}, {"type": "locatedAt", "sentence": "I will now hand over to our head of R&D, Anders Pedersen, to go through some updates from R&D pipeline.", "score": 0.463681, "arguments": [{"text": "Anders Pedersen", "location": [16163, 16178], "entities": [{"type": "Person", "text": "Anders Pedersen"}]}, {"text": "pipeline", "location": [16216, 16224], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "employedBy", "sentence": "H Lundbeck A/S ( OTC:HLUKF ) Q3 2018 Earnings Conference Call November 7, 2018 7:00 AM ET Executives Deborah Dunsire - CEO & President Anders G\u00f6tzsche - EVP & CFO Anders Pedersen - EVP, Research & Development Peter Anastasiou - EVP, North America Jacob Tolstrup - EVP, Commercial Operations Analysts Trung Huynh - Cr\u00e9dit Suisse James Gordon - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Michael Novod - Nordea Markets Martin Parkh\u00e6i - Danske Bank Timothy Race - Deutsche Bank Peter Sehested - Handelsbanken Marietta Miemietz - Primavenue Advisory Services Limited Operator Ladies and gentlemen, welcome to the H. Lundbeck interim report for the third quarter, first nine months of 2018.", "score": 0.579989, "arguments": [{"text": "James Gordon", "location": [328, 340], "entities": [{"type": "Person", "text": "James Gordon"}]}, {"text": "Commercial Operations\nAnalysts\nTrung Huynh - Cr\u00e9dit Suisse", "location": [269, 327], "entities": [{"type": "Organization", "text": "Commercial Operations\nAnalysts\nTrung Huynh - Cr\u00e9dit Suisse"}]}]}, {"type": "agentOf", "sentence": "First, let me start by saying that the outcome of 35700 was a disappointment and illustrates how difficult it is to reach significant superiority with new medicines, especially for treatment-resistant patients.", "score": 0.74551, "arguments": [{"text": "me", "location": [16302, 16304], "entities": [{"type": "Person", "text": "me"}]}, {"text": "saying", "location": [16314, 16320], "entities": [{"type": "EventCommunication", "text": "saying"}]}]}, {"type": "basedIn", "sentence": "35700 aside, I am pleased that we have been able to move the portfolio forward, and we have in the last 5 to 6 months been able to take 3 projects into clinical testing within our core areas.", "score": 0.333145, "arguments": [{"text": "our", "location": [16725, 16728], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "areas", "location": [16734, 16739], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "locatedAt", "sentence": "In addition, we have added Foliglurax to the Phase II pipeline, coming in from our acquisition of Prexton Pharmaceuticals in March of 2018.", "score": 0.694035, "arguments": [{"text": "we", "location": [16754, 16756], "entities": [{"type": "Person", "text": "we"}]}, {"text": "pipeline", "location": [16795, 16803], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "agentOf", "sentence": "In addition, we have added Foliglurax to the Phase II pipeline, coming in from our acquisition of Prexton Pharmaceuticals in March of 2018.", "score": 0.6491, "arguments": [{"text": "our", "location": [16820, 16823], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "acquisition", "location": [16824, 16835], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "In addition, we have added Foliglurax to the Phase II pipeline, coming in from our acquisition of Prexton Pharmaceuticals in March of 2018.", "score": 0.877205, "arguments": [{"text": "March of 2018", "location": [16866, 16879], "entities": [{"type": "Date", "text": "March of 2018"}]}, {"text": "acquisition", "location": [16824, 16835], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "We also continued progression in other areas of the pipeline.", "score": 0.434649, "arguments": [{"text": "We", "location": [16881, 16883], "entities": [{"type": "Organization", "text": "We"}]}, {"text": "areas", "location": [16920, 16925], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "locatedAt", "sentence": "We also continued progression in other areas of the pipeline.", "score": 0.806187, "arguments": [{"text": "areas", "location": [16920, 16925], "entities": [{"type": "Location", "text": "areas"}]}, {"text": "pipeline", "location": [16933, 16941], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "ownerOf", "sentence": "We continue the effort of supplementing our pipeline through accessing external innovation to report our own project or to bring in additional assets.", "score": 0.749431, "arguments": [{"text": "our", "location": [17155, 17158], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [17159, 17167], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "employedBy", "sentence": "This is clearly a disappointing news for our patients and the clinical centers who have worked with us, as well as for us internally in Lundbeck.", "score": 0.745131, "arguments": [{"text": "patients", "location": [17762, 17770], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "our", "location": [17758, 17761], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "partOfMany", "sentence": "This is clearly a disappointing news for our patients and the clinical centers who have worked with us, as well as for us internally in Lundbeck.", "score": 0.547956, "arguments": [{"text": "patients", "location": [17762, 17770], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "who", "location": [17796, 17799], "entities": [{"type": "Person", "text": "who"}]}]}, {"type": "employedBy", "sentence": "Together with me are our Chief Financial Officer, Anders G\u00f6tzsche; our head of R&D, Anders Pedersen; Peter Anastasiou, EVP of North America; Jacob Tolstrup, EVP of commercial operations.", "score": 0.697322, "arguments": [{"text": "Chief Financial Officer", "location": [1177, 1200], "entities": [{"type": "Person", "text": "Chief Financial Officer"}]}, {"text": "our", "location": [1173, 1176], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "partOfMany", "sentence": "This is clearly a disappointing news for our patients and the clinical centers who have worked with us, as well as for us internally in Lundbeck.", "score": 0.793577, "arguments": [{"text": "patients", "location": [17762, 17770], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "us", "location": [17817, 17819], "entities": [{"type": "Person", "text": "us"}]}]}, {"type": "partOfMany", "sentence": "This is clearly a disappointing news for our patients and the clinical centers who have worked with us, as well as for us internally in Lundbeck.", "score": 0.528667, "arguments": [{"text": "us", "location": [17836, 17838], "entities": [{"type": "Person", "text": "us"}]}, {"text": "patients", "location": [17762, 17770], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "partOfMany", "sentence": "This is clearly a disappointing news for our patients and the clinical centers who have worked with us, as well as for us internally in Lundbeck.", "score": 0.512084, "arguments": [{"text": "Lundbeck", "location": [17853, 17861], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "us", "location": [17836, 17838], "entities": [{"type": "Person", "text": "us"}]}]}, {"type": "hasAttribute", "sentence": "We'll continue to build our future strategy on Lundbeck's core strengths, our skills and knowledge in disease biology and technologies within psychiatry and neurology.", "score": 0.532285, "arguments": [{"text": "Lundbeck", "location": [19563, 19571], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "disease", "location": [19618, 19625], "entities": [{"type": "HealthCondition", "text": "disease"}]}]}, {"type": "ownerOf", "sentence": "We'll optimize the company's ability to create long-term sustainable growth by capitalizing on the marketed brands, advancing and indeed accelerating assets within our internal R&D pipeline, and supplementing those with high-quality external innovation as we refresh and replenish our pipeline.", "score": 0.773209, "arguments": [{"text": "our", "location": [19848, 19851], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [19865, 19873], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "ownerOf", "sentence": "We'll optimize the company's ability to create long-term sustainable growth by capitalizing on the marketed brands, advancing and indeed accelerating assets within our internal R&D pipeline, and supplementing those with high-quality external innovation as we refresh and replenish our pipeline.", "score": 0.798603, "arguments": [{"text": "our", "location": [19965, 19968], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "pipeline", "location": [19969, 19977], "entities": [{"type": "Facility", "text": "pipeline"}]}]}, {"type": "partOf", "sentence": "We are looking forward to present the conclusions from our strategic review with the Annual Report in 2018 early next year.", "score": 0.480612, "arguments": [{"text": "our", "location": [20034, 20037], "entities": [{"type": "Organization", "text": "our"}]}, {"text": "Annual Report", "location": [20064, 20077], "entities": [{"type": "Organization", "text": "Annual Report"}]}]}, {"type": "agentOf", "sentence": "Question-and-Answer Session Operator [Operator Instructions].", "score": 0.329615, "arguments": [{"text": "Operator", "location": [20243, 20251], "entities": [{"type": "Organization", "text": "Operator"}]}, {"text": "Session", "location": [20235, 20242], "entities": [{"type": "EventMeeting", "text": "Session"}]}]}, {"type": "partOf", "sentence": "Question-and-Answer Session Operator [Operator Instructions].", "score": 0.551682, "arguments": [{"text": "Operator Instructions", "location": [20253, 20274], "entities": [{"type": "Organization", "text": "Operator Instructions"}]}, {"text": "Operator", "location": [20243, 20251], "entities": [{"type": "Organization", "text": "Operator"}]}]}, {"type": "partOf", "sentence": "Operator [Operator Instructions].", "score": 0.553918, "arguments": [{"text": "Operator Instructions", "location": [45151, 45172], "entities": [{"type": "Organization", "text": "Operator Instructions"}]}, {"text": "Operator", "location": [45141, 45149], "entities": [{"type": "Organization", "text": "Operator"}]}]}, {"type": "partOf", "sentence": "And our first question comes from the line of Trung Huynh from Cr\u00e9dit Suisse.", "score": 0.793609, "arguments": [{"text": "Trung Huynh", "location": [20323, 20334], "entities": [{"type": "Organization", "text": "Trung Huynh"}]}, {"text": "Cr\u00e9dit Suisse", "location": [20340, 20353], "entities": [{"type": "Organization", "text": "Cr\u00e9dit Suisse"}]}]}, {"type": "agentOf", "sentence": "Firstly, as this is the first time we are talking since I joined Lundbeck on September 3, let me start with some comments on why I chose to join Lundbeck and how I see the future.", "score": 0.930558, "arguments": [{"text": "we", "location": [1522, 1524], "entities": [{"type": "Person", "text": "we"}]}, {"text": "talking", "location": [1529, 1536], "entities": [{"type": "EventCommunication", "text": "talking"}]}]}, {"type": "partOf", "sentence": "Trung Huynh Trung from Cr\u00e9dit Suisse.", "score": 0.722962, "arguments": [{"text": "Trung Huynh\nTrung", "location": [20355, 20372], "entities": [{"type": "Organization", "text": "Trung Huynh\nTrung"}]}, {"text": "Cr\u00e9dit Suisse", "location": [20378, 20391], "entities": [{"type": "Organization", "text": "Cr\u00e9dit Suisse"}]}]}, {"type": "locatedAt", "sentence": "Just on your priorities for cash, could you give us an idea what areas of focus you're looking at?", "score": 0.725689, "arguments": [{"text": "us", "location": [20791, 20793], "entities": [{"type": "Person", "text": "us"}]}, {"text": "areas", "location": [20807, 20812], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "locatedAt", "sentence": "Just on your priorities for cash, could you give us an idea what areas of focus you're looking at?", "score": 0.556767, "arguments": [{"text": "you", "location": [20822, 20825], "entities": [{"type": "Person", "text": "you"}]}, {"text": "areas", "location": [20807, 20812], "entities": [{"type": "Location", "text": "areas"}]}]}, {"type": "agentOf", "sentence": "Lundbeck's spoken about doing smaller deals in the past, returning more economics.", "score": 0.988336, "arguments": [{"text": "Lundbeck", "location": [20841, 20849], "entities": [{"type": "Person", "text": "Lundbeck"}]}, {"text": "spoken", "location": [20852, 20858], "entities": [{"type": "EventCommunication", "text": "spoken"}]}]}, {"type": "agentOf", "sentence": "You mentioned an inventory fluctuation and administrative burdens causing this backlog to patients.", "score": 0.97406, "arguments": [{"text": "You", "location": [21033, 21036], "entities": [{"type": "Person", "text": "You"}]}, {"text": "mentioned", "location": [21037, 21046], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "agentOf", "sentence": "Deborah Dunsire So the first two months at Lundbeck I think have confirmed what I saw from the outside.", "score": 0.504125, "arguments": [{"text": "Deborah Dunsire", "location": [21269, 21284], "entities": [{"type": "Person", "text": "Deborah Dunsire"}]}, {"text": "confirmed", "location": [21334, 21343], "entities": [{"type": "EventCommunication", "text": "confirmed"}]}]}, {"type": "hasAttribute", "sentence": "It's a company with a great heritage, a real passion and commitment around the patients facing the burden of diseases of the brain.", "score": 0.92755, "arguments": [{"text": "patients", "location": [21452, 21460], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diseases", "location": [21482, 21490], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "employedBy", "sentence": "It's been tremendous to get to know the people within the company and see those skills and that passion manifest really throughout the organization, not only here in Denmark, but also around the world.", "score": 0.545534, "arguments": [{"text": "people", "location": [21627, 21633], "entities": [{"type": "Person", "text": "people"}]}, {"text": "company", "location": [21645, 21652], "entities": [{"type": "Organization", "text": "company"}]}]}, {"type": "locatedAt", "sentence": "It's been tremendous to get to know the people within the company and see those skills and that passion manifest really throughout the organization, not only here in Denmark, but also around the world.", "score": 0.695915, "arguments": [{"text": "organization", "location": [21722, 21734], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "Denmark", "location": [21753, 21760], "entities": [{"type": "GeopoliticalEntity", "text": "Denmark"}]}]}, {"type": "locatedAt", "sentence": "It's been tremendous to get to know the people within the company and see those skills and that passion manifest really throughout the organization, not only here in Denmark, but also around the world.", "score": 0.635499, "arguments": [{"text": "organization", "location": [21722, 21734], "entities": [{"type": "Organization", "text": "organization"}]}, {"text": "world", "location": [21782, 21787], "entities": [{"type": "GeopoliticalEntity", "text": "world"}]}]}, {"type": "hasAttribute", "sentence": "Lundbeck has had a long and successful history of bringing new medicines forward in the fields of neurology and psychiatry to drive better outcomes for people living with these diseases.", "score": 0.644091, "arguments": [{"text": "people", "location": [1819, 1825], "entities": [{"type": "Person", "text": "people"}]}, {"text": "diseases", "location": [1844, 1852], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "partOfMany", "sentence": "But I reiterate, we need to invest for growth and we'll need to invest behind our marketed brands to be sure that we can capitalize on the right patients and the base patients for those brands, accelerate the internal pipeline and look for opportunities and indications where we may be able to streamline and accelerate development.", "score": 0.805414, "arguments": [{"text": "patients", "location": [22216, 22224], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "those", "location": [22251, 22256], "entities": [{"type": "Person", "text": "those"}]}]}, {"type": "partOfMany", "sentence": "But I reiterate, we need to invest for growth and we'll need to invest behind our marketed brands to be sure that we can capitalize on the right patients and the base patients for those brands, accelerate the internal pipeline and look for opportunities and indications where we may be able to streamline and accelerate development.", "score": 0.775536, "arguments": [{"text": "patients", "location": [22238, 22246], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "those", "location": [22251, 22256], "entities": [{"type": "Person", "text": "those"}]}]}, {"type": "agentOf", "sentence": "So with every investment, we'll be asking ourselves the question, how will we gain a return for our shareholders, based on this investment?", "score": 0.940904, "arguments": [{"text": "we", "location": [22740, 22742], "entities": [{"type": "Person", "text": "we"}]}, {"text": "asking", "location": [22749, 22755], "entities": [{"type": "EventCommunication", "text": "asking"}]}]}, {"type": "affectedBy", "sentence": "So with every investment, we'll be asking ourselves the question, how will we gain a return for our shareholders, based on this investment?", "score": 0.946791, "arguments": [{"text": "ourselves", "location": [22756, 22765], "entities": [{"type": "Person", "text": "ourselves"}]}, {"text": "asking", "location": [22749, 22755], "entities": [{"type": "EventCommunication", "text": "asking"}]}]}, {"type": "employedBy", "sentence": "So with every investment, we'll be asking ourselves the question, how will we gain a return for our shareholders, based on this investment?", "score": 0.836989, "arguments": [{"text": "shareholders", "location": [22814, 22826], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [22810, 22813], "entities": [{"type": "Organization", "text": "our"}]}]}, {"type": "agentOf", "sentence": "And so on the two specific issues that you asked about in terms of inventory fluctuations, of course, there's always fluctuations that occur between quarter-to-quarter, that clearly happened in our view between Q2 and Q3 that affects Q3 numbers.", "score": 0.958653, "arguments": [{"text": "you", "location": [23310, 23313], "entities": [{"type": "Person", "text": "you"}]}, {"text": "asked", "location": [23314, 23319], "entities": [{"type": "EventCommunication", "text": "asked"}]}]}, {"type": "agentOf", "sentence": "And then also on the backlog, let me describe that for a second.", "score": 0.981765, "arguments": [{"text": "me", "location": [23551, 23553], "entities": [{"type": "Person", "text": "me"}]}, {"text": "describe", "location": [23554, 23562], "entities": [{"type": "EventCommunication", "text": "describe"}]}]}, {"type": "agentOf", "sentence": "And we are on track, as we said in the release, to have that backlog resolved in the fourth quarter.", "score": 0.920826, "arguments": [{"text": "we", "location": [23857, 23859], "entities": [{"type": "Organization", "text": "we"}]}, {"text": "said", "location": [23860, 23864], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "And finally, I would end by saying on Northera that there still remains a tremendous unmet need in the NOH market.", "score": 0.632288, "arguments": [{"text": "I", "location": [24121, 24122], "entities": [{"type": "Person", "text": "I"}]}, {"text": "saying", "location": [24136, 24142], "entities": [{"type": "EventCommunication", "text": "saying"}]}]}, {"type": "hasAttribute", "sentence": "There's a growing recognition of NOH, Neurogenic Orthostatic Hypotension, as an issue in neurologic diseases like Parkinson's, and the drug continues to deliver great results and very tolerable and is, of course, the only product that's indicated for symptomatic relief of NOH.", "score": 0.924472, "arguments": [{"text": "Parkinson", "location": [24337, 24346], "entities": [{"type": "Person", "text": "Parkinson"}]}, {"text": "diseases", "location": [24323, 24331], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}], "keywords": [{"text": "Deborah Dunsire", "sentiment": {"score": 0.636638, "label": "positive"}, "relevance": 0.987985}, {"text": "growth", "sentiment": {"score": -0.0368768, "label": "negative"}, "relevance": 0.856775}, {"text": "Anders", "sentiment": {"score": 0.535857, "label": "positive"}, "relevance": 0.851611}, {"text": "Anders G\u00f6tzsche", "sentiment": {"score": 0.477496, "label": "positive"}, "relevance": 0.829915}, {"text": "local currencies", "sentiment": {"score": 0.343426, "label": "positive"}, "relevance": 0.778721}, {"text": "Lundbeck", "sentiment": {"score": 0.0669688, "label": "positive"}, "relevance": 0.690969}, {"text": "Peter Anastasiou", "sentiment": {"score": 0.437888, "label": "positive"}, "relevance": 0.674666}, {"text": "Anders Pedersen", "sentiment": {"score": 0.473752, "label": "positive"}, "relevance": 0.656122}, {"text": "long-term sustainable growth", "sentiment": {"score": 0.538662, "label": "positive"}, "relevance": 0.653099}, {"text": "question", "sentiment": {"score": 0.747602, "label": "positive"}, "relevance": 0.630879}, {"text": "strong financial position", "sentiment": {"score": 0.567341, "label": "positive"}, "relevance": 0.629474}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611355}, {"text": "pipeline", "sentiment": {"score": 0.0878453, "label": "positive"}, "relevance": 0.607334}, {"text": "external innovation", "sentiment": {"score": 0.666307, "label": "positive"}, "relevance": 0.601648}, {"text": "company", "sentiment": {"score": -0.0101466, "label": "negative"}, "relevance": 0.580671}, {"text": "key products", "sentiment": {"score": 0.562431, "label": "positive"}, "relevance": 0.565486}, {"text": "Michael Novod", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565457}, {"text": "Anders Gersel", "sentiment": {"score": 0.509903, "label": "positive"}, "relevance": 0.55858}, {"text": "profitable growth", "sentiment": {"score": 0.754592, "label": "positive"}, "relevance": 0.553599}, {"text": "strong growth", "sentiment": {"score": 0.532476, "label": "positive"}, "relevance": 0.550311}, {"text": "Martin Parkh\u00f8i", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550004}, {"text": "patients", "sentiment": {"score": 0.0175225, "label": "positive"}, "relevance": 0.541054}, {"text": "Lundbeck interim report", "sentiment": {"score": 0.496603, "label": "positive"}, "relevance": 0.533461}, {"text": "time", "sentiment": {"score": 0.15108, "label": "positive"}, "relevance": 0.531777}, {"text": "Wimal Kapadia", "sentiment": {"score": 0.52585, "label": "positive"}, "relevance": 0.530472}, {"text": "new medicines", "sentiment": {"score": 0.219764, "label": "positive"}, "relevance": 0.530073}, {"text": "International Markets", "sentiment": {"score": 0.521128, "label": "positive"}, "relevance": 0.528891}, {"text": "sales", "sentiment": {"score": 0.174805, "label": "positive"}, "relevance": 0.52676}, {"text": "long-term profitable growth", "sentiment": {"score": 0.534104, "label": "positive"}, "relevance": 0.526439}, {"text": "R&D", "sentiment": {"score": 0.200698, "label": "positive"}, "relevance": 0.525298}, {"text": "strong financial foundation", "sentiment": {"score": 0.793189, "label": "positive"}, "relevance": 0.524863}, {"text": "emergent sexual dysfunction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52139}, {"text": "operator", "sentiment": {"score": 0.274555, "label": "positive"}, "relevance": 0.521179}, {"text": "line", "sentiment": {"score": 0.0731868, "label": "positive"}, "relevance": 0.520906}, {"text": "Onfi", "sentiment": {"score": -0.025227, "label": "negative"}, "relevance": 0.520147}, {"text": "revenue", "sentiment": {"score": 0.128966, "label": "positive"}, "relevance": 0.5194}, {"text": "Executive Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517604}, {"text": "cost", "sentiment": {"score": 0.0585429, "label": "positive"}, "relevance": 0.517474}, {"text": "volume share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513963}, {"text": "strong continued growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51336}, {"text": "internal pipeline", "sentiment": {"score": 0.919275, "label": "positive"}, "relevance": 0.512962}, {"text": "tax rate", "sentiment": {"score": -0.297773, "label": "negative"}, "relevance": 0.50961}, {"text": "unmet need", "sentiment": {"score": 0.835376, "label": "positive"}, "relevance": 0.509422}, {"text": "demand growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509362}, {"text": "Nordea Markets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507718}, {"text": "sales growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507409}, {"text": "strategic review", "sentiment": {"score": 0.731895, "label": "positive"}, "relevance": 0.506875}, {"text": "key brands", "sentiment": {"score": 0.50491, "label": "positive"}, "relevance": 0.506722}, {"text": "Trung Huynh", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505812}, {"text": "EBIT margin", "sentiment": {"score": 0.470241, "label": "positive"}, "relevance": 0.505514}]}, "extracted_metadata": {"sha1": "348d80ae2af121c7c6200fdab8a44501ef44632b", "filename": "1541938843964.zip-436a047dc67ce32c4e010fe235df8e2e.xml", "file_type": "json"}, "title": "H Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q3 2018 Results - Earnings Call Transcript", "forum_title": "All Articles on Seeking Alpha"}, {"id": "Ck5Tf02NCqW0tT6grMfD7fP5y8N3bA1Km8vp4RzEH7iMVJ9bMVYCxGUr3r9Sbdj0", "result_metadata": {"score": 21.593346}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.356536, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Marketing", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Marketing strategy", "relevance": 0.853618, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_strategy"}], "categories": [{"score": 0.787145, "label": "/business and industrial/advertising and marketing/marketing"}], "relations": [{"type": "partOf", "sentence": "Stop Protesting And Complaining And Begin Your Own Special GSK3B Marketing Strategy Preferably", "score": 0.886692, "arguments": [{"text": "GSK3B Marketing Strategy Preferably", "location": [59, 94], "entities": [{"type": "Organization", "text": "GSK3B Marketing Strategy Preferably"}]}, {"text": "Special", "location": [51, 58], "entities": [{"type": "Organization", "text": "Special"}]}]}], "keywords": [{"text": "Special GSK3B Marketing", "sentiment": {"score": -0.356536, "label": "negative"}, "relevance": 0.937645}, {"text": "Stop", "sentiment": {"score": -0.356536, "label": "negative"}, "relevance": 0.631111}, {"text": "Strategy", "sentiment": {"score": -0.356536, "label": "negative"}, "relevance": 0.455093}]}, "crawl_date": "2018-11-11T05:30:21Z", "url": "http://articles.cia.pm/article.php?id=1924677", "host": "articles.cia.pm", "text": "Abdelmalek - Grant/Research Support: Mochida Pharmaceuticals; Speaking and Teaching: Takeda Pharmaceuticals Anna Mae Diehl - Consulting: Bristol Myers Squibb, Synergy, GlaxoSmithKline, Norgine; Grant/Research Support: GlaxoSmithKline The following people have nothing to disclose: Cynthia D.", "country": "PM", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-11T05:19:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.419018, "label": "negative"}, "text": "interferon", "relevance": 0.93164, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "VitE", "relevance": 0.82859, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.253009, "label": "negative"}, "text": "Eliga Vinter", "relevance": 0.707433, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals", "relevance": 0.516025, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "hepatocellular carcinoma", "relevance": 0.503625, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PIVENS", "relevance": 0.486821, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.47868, "label": "negative"}, "text": "chronic hepatitis", "relevance": 0.483356, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor"], "name": "Hepatitis", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}}, {"count": 1, "sentiment": {"score": 0.467575, "label": "positive"}, "text": "Bristol Myers Squibb", "relevance": 0.48157, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anna Mae Diehl", "relevance": 0.469458, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.315729, "label": "negative"}, "text": "Mochida Pharmaceuticals", "relevance": 0.464077, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.460712, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Manal F. Abdelmalek", "relevance": 0.456745, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.25071, "label": "positive"}, "text": "Cynthia D. Guy", "relevance": 0.412452, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James Burchette", "relevance": 0.404083, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.523643, "label": "positive"}, "text": "Synergy", "relevance": 0.3994, "type": "Company", "disambiguation": {"subtype": [], "name": "Synergy (electricity corporation)", "dbpedia_resource": "http://dbpedia.org/resource/Synergy_(electricity_corporation)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ayako Suzuki", "relevance": 0.392946, "type": "Person"}], "sentiment": {"document": {"score": 0.234695, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the number of Shh+ hepatocytes", "keywords": [{"text": "Shh+ hepatocytes"}, {"text": "number"}]}, "sentence": " RESULTS Regardless of the treatment arm, changes in the number of Shh+ hepatocytes were correlated with K8/18/Ub foci (r2=0.47, p<0.001) and AST (r2=0.15, p=0.002).", "object": {"text": "correlated with K8/18/Ub foci", "keywords": [{"text": "K8/18/Ub foci"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Shh+ hepatocytes", "keywords": [{"text": "Shh+ hepatocytes"}]}, "sentence": " RESULTS Regardless of the treatment arm, changes in the number of Shh+ hepatocytes were correlated with K8/18/Ub foci (r2=0.47, p<0.001) and AST (r2=0.15, p=0.002).", "object": {"text": "with K8/18/Ub foci", "keywords": [{"text": "K8/18/Ub foci"}]}, "action": {"verb": {"text": "correlate", "tense": "past"}, "text": "were correlated", "normalized": "be correlate"}}, {"subject": {"text": "the VitE group", "keywords": [{"text": "VitE group"}], "entities": [{"type": "Company", "text": "VitE"}]}, "sentence": " Compared to the placebo group, the VitE group showed a greater reduction in the number of Shh+ hepatocytes (p<0.05) and K/8/1 8/Ub foci (p=0.08).", "object": {"text": "a greater reduction in the number of Shh+ hepatocytes (p<0.05) and K/8/1 8/Ub foci (p=0.08)", "keywords": [{"text": "greater reduction"}, {"text": "K/8/1 8/Ub"}, {"text": "number"}, {"text": "Shh+"}]}, "action": {"verb": {"text": "show", "tense": "past"}, "text": "showed", "normalized": "show"}}, {"subject": {"text": "the VitE group", "keywords": [{"text": "VitE group"}], "entities": [{"type": "Company", "text": "VitE"}]}, "sentence": " After adjusting for baseline numbers of Shh+ hepatocytes or K8/18/\ufffd\ufffdb www.selleckchem.com foci, the VitE group showed a greater decrease in Shh+ hepatocytes (p<0.04) and K8/18/Ub foci (p<0.04) by multiple linear regression analysis.", "object": {"text": "a greater decrease in Shh+ hepatocytes", "keywords": [{"text": "Shh+ hepatocytes"}, {"text": "greater decrease"}]}, "action": {"verb": {"text": "show", "tense": "past"}, "text": "showed", "normalized": "show"}}, {"subject": {"text": "changes in ballooning (p=0.004) and fibrosis stage (p=0.02),", "keywords": [{"text": "fibrosis stage"}, {"text": "changes"}, {"text": "p=0.004"}, {"text": "p=0.02"}]}, "sentence": " Similarly, changes in serum aminotransferases, AST (partial r2=0.75, p<0.0001) and ALT (partial r2=0.26, p<0.0001), as well as changes in ballooning (p=0.004) and fibrosis stage (p=0.02), were also associated with changes in Shh+ hepatocytes.", "object": {"text": "with changes in Shh+ hepatocytes", "keywords": [{"text": "Shh+ hepatocytes"}, {"text": "changes"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "were also associated", "normalized": "be also associate"}}, {"subject": {"text": "changes in the numbers of Shh+ hepatocytes", "keywords": [{"text": "Shh+ hepatocytes"}, {"text": "changes"}, {"text": "numbers"}]}, "sentence": " Furthermore, changes in the numbers of Shh+ hepatocytes were associated with changes in the numbers of Shh-responsive progenitors (gli2+/sox9+ cells) (p=0.03), i. e., ductular reaction resolution, by multiple ordinal logistic regression after adjusting for baseline values.", "object": {"text": "associated with changes in the numbers of Shh-responsive progenitors (gli2+/sox9+ cells) (p=0.03), i. e., ductular reaction resolution, by multiple ordinal logistic regression after adjusting for baseline values", "keywords": [{"text": "ordinal logistic regression"}, {"text": "ductular reaction resolution"}, {"text": "baseline values"}, {"text": "Shh-responsive progenitors"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "hepatocytes", "keywords": [{"text": "hepatocytes"}]}, "sentence": " Furthermore, changes in the numbers of Shh+ hepatocytes were associated with changes in the numbers of Shh-responsive progenitors (gli2+/sox9+ cells) (p=0.03), i. e., ductular reaction resolution, by multiple ordinal logistic regression after adjusting for baseline values.", "object": {"text": "with changes in the numbers of Shh-responsive progenitors (gli2+/sox9+ cells) (p=0.03), i. e., ductular reaction resolution, by multiple ordinal logistic regression after adjusting for baseline values", "keywords": [{"text": "ordinal logistic regression"}, {"text": "ductular reaction resolution"}, {"text": "baseline values"}, {"text": "Shh-responsive progenitors"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "were associated", "normalized": "be associate"}}, {"subject": {"text": "Activated HSCs (\ufffd\ufffd SMA+ cells)", "keywords": [{"text": "\ufffd\ufffd SMA+ cells"}, {"text": "HSCs"}]}, "sentence": " Activated HSCs (\ufffd\ufffd SMA+ cells) tended to be associated (p=0.10) with changes in the numbers of Shh+ hepatocytes.", "object": {"text": "associated (p=0.10)"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "A response SAHA HDAC order to treatment (as established by the PIVENS study design)", "keywords": [{"text": "response SAHA HDAC"}, {"text": "PIVENS study design"}, {"text": "order"}, {"text": "treatment"}], "entities": [{"type": "Organization", "text": "PIVENS"}]}, "sentence": " A response SAHA HDAC order to treatment (as established by the PIVENS study design) was associated with a greater decrease in Shh+ hepatocytes compared to nonresponse (p=0.007).", "object": {"text": "associated with a greater decrease in Shh+ hepatocytes compared to nonresponse (p=0.007)", "keywords": [{"text": "Shh+ hepatocytes"}, {"text": "greater decrease"}, {"text": "p=0.007"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "the PIVENS study design)", "keywords": [{"text": "PIVENS study design"}], "entities": [{"type": "Organization", "text": "PIVENS"}]}, "sentence": " A response SAHA HDAC order to treatment (as established by the PIVENS study design) was associated with a greater decrease in Shh+ hepatocytes compared to nonresponse (p=0.007).", "object": {"text": "with a greater decrease in Shh+ hepatocytes compared to nonresponse", "keywords": [{"text": "Shh+ hepatocytes"}, {"text": "greater decrease"}, {"text": "nonresponse"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "was associated", "normalized": "be associate"}}, {"subject": {"text": "Inhibition of Hh pathway activity", "keywords": [{"text": "Hh pathway activity"}, {"text": "Inhibition"}]}, "sentence": " Inhibition of Hh pathway activity was accompanied by improved liver injury, fibrosis stage, and treatment response, implicating Hedgehog as a therapeutic target for VitE.", "object": {"text": "accompanied by improved liver injury", "keywords": [{"text": "improved liver injury"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by improved liver injury, fibrosis stage, and treatment response, implicating Hedgehog as a therapeutic target for VitE", "keywords": [{"text": "improved liver injury"}, {"text": "therapeutic target"}, {"text": "fibrosis stage"}, {"text": "VitE"}]}, "sentence": " Inhibition of Hh pathway activity was accompanied by improved liver injury, fibrosis stage, and treatment response, implicating Hedgehog as a therapeutic target for VitE.", "object": {"text": "Inhibition of Hh pathway activity", "keywords": [{"text": "Hh pathway activity"}, {"text": "Inhibition"}]}, "action": {"verb": {"text": "accompany", "tense": "past"}, "text": "was accompanied", "normalized": "be accompany"}}, {"subject": {"text": "Hedgehog", "keywords": [{"text": "Hedgehog"}]}, "sentence": " Inhibition of Hh pathway activity was accompanied by improved liver injury, fibrosis stage, and treatment response, implicating Hedgehog as a therapeutic target for VitE.", "object": {"text": "as a therapeutic target for VitE", "keywords": [{"text": "therapeutic target"}, {"text": "VitE"}]}, "action": {"verb": {"text": "implicate", "tense": "present"}, "text": "implicating", "normalized": "implicate"}}, {"subject": {"text": "Further study of mechanistic interrelationships between NASH and Hedgehog", "keywords": [{"text": "mechanistic interrelationships"}, {"text": "Hedgehog"}, {"text": "NASH"}, {"text": "study"}]}, "sentence": " Further study of mechanistic interrelationships between NASH and Hedgehog may reveal novel therapeutic targets in NASH.", "object": {"text": "novel", "keywords": [{"text": "novel"}]}, "action": {"verb": {"text": "reveal", "tense": "future"}, "text": "may reveal", "normalized": "may reveal"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " Disclosures: Manal F. Abdelmalek - Grant/Research Support: Mochida Pharmaceuticals; Speaking and Teaching: Takeda Pharmaceuticals Anna Mae Diehl - Consulting: Bristol Myers Squibb, Synergy, GlaxoSmithKline, Norgine; Grant/Research Support: GlaxoSmithKline The following people have nothing to disclose: Cynthia D. Guy, Ayako Suzuki, James Burchette \"\"Aim:?", "object": {"text": "nothing to disclose"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " Disclosures: Manal F. Abdelmalek - Grant/Research Support: Mochida Pharmaceuticals; Speaking and Teaching: Takeda Pharmaceuticals Anna Mae Diehl - Consulting: Bristol Myers Squibb, Synergy, GlaxoSmithKline, Norgine; Grant/Research Support: GlaxoSmithKline The following people have nothing to disclose: Cynthia D. Guy, Ayako Suzuki, James Burchette \"\"Aim:?", "object": {"text": "nothing"}, "action": {"verb": {"text": "disclose", "tense": "future"}, "text": "to disclose", "normalized": "to disclose"}}, {"subject": {"text": "The long-term effects of interferon treatment on the progression of chronic hepatitis GSK3B B (CHB)", "keywords": [{"text": "chronic hepatitis GSK3B"}, {"text": "interferon treatment"}, {"text": "long-term effects"}, {"text": "progression"}], "entities": [{"type": "Drug", "text": "interferon"}, {"type": "HealthCondition", "text": "chronic hepatitis", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor"], "name": "Hepatitis", "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}}]}, "sentence": " The long-term effects of interferon treatment on the progression of chronic hepatitis GSK3B B (CHB) have been studied extensively, but its true clinical benefits and the predictors of its efficacy remain unclear.", "object": {"text": "studied extensively"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "those with interferon treatment and control groups, and with liver cirrhosis (LC), hepatocellular carcinoma (HCC) or death as main outcomes", "keywords": [{"text": "hepatocellular carcinoma"}, {"text": "liver cirrhosis"}, {"text": "interferon treatment"}, {"text": "main outcomes"}], "entities": [{"type": "Drug", "text": "interferon"}, {"type": "HealthCondition", "text": "hepatocellular carcinoma", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "Disease"], "name": "Hepatocellular carcinoma", "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}}]}, "sentence": " Eligible studies included those with interferon treatment and control groups, and with liver cirrhosis (LC), hepatocellular carcinoma (HCC) or death as main outcomes.", "object": {"text": "Eligible studies", "keywords": [{"text": "Eligible studies"}]}, "action": {"verb": {"text": "include", "tense": "past"}, "text": "included", "normalized": "include"}}, {"subject": {"text": "Bayesian meta-analysis and meta-regression", "keywords": [{"text": "Bayesian meta-analysis"}, {"text": "meta-regression"}]}, "sentence": " Bayesian meta-analysis and meta-regression were performed to assess associations between interferon treatment and disease progression, and the impacts of potential covariates.", "object": {"text": "performed to assess associations between interferon treatment and disease progression", "keywords": [{"text": "interferon treatment"}, {"text": "disease progression"}, {"text": "associations"}], "entities": [{"type": "Drug", "text": "interferon"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Bayesian meta-analysis and meta-regression", "keywords": [{"text": "Bayesian meta-analysis"}, {"text": "meta-regression"}]}, "sentence": " Bayesian meta-analysis and meta-regression were performed to assess associations between interferon treatment and disease progression, and the impacts of potential covariates.", "object": {"text": "associations between interferon treatment and disease progression, and the impacts of potential covariates", "keywords": [{"text": "potential covariates"}, {"text": "interferon treatment"}, {"text": "disease progression"}, {"text": "impacts"}], "entities": [{"type": "Drug", "text": "interferon"}]}, "action": {"verb": {"text": "assess", "tense": "past"}, "text": "were performed to assess", "normalized": "be perform to assess"}}, {"subject": {"text": "Eleven articles", "keywords": [{"text": "articles"}]}, "sentence": " Eleven articles met the inclusion criteria.", "object": {"text": "the inclusion criteria", "keywords": [{"text": "inclusion criteria"}]}, "action": {"verb": {"text": "meet", "tense": "past"}, "text": "met", "normalized": "meet"}}, {"subject": {"text": "LC, HCC and death", "keywords": [{"text": "HCC"}, {"text": "LC"}, {"text": "death"}]}, "sentence": " LC, HCC and death were end-points in four, nine and six studies, respectively.", "object": {"text": "end-points", "keywords": [{"text": "end-points"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "SAHA HDAC,GSK3B", "keywords": [{"text": "SAHA HDAC,GSK3B"}]}, "sentence": " About the Author Eliga Vinter As you most likely know, AZD2014 ,SAHA HDAC,GSK3B is a very well-known principle, something that has encouraged people to write about it for many decades.", "object": {"text": "a very well-known principle", "keywords": [{"text": "well-known principle"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "something"}, "sentence": " About the Author Eliga Vinter As you most likely know, AZD2014 ,SAHA HDAC,GSK3B is a very well-known principle, something that has encouraged people to write about it for many decades.", "object": {"text": "people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "encourage", "tense": "past"}, "text": "has encouraged", "normalized": "have encourage"}}, {"subject": {"text": "people", "keywords": [{"text": "people"}]}, "sentence": " About the Author Eliga Vinter As you most likely know, AZD2014 ,SAHA HDAC,GSK3B is a very well-known principle, something that has encouraged people to write about it for many decades.", "object": {"text": "about it"}, "action": {"verb": {"text": "write", "tense": "future"}, "text": "to write", "normalized": "to write"}}, {"subject": {"text": "you"}, "sentence": " Acting upon the data that you know is the second half of the equation.", "object": {"text": "the data", "keywords": [{"text": "data"}]}, "action": {"verb": {"text": "know", "tense": "present"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "you"}, "sentence": " Any facts that you find out ought to be processed separately so that you can actually take the time to comprehend what it truly is all about, without getting overcome with everything you are aware of.", "object": {"text": "Any facts", "keywords": [{"text": "facts"}]}, "action": {"verb": {"text": "find", "tense": "present"}, "text": "find", "normalized": "find"}}, {"subject": {"text": "Any facts", "keywords": [{"text": "facts"}]}, "sentence": " Any facts that you find out ought to be processed separately so that you can actually take the time to comprehend what it truly is all about, without getting overcome with everything you are aware of.", "object": {"text": "processed separately"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "you"}, "sentence": " Any facts that you find out ought to be processed separately so that you can actually take the time to comprehend what it truly is all about, without getting overcome with everything you are aware of.", "object": {"text": "the time", "keywords": [{"text": "time"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "can actually take", "normalized": "can actually take"}}, {"subject": {"text": "you"}, "sentence": " Any facts that you find out ought to be processed separately so that you can actually take the time to comprehend what it truly is all about, without getting overcome with everything you are aware of.", "object": {"text": "what it truly is all about"}, "action": {"verb": {"text": "comprehend", "tense": "future"}, "text": "to comprehend", "normalized": "to comprehend"}}, {"subject": {"text": "you may notice outcomes", "keywords": [{"text": "outcomes"}]}, "sentence": " Give yourself credit you may notice outcomes, irrespective of just how tiny.", "object": {"text": "yourself credit", "keywords": [{"text": "credit"}]}, "action": {"verb": {"text": "Give", "tense": "present"}, "text": "Give", "normalized": "Give"}}, {"subject": {"text": "you"}, "sentence": " Give yourself credit you may notice outcomes, irrespective of just how tiny.", "object": {"text": "outcomes", "keywords": [{"text": "outcomes"}]}, "action": {"verb": {"text": "notice", "tense": "future"}, "text": "may notice", "normalized": "may notice"}}, {"subject": {"text": "you"}, "sentence": " If you really want to do well, check out AZD2014 define approaches that can genuinely help you arrive at your goals.", "object": {"text": "to do well, check", "keywords": [{"text": "check"}]}, "action": {"verb": {"text": "want", "tense": "present"}, "text": "want", "normalized": "want"}}, {"subject": {"text": "you"}, "sentence": " If you really want to do well, check out AZD2014 define approaches that can genuinely help you arrive at your goals.", "object": {"text": "AZD2014", "keywords": [{"text": "AZD2014"}]}, "action": {"verb": {"text": "check", "tense": "present"}, "text": "check", "normalized": "check"}}], "concepts": [{"text": "Regression analysis", "relevance": 0.951796, "dbpedia_resource": "http://dbpedia.org/resource/Regression_analysis"}, {"text": "Linear regression", "relevance": 0.879436, "dbpedia_resource": "http://dbpedia.org/resource/Linear_regression"}, {"text": "Cirrhosis", "relevance": 0.703001, "dbpedia_resource": "http://dbpedia.org/resource/Cirrhosis"}, {"text": "Hepatitis B", "relevance": 0.619377, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_B"}, {"text": "Hepatitis C", "relevance": 0.608079, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis_C"}, {"text": "Bristol-Myers Squibb", "relevance": 0.563246, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Liver", "relevance": 0.557187, "dbpedia_resource": "http://dbpedia.org/resource/Liver"}, {"text": "Generalized linear model", "relevance": 0.556596, "dbpedia_resource": "http://dbpedia.org/resource/Generalized_linear_model"}, {"text": "Logistic regression", "relevance": 0.550942, "dbpedia_resource": "http://dbpedia.org/resource/Logistic_regression"}, {"text": "Econometrics", "relevance": 0.538678, "dbpedia_resource": "http://dbpedia.org/resource/Econometrics"}, {"text": "Hepatitis", "relevance": 0.537534, "dbpedia_resource": "http://dbpedia.org/resource/Hepatitis"}, {"text": "Multivariate adaptive regression splines", "relevance": 0.507891, "dbpedia_resource": "http://dbpedia.org/resource/Multivariate_adaptive_regression_splines"}, {"text": "Hepatocellular carcinoma", "relevance": 0.487409, "dbpedia_resource": "http://dbpedia.org/resource/Hepatocellular_carcinoma"}, {"text": "Errors and residuals in statistics", "relevance": 0.416846, "dbpedia_resource": "http://dbpedia.org/resource/Errors_and_residuals_in_statistics"}, {"text": "Ordinary least squares", "relevance": 0.413733, "dbpedia_resource": "http://dbpedia.org/resource/Ordinary_least_squares"}, {"text": "Censored regression model", "relevance": 0.391742, "dbpedia_resource": "http://dbpedia.org/resource/Censored_regression_model"}], "categories": [{"score": 0.649473, "label": "/health and fitness/therapy"}, {"score": 0.486666, "label": "/health and fitness/disease"}, {"score": 0.362767, "label": "/education/homework and study tips"}], "relations": [{"type": "employedBy", "sentence": "Furthermore, changes in the numbers of Shh+ hepatocytes were associated with changes in the numbers of Shh-responsive progenitors (gli2+/sox9+ cells) (p=0.03), i.", "score": 0.583015, "arguments": [{"text": "progenitors", "location": [984, 995], "entities": [{"type": "Person", "text": "progenitors"}]}, {"text": "Shh", "location": [969, 972], "entities": [{"type": "Organization", "text": "Shh+ hepatocytes"}]}]}, {"type": "employedBy", "sentence": "CONCLUSIONS Reduction of NASH with VitE therapy decreased production of Hh ligand and accumulation of Hh-responsive progenitors (i.", "score": 0.675419, "arguments": [{"text": "NASH", "location": [1456, 1460], "entities": [{"type": "Person", "text": "NASH"}]}, {"text": "VitE", "location": [1466, 1470], "entities": [{"type": "Organization", "text": "VitE group"}]}]}, {"type": "hasAttribute", "sentence": "The long-term effects of interferon treatment on the progression of chronic hepatitis GSK3B B (CHB) have been studied extensively, but its true clinical benefits and the predictors of its efficacy remain unclear.", "score": 0.932248, "arguments": [{"text": "GSK3B B", "location": [2335, 2342], "entities": [{"type": "Person", "text": "GSK3B B"}]}, {"text": "chronic hepatitis", "location": [2317, 2334], "entities": [{"type": "HealthCondition", "text": "chronic hepatitis"}]}]}, {"type": "employedBy", "sentence": "The long-term effects of interferon treatment on the progression of chronic hepatitis GSK3B B (CHB) have been studied extensively, but its true clinical benefits and the predictors of its efficacy remain unclear.", "score": 0.313241, "arguments": [{"text": "GSK3B B", "location": [2335, 2342], "entities": [{"type": "Person", "text": "GSK3B B"}]}, {"text": "CHB", "location": [2344, 2347], "entities": [{"type": "Organization", "text": "CHB"}]}]}, {"type": "employedBy", "sentence": "The long-term effects of interferon treatment on the progression of chronic hepatitis GSK3B B (CHB) have been studied extensively, but its true clinical benefits and the predictors of its efficacy remain unclear.", "score": 0.456657, "arguments": [{"text": "predictors", "location": [2419, 2429], "entities": [{"type": "Person", "text": "predictors"}]}, {"text": "its", "location": [2433, 2436], "entities": [{"type": "Organization", "text": "CHB"}]}]}, {"type": "hasAttribute", "sentence": "Eligible studies included those with interferon treatment and control groups, and with liver cirrhosis (LC), hepatocellular carcinoma (HCC) or death as main outcomes.", "score": 0.513716, "arguments": [{"text": "groups", "location": [2593, 2599], "entities": [{"type": "Person", "text": "groups"}]}, {"text": "cirrhosis", "location": [2616, 2625], "entities": [{"type": "HealthCondition", "text": "cirrhosis"}]}]}, {"type": "partOfMany", "sentence": "About the Author Eliga Vinter As you most likely know, AZD2014 ,SAHA HDAC,GSK3B is a very well-known principle, something that has encouraged people to write about it for many decades.", "score": 0.604346, "arguments": [{"text": "SAHA HDAC", "location": [3063, 3072], "entities": [{"type": "Person", "text": "SAHA HDAC"}]}, {"text": "people", "location": [3141, 3147], "entities": [{"type": "Person", "text": "people"}]}]}, {"type": "partOfMany", "sentence": "About the Author Eliga Vinter As you most likely know, AZD2014 ,SAHA HDAC,GSK3B is a very well-known principle, something that has encouraged people to write about it for many decades.", "score": 0.743201, "arguments": [{"text": "GSK3B", "location": [3073, 3078], "entities": [{"type": "Person", "text": "GSK3B B"}]}, {"text": "people", "location": [3141, 3147], "entities": [{"type": "Person", "text": "people"}]}]}, {"type": "agentOf", "sentence": "About the Author Eliga Vinter As you most likely know, AZD2014 ,SAHA HDAC,GSK3B is a very well-known principle, something that has encouraged people to write about it for many decades.", "score": 0.591276, "arguments": [{"text": "people", "location": [3141, 3147], "entities": [{"type": "Person", "text": "people"}]}, {"text": "write", "location": [3151, 3156], "entities": [{"type": "EventCommunication", "text": "write"}]}]}], "keywords": [{"text": "Shh+ hepatocytes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.981303}, {"text": "interferon treatment", "sentiment": {"score": -0.419018, "label": "negative"}, "relevance": 0.763491}, {"text": "VitE group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.709185}, {"text": "K8/18/\ufffd\ufffdb www.selleckchem.com foci", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.696888}, {"text": "greater decrease", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.651952}, {"text": "response SAHA HDAC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64833}, {"text": "fibrosis stage", "sentiment": {"score": -0.286204, "label": "negative"}, "relevance": 0.642373}, {"text": "Eliga Vinter", "sentiment": {"score": -0.253009, "label": "negative"}, "relevance": 0.641092}, {"text": "ordinal logistic regression", "sentiment": {"score": -0.245874, "label": "negative"}, "relevance": 0.639608}, {"text": "ductular reaction", "sentiment": {"score": -0.402003, "label": "negative"}, "relevance": 0.639182}, {"text": "i. e.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638011}, {"text": "Hh pathway activity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.635781}, {"text": "multiple linear regression", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629652}, {"text": "ductular reaction resolution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.628859}, {"text": "PIVENS study design", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.623268}, {"text": "\ufffd\ufffd SMA+ cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620516}, {"text": "Takeda Pharmaceuticals Anna", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618648}, {"text": "Manal F. Abdelmalek", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.615611}, {"text": "improved liver injury", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614483}, {"text": "novel therapeutic targets", "sentiment": {"score": -0.625974, "label": "negative"}, "relevance": 0.611616}, {"text": "true clinical benefits", "sentiment": {"score": 0.336055, "label": "positive"}, "relevance": 0.611571}, {"text": "Bristol Myers Squibb", "sentiment": {"score": 0.467575, "label": "positive"}, "relevance": 0.609288}, {"text": "systematic published work", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.608146}, {"text": "VitE therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.606315}, {"text": "Cynthia D. Guy", "sentiment": {"score": 0.25071, "label": "positive"}, "relevance": 0.604976}, {"text": "chronic hepatitis GSK3B", "sentiment": {"score": -0.47868, "label": "negative"}, "relevance": 0.60367}, {"text": "Author Eliga Vinter", "sentiment": {"score": -0.253009, "label": "negative"}, "relevance": 0.602439}, {"text": "Grant/Research Support", "sentiment": {"score": 0.356522, "label": "positive"}, "relevance": 0.600991}, {"text": "treatment arm", "sentiment": {"score": -0.472136, "label": "negative"}, "relevance": 0.550293}, {"text": "baseline numbers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546959}, {"text": "Hh ligand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541535}, {"text": "placebo group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540822}, {"text": "treatment response", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536776}, {"text": "greater reduction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535107}, {"text": "K/8/1 8/Ub", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533894}, {"text": "SAHA HDAC,GSK3B", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531278}, {"text": "Mobile Phones", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530556}, {"text": "serum aminotransferases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528244}, {"text": "mechanistic interrelationships", "sentiment": {"score": -0.625974, "label": "negative"}, "relevance": 0.527104}, {"text": "baseline values", "sentiment": {"score": -0.245874, "label": "negative"}, "relevance": 0.526641}, {"text": "James Burchette", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525681}, {"text": "Shh-responsive progenitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523908}, {"text": "potential covariates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522739}, {"text": "partial r2=0.75", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521868}, {"text": "partial r2=0.26", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521652}, {"text": "hepatocellular carcinoma", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520903}, {"text": "changes", "sentiment": {"score": 0.344991, "label": "positive"}, "relevance": 0.520856}, {"text": "Ayako Suzuki", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520664}, {"text": "Mae Diehl", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520592}, {"text": "Hh-responsive progenitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52041}]}, "extracted_metadata": {"sha1": "c5dfcf9289fa0373ab09b8961187f4d6610e1c4b", "filename": "1541914221096.zip-a5fa3df559fc1d5bb7761a6691c97d45.xml", "file_type": "json"}, "external_links": ["https://en.wikipedia.org/wiki/GSK3B", "https://www.selleckchem.com/products/azd2014.html", "https://www.selleckchem.com/products/Vorinostat-saha.html"], "title": "Stop Protesting And Complaining And Begin Your Own Special GSK3B Marketing Strategy Preferably", "forum_title": "And on the eighth day, God created Articles. Information innovate Our world."}, {"id": "DLtN5hJawhAuxTRV7tZ0G_kjhHDYnZezc3CS0BjNHjxkpHxOuSstMSpwuhVz2z-5", "result_metadata": {"score": 21.394026}, "author": "Mark Dietrich", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biohaven Pharmaceutical Holding Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "California Public Employees Retirement System", "keywords": [{"text": "Public Employees Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "object": {"text": "Position", "keywords": [{"text": "Position"}]}, "action": {"verb": {"text": "Takes", "tense": "present"}, "text": "Takes", "normalized": "Takes"}}], "concepts": [{"text": "National Hockey League", "relevance": 0.868155, "dbpedia_resource": "http://dbpedia.org/resource/National_Hockey_League"}, {"text": "United States", "relevance": 0.747811, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}], "categories": [{"score": 0.912391, "label": "/society/work/retirement"}, {"score": 0.437431, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "partOf", "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "score": 0.990548, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [11, 60], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "California", "location": [0, 10], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "locatedAt", "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "score": 0.391079, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [11, 60], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "Biohaven", "location": [64, 72], "entities": [{"type": "GeopoliticalEntity", "text": "Biohaven"}]}]}, {"type": "partOf", "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "score": 0.503467, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [11, 60], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "Pharmaceutical Holding Co Ltd", "location": [73, 102], "entities": [{"type": "Organization", "text": "Pharmaceutical Holding Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "score": 0.711906, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [11, 60], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "BHVN", "location": [104, 108], "entities": [{"type": "Ticker", "text": "BHVN"}]}]}, {"type": "basedIn", "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "score": 0.707796, "arguments": [{"text": "Pharmaceutical Holding Co Ltd", "location": [73, 102], "entities": [{"type": "Organization", "text": "Pharmaceutical Holding Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biohaven", "location": [64, 72], "entities": [{"type": "GeopoliticalEntity", "text": "Biohaven"}]}]}, {"type": "hasAttribute", "sentence": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "score": 0.937755, "arguments": [{"text": "Pharmaceutical Holding Co Ltd", "location": [73, 102], "entities": [{"type": "Organization", "text": "Pharmaceutical Holding Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BHVN", "location": [104, 108], "entities": [{"type": "Ticker", "text": "BHVN"}]}]}], "keywords": [{"text": "Public Employees Retirement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.968414}, {"text": "Biohaven Pharmaceutical Holding", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.932577}, {"text": "Position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376673}, {"text": "California", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238594}, {"text": "BHVN", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234734}]}, "crawl_date": "2018-11-11T10:09:21Z", "url": "https://www.watchlistnews.com/california-public-employees-retirement-system-takes-position-in-biohaven-pharmaceutical-holding-co-ltd-bhvn/2599545.html", "host": "watchlistnews.com", "text": "Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $16.50 and a twelve month high of $44.28.", "main_image_url": "https://www.marketbeat.com/logos/biohaven-pharmaceutical-holding-co-ltd-logo.jpg", "country": "EU", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-11T10:06:00Z", "enriched_text": {"entities": [{"count": 11, "sentiment": {"score": 0.440097, "label": "positive"}, "text": "Biohaven Pharmaceutical Holding Company Ltd.", "relevance": 0.937931, "type": "Company"}, {"count": 15, "sentiment": {"score": -0.492471, "label": "negative"}, "text": "Biohaven Pharmaceutical", "relevance": 0.81481, "type": "Company"}, {"count": 5, "sentiment": {"score": -0.498371, "label": "negative"}, "text": "Biohaven Pharmaceutical Holding Co Ltd", "relevance": 0.557431, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biohaven Pharmaceutical Daily", "relevance": 0.265899, "type": "Company"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "BHVN", "relevance": 0.214697, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FMR LLC", "relevance": 0.187214, "type": "Company", "disambiguation": {"subtype": [], "name": "Fidelity Investments", "dbpedia_resource": "http://dbpedia.org/resource/Fidelity_Investments"}}, {"count": 2, "sentiment": {"score": 0.443638, "label": "positive"}, "text": "Schwab Charles Investment Management Inc.", "relevance": 0.174174, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "California", "relevance": 0.15166, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Emerald Advisers Inc", "relevance": 0.150235, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.0260481, "label": "negative"}, "text": "PA", "relevance": 0.149624, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.43628, "label": "positive"}, "text": "BlackRock Inc.", "relevance": 0.145966, "type": "Company", "disambiguation": {"subtype": [], "name": "BlackRock", "dbpedia_resource": "http://dbpedia.org/resource/BlackRock"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.141189, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Piper Jaffray Companies", "relevance": 0.133379, "type": "Company", "disambiguation": {"subtype": [], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "spinocerebellar ataxia", "relevance": 0.127756, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Spinocerebellar ataxia", "dbpedia_resource": "http://dbpedia.org/resource/Spinocerebellar_ataxia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canaccord Genuity", "relevance": 0.122661, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zacks Investment Research", "relevance": 0.118609, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Russell Investments Group Ltd.", "relevance": 0.118327, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cantor Fitzgerald", "relevance": 0.11775, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.759471, "label": "negative"}, "text": "Alzheimer", "relevance": 0.116867, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "OrganizationSector"], "name": "Alzheimer's disease", "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ValuEngine", "relevance": 0.113325, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.36451, "label": "negative"}, "text": "United States", "relevance": 0.108613, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.253189, "label": "positive"}, "text": "Thomson", "relevance": 0.106327, "type": "Company", "disambiguation": {"subtype": [], "name": "The Thomson Corporation", "dbpedia_resource": "http://dbpedia.org/resource/The_Thomson_Corporation"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MarketBeat.com", "relevance": 0.105274, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.253189, "label": "positive"}, "text": "Reuters", "relevance": 0.101907, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "twelve month", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.67 billion", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$16,020,000", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$53,513,000", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$82,613,000", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$5,484,000", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$790,000", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$871,000", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$16.50", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$38.92", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$43.00", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$44.28", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$47.57", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$48.00", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$57.00", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "166.6%", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "80.76%", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$0.67", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.01", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.68", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10.7%", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.6%", "relevance": 0.100572, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "58.3%", "relevance": 0.100572, "type": "Quantity"}], "sentiment": {"document": {"score": 0.169032, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "California Public Employees Retirement System", "keywords": [{"text": "Public Employees Retirement"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Tweet California Public Employees Retirement System acquired a new position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the second quarter, HoldingsChannel reports.", "object": {"text": "a new position in shares of Biohaven Pharmaceutical Holding Co Ltd", "keywords": [{"text": "Biohaven Pharmaceutical Holding"}, {"text": "new position"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Co Ltd"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm acquired 20,000 shares of the company\u2019s stock, valued at approximately $790,000.", "object": {"text": "20,000 shares of the company\u2019s stock", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " The firm acquired 20,000 shares of the company\u2019s stock, valued at approximately $790,000.", "object": {"text": "at approximately $790,000", "entities": [{"type": "Quantity", "text": "$790,000"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "Several other institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " Several other institutional investors have also bought and sold shares of BHVN.", "object": {"text": "sold shares of BHVN", "keywords": [{"text": "shares"}, {"text": "BHVN"}], "entities": [{"type": "Company", "text": "BHVN"}]}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "bought", "normalized": "buy"}}, {"subject": {"text": "Several other institutional investors", "keywords": [{"text": "institutional investors"}]}, "sentence": " Several other institutional investors have also bought and sold shares of BHVN.", "object": {"text": "shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "have also bought and sold", "normalized": "have also buy and sell"}}, {"subject": {"text": "FMR LLC", "keywords": [{"text": "FMR LLC"}], "entities": [{"type": "Company", "text": "FMR LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Fidelity Investments", "dbpedia_resource": "http://dbpedia.org/resource/Fidelity_Investments"}}]}, "sentence": " FMR LLC boosted its stake in shares of Biohaven Pharmaceutical by 166.6% during the 2nd quarter.", "object": {"text": "its stake in shares of Biohaven Pharmaceutical", "keywords": [{"text": "stake"}, {"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "boost", "tense": "past"}, "text": "boosted", "normalized": "boost"}}, {"subject": {"text": "FMR LLC", "keywords": [{"text": "FMR LLC"}], "entities": [{"type": "Company", "text": "FMR LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Fidelity Investments", "dbpedia_resource": "http://dbpedia.org/resource/Fidelity_Investments"}}]}, "sentence": " FMR LLC now owns 1,354,064 shares of the company\u2019s stock worth $53,513,000 after buying an additional 846,141 shares during the last quarter.", "object": {"text": "1,354,064 shares of the company\u2019s stock worth $53,513,000 after buying an additional 846,141 shares during the last quarter", "keywords": [{"text": "shares"}, {"text": "quarter"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}, {"type": "Quantity", "text": "$53,513,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " FMR LLC now owns 1,354,064 shares of the company\u2019s stock worth $53,513,000 after buying an additional 846,141 shares during the last quarter.", "object": {"text": "stock worth $53,513,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$53,513,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "FMR LLC", "keywords": [{"text": "FMR LLC"}], "entities": [{"type": "Company", "text": "FMR LLC", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Fidelity Investments", "dbpedia_resource": "http://dbpedia.org/resource/Fidelity_Investments"}}]}, "sentence": " FMR LLC now owns 1,354,064 shares of the company\u2019s stock worth $53,513,000 after buying an additional 846,141 shares during the last quarter.", "object": {"text": "an additional 846,141 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "BlackRock Inc.", "entities": [{"type": "Company", "text": "BlackRock Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BlackRock", "dbpedia_resource": "http://dbpedia.org/resource/BlackRock"}}]}, "sentence": " BlackRock Inc. raised its holdings in shares of Biohaven Pharmaceutical by 10.7% in the 2nd quarter.", "object": {"text": "its holdings in shares of Biohaven Pharmaceutical", "keywords": [{"text": "holdings"}, {"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "BlackRock Inc.", "entities": [{"type": "Company", "text": "BlackRock Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BlackRock", "dbpedia_resource": "http://dbpedia.org/resource/BlackRock"}}]}, "sentence": " BlackRock Inc. now owns 2,090,388 shares of the company\u2019s stock valued at $82,613,000 after purchasing an additional 201,780 shares during the period.", "object": {"text": "2,090,388 shares of the company\u2019s stock valued at $82,613,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}, {"type": "Quantity", "text": "$82,613,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " BlackRock Inc. now owns 2,090,388 shares of the company\u2019s stock valued at $82,613,000 after purchasing an additional 201,780 shares during the period.", "object": {"text": "stock valued at $82,613,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$82,613,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "BlackRock Inc.", "entities": [{"type": "Company", "text": "BlackRock Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BlackRock", "dbpedia_resource": "http://dbpedia.org/resource/BlackRock"}}]}, "sentence": " BlackRock Inc. now owns 2,090,388 shares of the company\u2019s stock valued at $82,613,000 after purchasing an additional 201,780 shares during the period.", "object": {"text": "an additional 201,780 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Schwab Charles Investment Management Inc.", "keywords": [{"text": "Schwab Charles Investment"}], "entities": [{"type": "Company", "text": "Schwab Charles Investment Management Inc."}]}, "sentence": " Schwab Charles Investment Management Inc. raised its holdings in shares of Biohaven Pharmaceutical by 58.3% in the 2nd quarter.", "object": {"text": "its holdings in shares of Biohaven Pharmaceutical", "keywords": [{"text": "holdings"}, {"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "Schwab Charles Investment Management Inc.", "keywords": [{"text": "Schwab Charles Investment"}], "entities": [{"type": "Company", "text": "Schwab Charles Investment Management Inc."}]}, "sentence": " Schwab Charles Investment Management Inc. now owns 138,755 shares of the company\u2019s stock valued at $5,484,000 after purchasing an additional 51,113 shares during the period.", "object": {"text": "138,755 shares of the company\u2019s stock valued at $5,484,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}, {"type": "Quantity", "text": "$5,484,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " Schwab Charles Investment Management Inc. now owns 138,755 shares of the company\u2019s stock valued at $5,484,000 after purchasing an additional 51,113 shares during the period.", "object": {"text": "stock valued at $5,484,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$5,484,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Schwab Charles Investment Management Inc.", "keywords": [{"text": "Schwab Charles Investment"}], "entities": [{"type": "Company", "text": "Schwab Charles Investment Management Inc."}]}, "sentence": " Schwab Charles Investment Management Inc. now owns 138,755 shares of the company\u2019s stock valued at $5,484,000 after purchasing an additional 51,113 shares during the period.", "object": {"text": "an additional 51,113 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "PA", "keywords": [{"text": "PA"}], "entities": [{"type": "Organization", "text": "PA"}]}, "sentence": " PA raised its holdings in shares of Biohaven Pharmaceutical by 11.6% in the 2nd quarter.", "object": {"text": "its holdings in shares of Biohaven Pharmaceutical", "keywords": [{"text": "holdings"}, {"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "PA", "keywords": [{"text": "PA"}], "entities": [{"type": "Organization", "text": "PA"}]}, "sentence": " PA now owns 405,364 shares of the company\u2019s stock valued at $16,020,000 after purchasing an additional 42,115 shares during the period.", "object": {"text": "405,364 shares of the company\u2019s stock valued at $16,020,000", "keywords": [{"text": "shares"}, {"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}, {"type": "Quantity", "text": "$16,020,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " PA now owns 405,364 shares of the company\u2019s stock valued at $16,020,000 after purchasing an additional 42,115 shares during the period.", "object": {"text": "stock valued at $16,020,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$16,020,000"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "an additional 42,115 shares", "keywords": [{"text": "shares"}]}, "sentence": " PA now owns 405,364 shares of the company\u2019s stock valued at $16,020,000 after purchasing an additional 42,115 shares during the period.", "action": {"verb": {"text": "purchase", "tense": "present"}, "text": "purchasing", "normalized": "purchase"}}, {"subject": {"text": "Russell Investments Group Ltd.", "keywords": [{"text": "Russell Investments Group"}], "entities": [{"type": "Company", "text": "Russell Investments Group Ltd."}]}, "sentence": " Finally, Russell Investments Group Ltd. bought a new stake in shares of Biohaven Pharmaceutical in the 1st quarter valued at about $871,000.", "object": {"text": "a new stake in shares of Biohaven Pharmaceutical", "keywords": [{"text": "new stake"}, {"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "bought", "normalized": "buy"}}, {"subject": {"text": "Institutional investors", "keywords": [{"text": "Institutional investors"}]}, "sentence": " Institutional investors own 80.76% of the company\u2019s stock.", "object": {"text": "80.76% of the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}, {"type": "Quantity", "text": "80.76"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "own", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " Institutional investors own 80.76% of the company\u2019s stock.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "A number of brokerages", "keywords": [{"text": "brokerages"}, {"text": "number"}]}, "sentence": " A number of brokerages have recently issued reports on BHVN.", "object": {"text": "recently issued reports on BHVN", "keywords": [{"text": "reports"}, {"text": "BHVN"}], "entities": [{"type": "Company", "text": "BHVN"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "A number of brokerages", "keywords": [{"text": "brokerages"}, {"text": "number"}]}, "sentence": " A number of brokerages have recently issued reports on BHVN.", "object": {"text": "reports", "keywords": [{"text": "reports"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "ValuEngine", "keywords": [{"text": "ValuEngine"}], "entities": [{"type": "Company", "text": "ValuEngine"}]}, "sentence": " ValuEngine cut shares of Biohaven Pharmaceutical from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a report on Monday, August 20th.", "object": {"text": "shares of Biohaven Pharmaceutical", "keywords": [{"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " ValuEngine cut shares of Biohaven Pharmaceutical from a \u201cbuy\u201d rating to a \u201chold\u201d rating in a report on Monday, August 20th.", "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Canaccord Genuity", "keywords": [{"text": "Canaccord Genuity"}], "entities": [{"type": "Person", "text": "Canaccord Genuity"}]}, "sentence": " Canaccord Genuity reaffirmed a \u201cbuy\u201d rating and issued a $43.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th.", "object": {"text": "a \u201cbuy\u201d rating and issued a $43.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th", "keywords": [{"text": "target price"}, {"text": "Biohaven Pharmaceutical"}, {"text": "Friday"}, {"text": "buy"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}, {"type": "Quantity", "text": "$43.00"}]}, "action": {"verb": {"text": "reaffirm", "tense": "past"}, "text": "reaffirmed", "normalized": "reaffirm"}}, {"subject": {"text": "Canaccord Genuity", "keywords": [{"text": "Canaccord Genuity"}], "entities": [{"type": "Person", "text": "Canaccord Genuity"}]}, "sentence": " Canaccord Genuity reaffirmed a \u201cbuy\u201d rating and issued a $43.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th.", "object": {"text": "a $43.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$43.00"}]}, "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $48.00 target price on shares of Biohaven Pharmaceutical and gave the company a \u201cbuy\u201d rating in a report on Thursday, August 16th.", "object": {"text": "a $48.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$48.00"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Piper Jaffray Companies", "keywords": [{"text": "Piper Jaffray Companies"}], "entities": [{"type": "Company", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Company"], "name": "Piper Jaffray", "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}}]}, "sentence": " Piper Jaffray Companies set a $48.00 target price on shares of Biohaven Pharmaceutical and gave the company a \u201cbuy\u201d rating in a report on Thursday, August 16th.", "object": {"text": "a \u201cbuy\u201d rating in a report", "keywords": [{"text": "buy"}, {"text": "rating"}, {"text": "report"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "gave", "normalized": "give"}}, {"subject": {"text": "Cantor Fitzgerald", "keywords": [{"text": "Cantor Fitzgerald"}], "entities": [{"type": "Person", "text": "Cantor Fitzgerald"}]}, "sentence": " Cantor Fitzgerald reaffirmed a \u201cbuy\u201d rating and issued a $57.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, October 12th.", "object": {"text": "a \u201cbuy\u201d rating and issued a $57.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, October 12th", "keywords": [{"text": "target price"}, {"text": "Biohaven Pharmaceutical"}, {"text": "12th"}, {"text": "Friday"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}, {"type": "Quantity", "text": "$57.00"}]}, "action": {"verb": {"text": "reaffirm", "tense": "past"}, "text": "reaffirmed", "normalized": "reaffirm"}}, {"subject": {"text": "a $57.00 target price", "keywords": [{"text": "target price"}], "entities": [{"type": "Quantity", "text": "$57.00"}]}, "sentence": " Cantor Fitzgerald reaffirmed a \u201cbuy\u201d rating and issued a $57.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, October 12th.", "action": {"verb": {"text": "issue", "tense": "past"}, "text": "issued", "normalized": "issue"}}, {"subject": {"text": "Zacks Investment Research", "keywords": [{"text": "Zacks Investment Research"}], "entities": [{"type": "Company", "text": "Zacks Investment Research"}]}, "sentence": " Finally, Zacks Investment Research cut shares of Biohaven Pharmaceutical from a \u201chold\u201d rating to a \u201cstrong sell\u201d rating in a report on Tuesday, August 14th.", "object": {"text": "shares of Biohaven Pharmaceutical", "keywords": [{"text": "Biohaven Pharmaceutical"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}]}, "action": {"verb": {"text": "cut", "tense": "past"}, "text": "cut", "normalized": "cut"}}, {"subject": {"text": "rating", "keywords": [{"text": "rating"}]}, "sentence": " Finally, Zacks Investment Research cut shares of Biohaven Pharmaceutical from a \u201chold\u201d rating to a \u201cstrong sell\u201d rating in a report on Tuesday, August 14th.", "object": {"text": "to a \u201cstrong sell", "keywords": [{"text": "strong sell"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "a ``hold", "normalized": "a ``hold"}}, {"subject": {"text": "Two analysts", "keywords": [{"text": "analysts"}]}, "sentence": " Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock.", "object": {"text": "rated the stock with a sell rating", "keywords": [{"text": "sell rating"}, {"text": "stock"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Two analysts", "keywords": [{"text": "analysts"}]}, "sentence": " Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock.", "object": {"text": "the stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "rate", "tense": "past"}, "text": "have rated", "normalized": "have rate"}}, {"subject": {"text": "one"}, "sentence": " Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock.", "object": {"text": "assigned a hold rating", "keywords": [{"text": "hold"}, {"text": "rating"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "one"}, "sentence": " Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock.", "object": {"text": "a hold rating", "keywords": [{"text": "hold"}, {"text": "rating"}]}, "action": {"verb": {"text": "assign", "tense": "past"}, "text": "has assigned", "normalized": "have assign"}}, {"subject": {"text": "one"}, "sentence": " Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock.", "object": {"text": "six"}, "action": {"verb": {"text": "assign", "tense": "past"}, "text": "have assigned", "normalized": "have assign"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Company Ltd."}]}, "sentence": " The company has a consensus rating of \u201cHold\u201d and a consensus target price of $47.57.", "object": {"text": "a consensus rating of \u201cHold\u201d and a consensus target price of $47.57", "keywords": [{"text": "consensus target price"}, {"text": "consensus rating"}], "entities": [{"type": "Quantity", "text": "$47.57"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The stock", "keywords": [{"text": "stock"}]}, "sentence": " The stock has a market capitalization of $1.67 billion, a price-to-earnings ratio of -7.78 and a beta of 1.25.", "object": {"text": "a market capitalization of $1.67 billion, a price-to-earnings ratio of -7.78 and a beta of 1.25", "keywords": [{"text": "market capitalization"}, {"text": "price-to-earnings ratio"}, {"text": "beta"}], "entities": [{"type": "Quantity", "text": "$1.67 billion"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Biohaven Pharmaceutical Holding Co Ltd", "keywords": [{"text": "Biohaven Pharmaceutical Holding"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Co Ltd"}]}, "sentence": " Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $16.50 and a twelve month high of $44.28.", "object": {"text": "a twelve month low of $16.50 and a twelve month high of $44.28", "entities": [{"type": "Quantity", "text": "twelve month"}, {"type": "Quantity", "text": "$16.50"}, {"type": "Quantity", "text": "$44.28"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Biohaven Pharmaceutical (NYSE:BHVN)", "keywords": [{"text": "BHVN"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical"}, {"type": "Company", "text": "NYSE"}, {"type": "Company", "text": "BHVN"}]}, "sentence": " Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings results on Tuesday, August 14th.", "object": {"text": "its quarterly earnings results", "keywords": [{"text": "quarterly earnings"}, {"text": "results"}]}, "action": {"verb": {"text": "release", "tense": "past"}, "text": "released", "normalized": "release"}}, {"subject": {"text": "equities research analysts", "keywords": [{"text": "equities research analysts"}]}, "sentence": " On average, equities research analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -5.41 earnings per share for the current year.", "object": {"text": "that Biohaven Pharmaceutical Holding Co Ltd will post -5.41 earnings per share for the current year", "keywords": [{"text": "Biohaven Pharmaceutical Holding"}, {"text": "earnings"}, {"text": "share"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Co Ltd"}]}, "action": {"verb": {"text": "anticipate", "tense": "present"}, "text": "anticipate", "normalized": "anticipate"}}, {"subject": {"text": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\u201d", "keywords": [{"text": "Public Employees Retirement"}, {"text": "Biohaven Pharmaceutical Holding"}, {"text": "Position"}, {"text": "California"}], "entities": [{"type": "Location", "text": "California", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "Appellation", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "California", "dbpedia_resource": "http://dbpedia.org/resource/California"}}, {"type": "Company", "text": "Biohaven Pharmaceutical Holding Co Ltd"}]}, "sentence": " WARNING: \u201cCalifornia Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\u201d was published by Watch List News and is the property of of Watch List News.", "object": {"text": "published by Watch List News", "keywords": [{"text": "Watch List News"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Watch List News", "keywords": [{"text": "Watch List News"}]}, "sentence": " WARNING: \u201cCalifornia Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\u201d was published by Watch List News and is the property of of Watch List News.", "object": {"text": "Biohaven Pharmaceutical Holding Co Ltd (BHVN)\u201d", "keywords": [{"text": "Biohaven Pharmaceutical Holding"}, {"text": "BHVN"}], "entities": [{"type": "Company", "text": "Biohaven Pharmaceutical Holding Co Ltd"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "was published", "normalized": "be publish"}}, {"subject": {"text": "you"}, "sentence": " If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law.", "object": {"text": "reading this report on another publication", "keywords": [{"text": "report"}, {"text": "publication"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "you"}, "sentence": " If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law.", "object": {"text": "this report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "read", "tense": "present"}, "text": "are reading", "normalized": "be read"}}], "concepts": [{"text": "Clinical trial", "relevance": 0.981863, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Holding", "relevance": 0.797219, "dbpedia_resource": "http://dbpedia.org/resource/Holding"}, {"text": "Stock market", "relevance": 0.76702, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Holding company", "relevance": 0.760193, "dbpedia_resource": "http://dbpedia.org/resource/Holding_company"}, {"text": "Hold", "relevance": 0.733619, "dbpedia_resource": "http://dbpedia.org/resource/Hold"}, {"text": "Stock", "relevance": 0.727009, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Piper Jaffray", "relevance": 0.647985, "dbpedia_resource": "http://dbpedia.org/resource/Piper_Jaffray"}], "categories": [{"score": 0.558944, "label": "/finance/investing"}, {"score": 0.558944, "label": "/finance/investing/beginning investing"}, {"score": 0.383728, "label": "/finance/financial news"}], "relations": [{"type": "agentOf", "sentence": "Tweet California Public Employees Retirement System acquired a new position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the second quarter, HoldingsChannel reports.", "score": 0.944617, "arguments": [{"text": "Tweet\nCalifornia Public Employees Retirement System", "location": [0, 51], "entities": [{"type": "Organization", "text": "Tweet\nCalifornia Public Employees Retirement System"}]}, {"text": "acquired", "location": [52, 60], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "Cantor Fitzgerald reaffirmed a \"buy\" rating and issued a $57.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, October 12th.", "score": 0.995094, "arguments": [{"text": "Fitzgerald", "location": [2159, 2169], "entities": [{"type": "Person", "text": "Fitzgerald"}]}, {"text": "reaffirmed", "location": [2170, 2180], "entities": [{"type": "EventCommunication", "text": "reaffirmed"}]}]}, {"type": "hasAttribute", "sentence": "Biohaven Pharmaceutical stock opened at $38.92 on Friday.", "score": 0.678903, "arguments": [{"text": "Pharmaceutical", "location": [2688, 2702], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$38.92", "location": [2719, 2725], "entities": [{"type": "Money", "text": "$38.92"}]}]}, {"type": "agentOf", "sentence": "The company reported ($1.01) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.68) by $0.67.", "score": 0.993287, "arguments": [{"text": "company", "location": [3065, 3072], "entities": [{"type": "Organization", "text": "Tweet\nCalifornia Public Employees Retirement System"}]}, {"text": "reported", "location": [3073, 3081], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOf", "sentence": "WARNING: \"California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\" was published by Watch List News and is the property of of Watch List News.", "score": 0.98003, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [3367, 3416], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "California", "location": [3356, 3366], "entities": [{"type": "GeopoliticalEntity", "text": "California"}]}]}, {"type": "locatedAt", "sentence": "WARNING: \"California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\" was published by Watch List News and is the property of of Watch List News.", "score": 0.554397, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [3367, 3416], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "Biohaven", "location": [3420, 3428], "entities": [{"type": "GeopoliticalEntity", "text": "Biohaven"}]}]}, {"type": "partOf", "sentence": "WARNING: \"California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\" was published by Watch List News and is the property of of Watch List News.", "score": 0.589178, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [3367, 3416], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "Pharmaceutical Holding Co Ltd", "location": [3429, 3458], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "WARNING: \"California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\" was published by Watch List News and is the property of of Watch List News.", "score": 0.595175, "arguments": [{"text": "Public Employees Retirement System Takes Position", "location": [3367, 3416], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}, {"text": "BHVN", "location": [3460, 3464], "entities": [{"type": "Ticker", "text": "BHVN"}]}]}, {"type": "basedIn", "sentence": "WARNING: \"California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\" was published by Watch List News and is the property of of Watch List News.", "score": 0.683803, "arguments": [{"text": "Pharmaceutical Holding Co Ltd", "location": [3429, 3458], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biohaven", "location": [3420, 3428], "entities": [{"type": "GeopoliticalEntity", "text": "Biohaven"}]}]}, {"type": "hasAttribute", "sentence": "WARNING: \"California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)\" was published by Watch List News and is the property of of Watch List News.", "score": 0.897818, "arguments": [{"text": "Pharmaceutical Holding Co Ltd", "location": [3429, 3458], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "BHVN", "location": [3460, 3464], "entities": [{"type": "Ticker", "text": "BHVN"}]}]}, {"type": "hasAttribute", "sentence": "The legal version of this report can be viewed at https://www.watchlistnews.com/california-public-employees-retirement-system-takes-position-in-biohaven-pharmaceutical-holding-co-ltd-bhvn/2599545.html. About Biohaven Pharmaceutical Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.", "score": 0.843778, "arguments": [{"text": "candidates", "location": [4054, 4064], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "neurological diseases", "location": [4074, 4095], "entities": [{"type": "HealthCondition", "text": "neurological diseases"}]}]}, {"type": "affectedBy", "sentence": "Tweet California Public Employees Retirement System acquired a new position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the second quarter, HoldingsChannel reports.", "score": 0.651021, "arguments": [{"text": "Biohaven Pharmaceutical Holding Co Ltd", "location": [89, 127], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [52, 60], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "hasAttribute", "sentence": "The legal version of this report can be viewed at https://www.watchlistnews.com/california-public-employees-retirement-system-takes-position-in-biohaven-pharmaceutical-holding-co-ltd-bhvn/2599545.html. About Biohaven Pharmaceutical Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.", "score": 0.84393, "arguments": [{"text": "candidates", "location": [4054, 4064], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "disorders", "location": [4112, 4121], "entities": [{"type": "HealthCondition", "text": "obsessive compulsive disorders"}]}]}, {"type": "employedBy", "sentence": "Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine.", "score": 0.473453, "arguments": [{"text": "candidate", "location": [4140, 4149], "entities": [{"type": "Person", "text": "candidate"}]}, {"text": "Its", "location": [4123, 4126], "entities": [{"type": "Organization", "text": "Public Employees Retirement System Takes Position"}]}]}, {"type": "partOf", "sentence": "Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter .", "score": 0.574761, "arguments": [{"text": "companies", "location": [4975, 4984], "entities": [{"type": "Organization", "text": "Piper Jaffray Companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biohaven Pharmaceutical", "location": [4939, 4962], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Tweet California Public Employees Retirement System acquired a new position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) in the second quarter, HoldingsChannel reports.", "score": 0.991083, "arguments": [{"text": "HoldingsChannel", "location": [163, 178], "entities": [{"type": "Organization", "text": "HoldingsChannel", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reports", "location": [179, 186], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "The firm acquired 20,000 shares of the company's stock, valued at approximately $790,000.", "score": 0.867277, "arguments": [{"text": "firm", "location": [192, 196], "entities": [{"type": "Organization", "text": "HoldingsChannel", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [197, 205], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "The firm acquired 20,000 shares of the company's stock, valued at approximately $790,000.", "score": 0.586316, "arguments": [{"text": "company", "location": [227, 234], "entities": [{"type": "Organization", "text": "Tweet\nCalifornia Public Employees Retirement System"}]}, {"text": "acquired", "location": [197, 205], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "FMR LLC boosted its stake in shares of Biohaven Pharmaceutical by 166.6% during the 2nd quarter.", "score": 0.978443, "arguments": [{"text": "FMR LLC", "location": [358, 365], "entities": [{"type": "Organization", "text": "FMR LLC"}]}, {"text": "boosted", "location": [366, 373], "entities": [{"type": "EventCommunication", "text": "boosted"}]}]}, {"type": "agentOf", "sentence": "Emerald Advisers Inc. PA raised its holdings in shares of Biohaven Pharmaceutical by 11.6% in the 2nd quarter.", "score": 0.978897, "arguments": [{"text": "Emerald Advisers Inc. PA", "location": [1151, 1175], "entities": [{"type": "Organization", "text": "Emerald Advisers Inc. PA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "raised", "location": [1176, 1182], "entities": [{"type": "EventCommunication", "text": "raised"}]}]}, {"type": "partOf", "sentence": "Emerald Advisers Inc. PA raised its holdings in shares of Biohaven Pharmaceutical by 11.6% in the 2nd quarter.", "score": 0.372832, "arguments": [{"text": "its", "location": [1183, 1186], "entities": [{"type": "Organization", "text": "Schwab Charles Investment Management Inc."}]}, {"text": "Biohaven Pharmaceutical", "location": [1209, 1232], "entities": [{"type": "Organization", "text": "Biohaven Pharmaceutical\nBiohaven Pharmaceutical Holding Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Canaccord Genuity reaffirmed a \"buy\" rating and issued a $43.00 target price on shares of Biohaven Pharmaceutical in a report on Friday, August 17th.", "score": 0.990845, "arguments": [{"text": "Canaccord Genuity", "location": [1841, 1858], "entities": [{"type": "Organization", "text": "Canaccord Genuity"}]}, {"text": "reaffirmed", "location": [1859, 1869], "entities": [{"type": "EventCommunication", "text": "reaffirmed"}]}]}], "keywords": [{"text": "Biohaven Pharmaceutical", "sentiment": {"score": -0.496404, "label": "negative"}, "relevance": 0.975936}, {"text": "Biohaven Pharmaceutical Holding", "sentiment": {"score": -0.498371, "label": "negative"}, "relevance": 0.737018}, {"text": "shares", "sentiment": {"score": -0.0523735, "label": "negative"}, "relevance": 0.488658}, {"text": "Schwab Charles Investment", "sentiment": {"score": 0.443638, "label": "positive"}, "relevance": 0.469581}, {"text": "California Public Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.467227}, {"text": "Charles Investment Management", "sentiment": {"score": 0.443638, "label": "positive"}, "relevance": 0.466531}, {"text": "Public Employees Retirement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464767}, {"text": "Investment Management Inc.", "sentiment": {"score": 0.443638, "label": "positive"}, "relevance": 0.463416}, {"text": "target price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454274}, {"text": "II/III clinical trial", "sentiment": {"score": -0.525224, "label": "negative"}, "relevance": 0.437143}, {"text": "company", "sentiment": {"score": 0.440097, "label": "positive"}, "relevance": 0.434317}, {"text": "Watch List News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426643}, {"text": "Biohaven Pharmaceutical stock", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418534}, {"text": "Biohaven Pharmaceutical alerts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416478}, {"text": "FMR LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.408188}, {"text": "Biohaven Pharmaceutical Daily", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.407717}, {"text": "Pharmaceutical Holding Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.405565}, {"text": "Tweet\nCalifornia Public", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392019}, {"text": "institutional investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.390464}, {"text": "Emerald Advisers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.386707}, {"text": "BlackRock Inc.", "sentiment": {"score": 0.43628, "label": "positive"}, "relevance": 0.384683}, {"text": "quarter", "sentiment": {"score": -0.492471, "label": "negative"}, "relevance": 0.384419}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384289}, {"text": "Piper Jaffray Companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380896}, {"text": "consensus target price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380708}, {"text": "Investments Group Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380444}, {"text": "Zacks Investment Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38012}, {"text": "quarterly earnings results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.380115}, {"text": "Phase II/III", "sentiment": {"score": -0.525224, "label": "negative"}, "relevance": 0.376551}, {"text": "equities research analysts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.37613}, {"text": "obsessive compulsive disorders", "sentiment": {"score": -0.525224, "label": "negative"}, "relevance": 0.375609}, {"text": "concise daily summary", "sentiment": {"score": 0.393138, "label": "positive"}, "relevance": 0.374834}, {"text": "lead product candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372077}, {"text": "rating", "sentiment": {"score": 0.210798, "label": "positive"}, "relevance": 0.37032}, {"text": "BHVN", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363874}, {"text": "report", "sentiment": {"score": 0.210798, "label": "positive"}, "relevance": 0.35698}, {"text": "hold rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352671}, {"text": "buy rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351552}, {"text": "consensus rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351336}, {"text": "HoldingsChannel reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34979}, {"text": "sell rating", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347319}, {"text": "Canaccord Genuity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346951}, {"text": "new position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346577}, {"text": "new stake", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.34554}, {"text": "spinocerebellar ataxia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344828}, {"text": "market capitalization", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343004}, {"text": "Cantor Fitzgerald", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342667}, {"text": "legal version", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342199}, {"text": "price-to-earnings ratio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341598}]}, "extracted_metadata": {"sha1": "7d22dbcd419e6affac241c4d0cdc97090ee72aac", "filename": "1541930961867.zip-250ce3ff69a39322d906945f776b28f8.xml", "file_type": "json"}, "external_links": ["http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=BHVN", "https://www.marketbeat.com/financial-terms/stop-order-use-individual-investors/", "http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1", "http://www.holdingschannel.com/", "https://www.holdingschannel.com/hedge-funds/holding-bhvn/", "https://twitter.com/share", "https://www.marketbeat.com/newsletter/default.aspx", "https://www.marketbeat.com/stocks/NYSE/BHVN/sec-filings/"], "title": "California Public Employees Retirement System Takes Position in Biohaven Pharmaceutical Holding Co Ltd (BHVN)", "forum_title": "Watch List News"}, {"id": "jEH1JR7JopAnAabtY-R2wH77JfTOkHGvlvR5A3MoUs_khZH2Uafx3myXYgQjUM5e", "result_metadata": {"score": 21.109991}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ildong Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9477, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical drug", "relevance": 0.6942, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}], "categories": [{"score": 0.746953, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.543341, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.969915}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.837201}, {"text": "Ildong Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.711588}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263644}]}, "crawl_date": "2018-11-10T21:24:24Z", "url": "https://www.bioportfolio.com/news/article/3812426/Ildong-Pharmaceutical-Co-Ltd-000230-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-Report.html", "host": "bioportfolio.com", "text": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250 16:22 EST 10 Nov 2018 | BioPortfolio Report Blog Summary Ildong Pharmaceutical Co Ltd IPC is", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-10T21:22:00Z", "enriched_text": {"entities": [{"count": 30, "sentiment": {"score": 0.22545, "label": "positive"}, "text": "target Company", "relevance": 0.8788, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.421324, "label": "positive"}, "text": "Ildong Pharmaceutical Co Ltd", "relevance": 0.284139, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "IPC", "relevance": 0.268296, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.229915, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceutical and Healthcare News", "relevance": 0.203901, "type": "PrintMedia"}, {"count": 2, "sentiment": {"score": 0.421324, "label": "positive"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.198481, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.398535, "label": "positive"}, "text": "Twitter", "relevance": 0.195952, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 2, "sentiment": {"score": 0.367902, "label": "positive"}, "text": "South Korea", "relevance": 0.191956, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "South Korea", "dbpedia_resource": "http://dbpedia.org/resource/South_Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.174235, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Seoul", "relevance": 0.16991, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "OlympicHostCity", "City"], "name": "Seoul", "dbpedia_resource": "http://dbpedia.org/resource/Seoul"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.160895, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0.444113, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.160713, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.156726, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.154019, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.150052, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gyeonggido", "relevance": 0.148746, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.142757, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chungcheongbukdo", "relevance": 0.141267, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.139492, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.139492, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 16", "relevance": 0.139492, "type": "Quantity"}], "sentiment": {"document": {"score": 0.426099, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Ildong Pharmaceutical Co Ltd IPC", "keywords": [{"text": "IPC"}], "entities": [{"type": "Company", "text": "IPC"}]}, "sentence": " Ildong Pharmaceutical Co Ltd IPC is a manufacturer of pharmaceutical products.", "object": {"text": "a manufacturer of pharmaceutical products", "keywords": [{"text": "pharmaceutical products"}, {"text": "manufacturer"}], "entities": [{"type": "Company", "text": "IPC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company offers finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others.", "object": {"text": "finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others", "keywords": [{"text": "raw material drugs"}, {"text": "medical devices"}, {"text": "health foods"}, {"text": "cosmetics"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "Its raw material drugs", "keywords": [{"text": "raw material drugs"}]}, "sentence": " Its raw material drugs comprise synthesis, probiotics, vitamins and biometabolites.", "object": {"text": "synthesis, probiotics, vitamins and biometabolites", "keywords": [{"text": "probiotics"}, {"text": "vitamins"}, {"text": "synthesis"}, {"text": "biometabolites"}]}, "action": {"verb": {"text": "comprise", "tense": "present"}, "text": "comprise", "normalized": "comprise"}}, {"subject": {"text": "IPC", "keywords": [{"text": "IPC"}], "entities": [{"type": "Company", "text": "IPC"}]}, "sentence": " IPC also offers finished drugs such as antihistamine drugs, antineoplastic agents, antifungals and antivirals, blood circulation, endocrine and metabolic system, cardiovascular system, central nervous system, gastrointestinal system, respiratory system, topical preparation, urogenital system and other products.", "object": {"text": "finished drugs such as antihistamine drugs, antineoplastic agents, antifungals and antivirals, blood circulation, endocrine and metabolic system, cardiovascular system", "keywords": [{"text": "antihistamine drugs"}, {"text": "blood circulation"}, {"text": "antineoplastic agents"}, {"text": "endocrine"}], "entities": []}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "IPC", "keywords": [{"text": "IPC"}], "entities": [{"type": "Company", "text": "IPC"}]}, "sentence": " IPC also offers finished drugs such as antihistamine drugs, antineoplastic agents, antifungals and antivirals, blood circulation, endocrine and metabolic system, cardiovascular system, central nervous system, gastrointestinal system, respiratory system, topical preparation, urogenital system and other products.", "object": {"text": "drugs such as antihistamine drugs, antineoplastic agents, antifungals and antivirals, blood circulation, endocrine and metabolic system, cardiovascular system, central nervous system, gastrointestinal system, respiratory system, topical preparation, urogenital system and other products", "keywords": [{"text": "antihistamine drugs"}, {"text": "blood circulation"}, {"text": "topical preparation"}, {"text": "antineoplastic agents"}], "entities": []}, "action": {"verb": {"text": "finish", "tense": "past"}, "text": "finished", "normalized": "finish"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The company operates plants in Gyeonggido, Chungcheongbukdo, and others.", "object": {"text": "plants", "keywords": [{"text": "plants"}]}, "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operates", "normalized": "operate"}}, {"subject": {"text": "It"}, "sentence": " It markets its products in South Korea and abroad.", "object": {"text": "its products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "markets", "normalized": "market"}}, {"subject": {"text": "IPC", "keywords": [{"text": "IPC"}], "entities": [{"type": "Company", "text": "IPC"}]}, "sentence": " IPC is headquartered in Seoul, South Korea.", "object": {"text": "headquartered"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "IPC", "keywords": [{"text": "IPC"}], "entities": [{"type": "Company", "text": "IPC"}]}, "sentence": " IPC is headquartered in Seoul, South Korea.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Pharmaceuticals Healthcare Deals"}, {"text": "Ildong Pharmaceutical"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "Ildong Pharmaceutical Co Ltd"}, {"type": "Company", "text": "Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Company", "text": "target Company"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "target Company"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Venture capital", "relevance": 0.936637, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Finance", "relevance": 0.901189, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Mergers and acquisitions", "relevance": 0.877885, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Central nervous system", "relevance": 0.77698, "dbpedia_resource": "http://dbpedia.org/resource/Central_nervous_system"}, {"text": "Nervous system", "relevance": 0.774474, "dbpedia_resource": "http://dbpedia.org/resource/Nervous_system"}, {"text": "Corporate finance", "relevance": 0.748152, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Investment", "relevance": 0.723263, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Pharmaceutical drug", "relevance": 0.666621, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacology", "relevance": 0.661368, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Circulatory System", "relevance": 0.661349, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_System"}], "categories": [{"score": 0.643323, "label": "/finance/financial news"}, {"score": 0.447163, "label": "/business and industrial"}, {"score": 0.406687, "label": "/business and industrial/business operations/management/business process"}], "relations": [{"type": "partOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250 16:22 EST 10 Nov 2018 | BioPortfolio Report Blog Summary Ildong Pharmaceutical Co Ltd IPC is a manufacturer of pharmaceutical products.", "score": 0.829296, "arguments": [{"text": "manufacturer", "location": [348, 360], "entities": [{"type": "Organization", "text": "Private Equity", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "pharmaceutical products", "location": [364, 387], "entities": [{"type": "Organization", "text": "pharmaceutical products", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [2830, 2839], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2807, 2814], "entities": [{"type": "Organization", "text": "BioPortfolio.com Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.438716, "arguments": [{"text": "executives", "location": [2976, 2986], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [2994, 3001], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.713979, "arguments": [{"text": "subsidiaries", "location": [3099, 3111], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "company", "location": [3119, 3126], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.689884, "arguments": [{"text": "competitors", "location": [3162, 3173], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3181, 3188], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.374818, "arguments": [{"text": "you", "location": [3341, 3344], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3363, 3370], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3437, 3440], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3444, 3451], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "employedBy", "sentence": "Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "score": 0.284605, "arguments": [{"text": "customers", "location": [4177, 4186], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "company", "location": [4134, 4141], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "locatedAt", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.337955, "arguments": [{"text": "company", "location": [4227, 4234], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}, {"text": "locations", "location": [4257, 4266], "entities": [{"type": "Location", "text": "locations"}]}]}, {"type": "locatedAt", "sentence": "The company operates plants in Gyeonggido, Chungcheongbukdo, and others.", "score": 0.962413, "arguments": [{"text": "plants", "location": [928, 934], "entities": [{"type": "Facility", "text": "plants"}]}, {"text": "Gyeonggido", "location": [938, 948], "entities": [{"type": "GeopoliticalEntity", "text": "Gyeonggido"}]}]}, {"type": "basedIn", "sentence": "IPC is headquartered in Seoul, South Korea.", "score": 0.864815, "arguments": [{"text": "IPC", "location": [1031, 1034], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}, {"text": "Seoul", "location": [1055, 1060], "entities": [{"type": "GeopoliticalEntity", "text": "Seoul"}]}]}, {"type": "locatedAt", "sentence": "IPC is headquartered in Seoul, South Korea.", "score": 0.985879, "arguments": [{"text": "Seoul", "location": [1055, 1060], "entities": [{"type": "GeopoliticalEntity", "text": "Seoul"}]}, {"text": "South Korea", "location": [1062, 1073], "entities": [{"type": "GeopoliticalEntity", "text": "South Korea", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "productOf", "sentence": "Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.887293, "arguments": [{"text": "Mergers", "location": [1234, 1241], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1224, 1231], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "productOf", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.535319, "arguments": [{"text": "Mergers", "location": [1851, 1858], "entities": [{"type": "Product", "text": "Mergers"}]}, {"text": "company", "location": [1815, 1822], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nIldong Pharmaceutical Co Ltd IPC"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.564807, "arguments": [{"text": "Type Chart", "location": [2114, 2124], "entities": [{"type": "Organization", "text": "Type Chart"}]}, {"text": "Deals", "location": [2105, 2110], "entities": [{"type": "Organization", "text": "BioPortfolio.com Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.576002, "arguments": [{"text": "Deals", "location": [2289, 2294], "entities": [{"type": "Organization", "text": "BioPortfolio.com Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals"}]}, {"text": "Region Chart", "location": [2298, 2310], "entities": [{"type": "Organization", "text": "Region Chart"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.706156, "arguments": [{"text": "Asia", "location": [2450, 2454], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2455, 2462], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "score": 0.656702, "arguments": [{"text": "Subsector Chart", "location": [2531, 2546], "entities": [{"type": "Organization", "text": "Subsector Chart"}]}, {"text": "Deals", "location": [2522, 2527], "entities": [{"type": "Organization", "text": "BioPortfolio.com Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals"}]}]}], "keywords": [{"text": "deals", "sentiment": {"score": 0.440525, "label": "positive"}, "relevance": 0.981225}, {"text": "financial deals", "sentiment": {"score": 0.572001, "label": "positive"}, "relevance": 0.949283}, {"text": "company", "sentiment": {"score": -0.0227156, "label": "negative"}, "relevance": 0.879984}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.421324, "label": "positive"}, "relevance": 0.844638}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598093}, {"text": "Financial Deals Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594875}, {"text": "eTrack deals database", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592714}, {"text": "major financial deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58802}, {"text": "detailed major deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560625}, {"text": "recent financial deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.557435}, {"text": "major recent deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548927}, {"text": "raw material drugs", "sentiment": {"score": -0.298956, "label": "negative"}, "relevance": 0.548541}, {"text": "Ildong Pharmaceutical", "sentiment": {"score": 0.421324, "label": "positive"}, "relevance": 0.51829}, {"text": "key deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.470325}, {"text": "detailed information", "sentiment": {"score": 0.677039, "label": "positive"}, "relevance": 0.438335}, {"text": "key competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414289}, {"text": "BioPortfolio.com Ildong Pharmaceutical", "sentiment": {"score": 0.398535, "label": "positive"}, "relevance": 0.410518}, {"text": "business segments", "sentiment": {"score": -0.352689, "label": "negative"}, "relevance": 0.384815}, {"text": "Alliances Profile", "sentiment": {"score": 0.421324, "label": "positive"}, "relevance": 0.368966}, {"text": "key financial metrics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.368279}, {"text": "target company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.367472}, {"text": "Twitter Track topics", "sentiment": {"score": 0.398535, "label": "positive"}, "relevance": 0.36228}, {"text": "Private Equity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349126}, {"text": "Venture Financing", "sentiment": {"score": 0.489186, "label": "positive"}, "relevance": 0.348524}, {"text": "Equity/Debt Offerings", "sentiment": {"score": 0.343645, "label": "positive"}, "relevance": 0.34463}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342542}, {"text": "Gain key insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338119}, {"text": "Access elaborate information", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.336181}, {"text": "key executives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.33364}, {"text": "major public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332679}, {"text": "core business segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329003}, {"text": "South Korea", "sentiment": {"score": 0.367902, "label": "positive"}, "relevance": 0.324757}, {"text": "business research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.301374}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.279956}, {"text": "Subsector Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261068}, {"text": "BioPortfolio Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257903}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251447}, {"text": "antihistamine drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25077}, {"text": "key centers", "sentiment": {"score": 0.539694, "label": "positive"}, "relevance": 0.250592}, {"text": "Report Updated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.24967}, {"text": "pharmaceutical products", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247714}, {"text": "Key elements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.247178}, {"text": "Advertisement Topics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246323}, {"text": "medical devices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242022}, {"text": "health foods", "sentiment": {"score": 0.231912, "label": "positive"}, "relevance": 0.240037}, {"text": "Acquisitions MAs", "sentiment": {"score": 0.444113, "label": "positive"}, "relevance": 0.237531}, {"text": "antineoplastic agents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233766}, {"text": "comprehensive data", "sentiment": {"score": 0.444113, "label": "positive"}, "relevance": 0.233057}, {"text": "Type Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233048}, {"text": "Business Description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231414}]}, "extracted_metadata": {"sha1": "8423d34ec162c2fc3aeb31a132b674ffe1946313", "filename": "1541885064495.zip-b1118e9a1d9116bf0c63008d044a16fd.xml", "file_type": "json"}, "title": "Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12102018 Prices from USD $250", "forum_title": "BioPortfolio Latest News"}, {"id": "VAxSh67OsVODD3wItF6d0goohk2hYLkF5o7X_HCnRGMz_kD9zjzybUlL7o-9b8Mw", "result_metadata": {"score": 21.04613}, "author": "ABMN Staff", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.540588, "label": "negative"}, "text": "Concert Pharmaceuticals Inc", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.997474, "label": "/art and entertainment/shows and events/concert"}, {"score": 0.329466, "label": "/art and entertainment/shows and events/classical concert"}], "relations": [{"type": "hasAttribute", "sentence": "Concert Pharmaceuticals Inc (CNCE) Shares Bought by", "score": 0.932631, "arguments": [{"text": "Concert Pharmaceuticals Inc", "location": [0, 27], "entities": [{"type": "Organization", "text": "Concert Pharmaceuticals Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "CNCE", "location": [29, 33], "entities": [{"type": "Ticker", "text": "CNCE"}]}]}], "keywords": [{"text": "Concert Pharmaceuticals", "sentiment": {"score": -0.540588, "label": "negative"}, "relevance": 0.997949}, {"text": "CNCE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667784}, {"text": "Shares", "sentiment": {"score": 0.41558, "label": "positive"}, "relevance": 0.66573}]}, "crawl_date": "2018-11-10T15:26:40Z", "url": "https://www.americanbankingnews.com/2018/11/10/concert-pharmaceuticals-inc-cnce-shares-bought-by-northern-trust-corp.html", "host": "americanbankingnews.com", "text": "Finally, Hartford Investment Management Co. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $259,000.", "main_image_url": "https://www.marketbeat.com/logos/concert-pharmaceuticals-inc-logo.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-10T09:17:00-06:00", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": 0.10221, "label": "positive"}, "text": "Concert Pharmaceuticals Inc", "relevance": 0.906504, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.10221, "label": "positive"}, "text": "Meeder Asset Management Inc.", "relevance": 0.325354, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hartford Investment Management Co.", "relevance": 0.182895, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambria Investment Management L.P.", "relevance": 0.182332, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Capital Fund Management S.A.", "relevance": 0.156517, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CNCE", "relevance": 0.147994, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Northern Trust Corp", "relevance": 0.141955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.683226, "label": "positive"}, "text": "Dynamic Technology Lab Private Ltd", "relevance": 0.133559, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "its Commission", "relevance": 0.119762, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$11,335,000", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$106,000", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$178,000", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$216,000", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$244,000", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$259,000", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "679.4%", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "75.88%", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.88%", "relevance": 0.119762, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "5.9%", "relevance": 0.119762, "type": "Quantity"}], "sentiment": {"document": {"score": 0.169943, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Northern Trust Corp", "keywords": [{"text": "Northern Trust Corp"}], "entities": [{"type": "Company", "text": "Northern Trust Corp"}]}, "sentence": "Northern Trust Corp lifted its position in Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 5.9% during the 2nd its Commission.", "object": {"text": "its position in Concert Pharmaceuticals Inc (NASDAQ", "keywords": [{"text": "Concert Pharmaceuticals"}, {"text": "position"}, {"text": "NASDAQ"}], "entities": [{"type": "Company", "text": "Concert Pharmaceuticals Inc"}]}, "action": {"verb": {"text": "lift", "tense": "past"}, "text": "lifted", "normalized": "lift"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 673,466 shares of the biotechnology company\u2019s stock after buying an additional 37,369 shares during the quarter. approximately 2.88% of Concert Pharmaceuticals worth $11,335,000 at the end of the most recent reporting period.", "object": {"text": "673,466 shares of the biotechnology company\u2019s stock", "keywords": [{"text": "biotechnology company"}, {"text": "shares"}, {"text": "stock"}]}, "action": {"verb": {"text": "own", "tense": "past"}, "text": "owned", "normalized": "own"}}, {"subject": {"text": "stock", "keywords": [{"text": "stock"}]}, "sentence": " The firm owned 673,466 shares of the biotechnology company\u2019s stock after buying an additional 37,369 shares during the quarter. approximately 2.88% of Concert Pharmaceuticals worth $11,335,000 at the end of the most recent reporting period.", "object": {"text": "the biotechnology company", "keywords": [{"text": "biotechnology company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The firm", "keywords": [{"text": "firm"}]}, "sentence": " The firm owned 673,466 shares of the biotechnology company\u2019s stock after buying an additional 37,369 shares during the quarter. approximately 2.88% of Concert Pharmaceuticals worth $11,335,000 at the end of the most recent reporting period.", "object": {"text": "an additional 37,369 shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "Several other hedge funds", "keywords": [{"text": "hedge funds"}], "entities": []}, "sentence": " Several other hedge funds have also recently bought and sold shares of CNCE.", "object": {"text": "shares of CNCE", "keywords": [{"text": "shares"}, {"text": "CNCE"}], "entities": [{"type": "Company", "text": "CNCE"}]}, "action": {"verb": {"text": "buy", "tense": "past"}, "text": "bought and sold", "normalized": "buy and sell"}}, {"subject": {"text": "Several other hedge funds", "keywords": [{"text": "hedge funds"}], "entities": []}, "sentence": " Several other hedge funds have also recently bought and sold shares of CNCE.", "object": {"text": "shares", "keywords": [{"text": "shares"}]}, "action": {"verb": {"text": "sell", "tense": "past"}, "text": "bought and sold", "normalized": "buy and sell"}}, {"subject": {"text": "Meeder Asset Management Inc.", "keywords": [{"text": "Meeder Asset Management"}], "entities": [{"type": "Company", "text": "Meeder Asset Management Inc."}]}, "sentence": " Meeder Asset Management Inc. raised its holdings in shares of Concert Pharmaceuticals by 679.4% in the 2nd quarter.", "object": {"text": "its holdings in shares of Concert Pharmaceuticals", "keywords": [{"text": "Concert Pharmaceuticals"}, {"text": "holdings"}, {"text": "shares"}], "entities": [{"type": "Company", "text": "Concert Pharmaceuticals Inc"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "Meeder Asset Management Inc.", "keywords": [{"text": "Meeder Asset Management"}], "entities": [{"type": "Company", "text": "Meeder Asset Management Inc."}]}, "sentence": " Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company\u2019s stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000.", "object": {"text": "6,305 shares of the biotechnology company\u2019s stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000", "keywords": [{"text": "Dynamic Technology Lab"}, {"text": "biotechnology company"}, {"text": "Concert Pharmaceuticals"}, {"text": "new position"}], "entities": [{"type": "Company", "text": "Dynamic Technology Lab Private Ltd"}, {"type": "Company", "text": "Concert Pharmaceuticals Inc"}, {"type": "Quantity", "text": "$106,000"}, {"type": "Quantity", "text": "$178,000"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "owns", "normalized": "own"}}, {"subject": {"text": "stock valued at $106,000", "keywords": [{"text": "stock"}], "entities": [{"type": "Quantity", "text": "$106,000"}]}, "sentence": " Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company\u2019s stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000.", "object": {"text": "the biotechnology company", "keywords": [{"text": "biotechnology company"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Meeder Asset Management Inc.", "keywords": [{"text": "Meeder Asset Management"}], "entities": [{"type": "Company", "text": "Meeder Asset Management Inc."}]}, "sentence": " Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company\u2019s stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000.", "object": {"text": "an additional 5,496 Dynamic Technology Lab Private Ltd", "keywords": [{"text": "Dynamic Technology Lab"}, {"text": "Private"}], "entities": [{"type": "Company", "text": "Dynamic Technology Lab Private Ltd"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}, {"subject": {"text": "Cambria Investment Management L.P.", "keywords": [{"text": "Cambria Investment Management"}, {"text": "L.P"}], "entities": [{"type": "Company", "text": "Cambria Investment Management L.P."}]}, "sentence": " Cambria Investment Management L.P. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $216,000.", "object": {"text": "a new position in Concert Pharmaceuticals", "keywords": [{"text": "Concert Pharmaceuticals"}, {"text": "new position"}], "entities": [{"type": "Company", "text": "Concert Pharmaceuticals Inc"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "Capital Fund Management S.A.", "keywords": [{"text": "Fund Management S.A"}, {"text": "Capital"}], "entities": [{"type": "Company", "text": "Capital Fund Management S.A."}]}, "sentence": " Capital Fund Management S.A. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $244,000.", "object": {"text": "a new position in Concert Pharmaceuticals", "keywords": [{"text": "Concert Pharmaceuticals"}, {"text": "new position"}], "entities": [{"type": "Company", "text": "Concert Pharmaceuticals Inc"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "Hartford Investment Management Co.", "keywords": [{"text": "Hartford Investment Management"}], "entities": [{"type": "Company", "text": "Hartford Investment Management Co."}]}, "sentence": " Finally, Hartford Investment Management Co. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $259,000.", "object": {"text": "a new position in Concert Pharmaceuticals", "keywords": [{"text": "Concert Pharmaceuticals"}, {"text": "new position"}], "entities": [{"type": "Company", "text": "Concert Pharmaceuticals Inc"}]}, "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "acquired", "normalized": "acquire"}}, {"subject": {"text": "Hedge", "keywords": [{"text": "Hedge"}]}, "sentence": " Hedge own 75.88% of the company\u2019s stock.", "object": {"text": "75.88% of the company\u2019s stock", "keywords": [{"text": "company"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "75.88"}]}, "action": {"verb": {"text": "own", "tense": "present"}, "text": "own", "normalized": "own"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " Hedge own 75.88% of the company\u2019s stock.", "object": {"text": "stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Collective investment scheme", "relevance": 0.96747, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}, {"text": "Investment", "relevance": 0.912454, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Financial services", "relevance": 0.833494, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services"}, {"text": "Hedge fund", "relevance": 0.691106, "dbpedia_resource": "http://dbpedia.org/resource/Hedge_fund"}, {"text": "Stock market", "relevance": 0.617765, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Investment management", "relevance": 0.57684, "dbpedia_resource": "http://dbpedia.org/resource/Investment_management"}, {"text": "Mutual fund", "relevance": 0.546029, "dbpedia_resource": "http://dbpedia.org/resource/Mutual_fund"}, {"text": "Active management", "relevance": 0.54164, "dbpedia_resource": "http://dbpedia.org/resource/Active_management"}], "categories": [{"score": 0.52238, "label": "/finance/investing"}, {"score": 0.52238, "label": "/finance/investing/beginning investing"}, {"score": 0.45533, "label": "/finance/investing/funds/hedge fund"}], "relations": [{"type": "partOf", "sentence": "Meeder Asset Management Inc. raised its holdings in shares of Concert Pharmaceuticals by 679.4% in the 2nd quarter.", "score": 0.404226, "arguments": [{"text": "its", "location": [478, 481], "entities": [{"type": "Organization", "text": "Northern Trust Corp"}]}, {"text": "Concert Pharmaceuticals", "location": [504, 527], "entities": [{"type": "Organization", "text": "Concert Pharmaceuticals Inc", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Finally, Hartford Investment Management Co. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $259,000.", "score": 0.906333, "arguments": [{"text": "Hartford Investment Management Co.", "location": [1076, 1110], "entities": [{"type": "Organization", "text": "Hartford Investment Management Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [1111, 1119], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Finally, Hartford Investment Management Co. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $259,000.", "score": 0.890801, "arguments": [{"text": "2nd quarter", "location": [1173, 1184], "entities": [{"type": "Date", "text": "2nd quarter"}]}, {"text": "acquired", "location": [1111, 1119], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company's stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000.", "score": 0.50915, "arguments": [{"text": "Dynamic Technology Lab Private Ltd", "location": [698, 732], "entities": [{"type": "Organization", "text": "Dynamic Technology Lab Private Ltd"}]}, {"text": "acquired", "location": [733, 741], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company's stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000.", "score": 0.570936, "arguments": [{"text": "Concert Pharmaceuticals", "location": [760, 783], "entities": [{"type": "Organization", "text": "Concert Pharmaceuticals Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [733, 741], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "Cambria Investment Management L.P. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $216,000.", "score": 0.570936, "arguments": [{"text": "Concert Pharmaceuticals", "location": [885, 908], "entities": [{"type": "Organization", "text": "Concert Pharmaceuticals Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [858, 866], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "Capital Fund Management S.A. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $244,000.", "score": 0.583285, "arguments": [{"text": "Concert Pharmaceuticals", "location": [1004, 1027], "entities": [{"type": "Organization", "text": "Concert Pharmaceuticals Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [977, 985], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "affectedBy", "sentence": "Finally, Hartford Investment Management Co. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $259,000.", "score": 0.570936, "arguments": [{"text": "Concert Pharmaceuticals", "location": [1138, 1161], "entities": [{"type": "Organization", "text": "Concert Pharmaceuticals Inc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [1111, 1119], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company's stock valued at $106,000 after buying an additional 5,496 Dynamic Technology Lab Private Ltd acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $178,000.", "score": 0.890801, "arguments": [{"text": "2nd quarter", "location": [795, 806], "entities": [{"type": "Date", "text": "2nd quarter"}]}, {"text": "acquired", "location": [733, 741], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "agentOf", "sentence": "Cambria Investment Management L.P. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $216,000.", "score": 0.905105, "arguments": [{"text": "Cambria Investment Management L.P.", "location": [823, 857], "entities": [{"type": "Organization", "text": "Cambria Investment Management L.P.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [858, 866], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Cambria Investment Management L.P. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $216,000.", "score": 0.890801, "arguments": [{"text": "2nd quarter", "location": [920, 931], "entities": [{"type": "Date", "text": "2nd quarter"}]}, {"text": "acquired", "location": [858, 866], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "basedIn", "sentence": "Capital Fund Management S.A. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $244,000.", "score": 0.694675, "arguments": [{"text": "Fund Management S.A.", "location": [956, 976], "entities": [{"type": "Organization", "text": "Fund Management S.A.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Capital", "location": [948, 955], "entities": [{"type": "GeopoliticalEntity", "text": "Capital"}]}]}, {"type": "agentOf", "sentence": "Capital Fund Management S.A. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $244,000.", "score": 0.911524, "arguments": [{"text": "Fund Management S.A.", "location": [956, 976], "entities": [{"type": "Organization", "text": "Fund Management S.A.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquired", "location": [977, 985], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}, {"type": "timeOf", "sentence": "Capital Fund Management S.A. acquired a new position in Concert Pharmaceuticals during the 2nd quarter worth $244,000.", "score": 0.895799, "arguments": [{"text": "2nd quarter", "location": [1039, 1050], "entities": [{"type": "Date", "text": "2nd quarter"}]}, {"text": "acquired", "location": [977, 985], "entities": [{"type": "EventBusiness", "text": "acquired"}]}]}], "keywords": [{"text": "Concert Pharmaceuticals", "sentiment": {"score": 0.204421, "label": "positive"}, "relevance": 0.944004}, {"text": "Meeder Asset Management", "sentiment": {"score": 0.204421, "label": "positive"}, "relevance": 0.807873}, {"text": "Asset Management Inc.", "sentiment": {"score": 0.204421, "label": "positive"}, "relevance": 0.767001}, {"text": "new position", "sentiment": {"score": 0.683226, "label": "positive"}, "relevance": 0.727471}, {"text": "Northern Trust Corp", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629819}, {"text": "biotechnology company", "sentiment": {"score": 0.683226, "label": "positive"}, "relevance": 0.613914}, {"text": "recent reporting period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609688}, {"text": "Dynamic Technology Lab", "sentiment": {"score": 0.683226, "label": "positive"}, "relevance": 0.596412}, {"text": "Cambria Investment Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592081}, {"text": "Capital Fund Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585139}, {"text": "Hartford Investment Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577575}, {"text": "hedge funds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519111}, {"text": "quarter", "sentiment": {"score": 0.204421, "label": "positive"}, "relevance": 0.517469}, {"text": "shares", "sentiment": {"score": 0.204421, "label": "positive"}, "relevance": 0.501755}, {"text": "stock", "sentiment": {"score": 0.683226, "label": "positive"}, "relevance": 0.454614}, {"text": "CNCE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441755}, {"text": "NASDAQ", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421829}, {"text": "Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.421712}, {"text": "holdings", "sentiment": {"score": -0.478805, "label": "negative"}, "relevance": 0.420782}, {"text": "firm", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420367}, {"text": "quarter.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420186}, {"text": "end", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420065}, {"text": "Private", "sentiment": {"score": 0.683226, "label": "positive"}, "relevance": 0.418728}, {"text": "L.P.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418318}]}, "extracted_metadata": {"sha1": "0489bed640a3c923b2fd1f8a154302fb0e750f38", "filename": "1541863600360.zip-b9ba409f2c614d21ab184fd5c2997a93.xml", "file_type": "json"}, "title": "Concert Pharmaceuticals Inc (CNCE) Shares Bought by", "forum_title": "Contrasting PCM (PCMI) and dELiA*s (DLIAQ) - American Banking News"}]}